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Abstract.
The Determination of Chromium in Human Serum and Urine. 
by George Murray.
A critical evaluation of the published data for chromium levels 
in serum and urine shows major discrepancies, indicating that further 
work to establish normal values for these parameters is necessary.
Methods have been developed for the determination of total 
protein-bound, and alpha-2-globulin-bound, chromium in serum, and 
chromium in urine.
The sample pretreatment for serum is based on concurrent protein 
precipitation and dehydration using propan-2-ol for the total 
protein-bound chromium, and 0.5M hydrochloric acid in propan-2-ol for 
the alpha-2-globulin-bound metal. The precipitates are washed in 
propan-2-ol, then in toluene. Urine aliquots equivalent to 20 umol 
creatinine are dried at 75° C. Acetic acid (plus 7.5% v.v. sulphuric 
acid) and 1,1,1,5,5,5-hexafluoropenta-2,4-dione are added to the serum 
precipitates and urine residues. The chromium in the specimens is 
converted to the beta-diketonate at 75° C, and the complex extracted 
with petroleum spirit. The excess diketone is removed by washing with 
phosphate buffer. The chromium is back-extracted with ammonia in EDTA 
solution and, after an evaporation step, dissolved in ammonium acetate 
solution.
Atomic absorption spectrometry with electrothermal atomisation 
is used to measure the chromium, and because of the matrix 
simplification achieved, background correction is not necessary.
The mean results on serum from normal subjects were 0.11 ug/L 
for total protein-bound chromium, and 0.07 ug/L for
alpha-2-globulin-bound chromium. The detection limit was 0.03 ug Cr/L 
for both serum parameters. The mean normal value for urinary chromium 
was 0.44 ug/ 10 mmol creatinine, with a detection limit of 0.05 ug Cr/ 
10 mmol creatinine. The analytical relative standard deviations for the 
three parameters at the above levels were : 7%, 9% and 13%
respectively.
The serum chromium parameters did not show a significant 
response to a glucose challenge.
Precautions against sample contamination were taken, and 
techniques for reagent purification, and equipment cleaning to a high 
standard were developed.
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AAS. Atomic absorption spectrometry.
EDTA. Ethylenediaminetetra-acetic acid.
ETA. Electrothermal atomisation.
GTF. Glucose tolerance factor.
(see chapter II, section 2.4.).
Hfacac. 1,1,1,5,5,5-Hexafluoropenta-2,4-dione.
OGTT. Oral glucose tolerance test.
RSD. Relative standard deviation.
SD. Standard deviation.
Tfacac. 1,1,1-trifluoropenta-2,4-dione.
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CHAPTER I.
TRACE METALS IN HUMAN NUTRITION AND DISEASE.
This chapter is an introduction to trace metals and in 
particular to those aspects which are important to the clinical 
chemist. The primary consideration is whether or not the determination 
of a particular trace metal in a sample from a patient under 
investigation has any value. That is : will the result of the trace
metal measurement influence the treatment of the patient to his or her 
advantage? The analytical result of a determination will clearly need 
to to be of acceptable precision and accuracy. Furthermore, reliable 
normal results are necessary for comparative purposes. Elements which 
are either essential for normal metabolism or important toxic agents 
are clearly possible candidates for useful measurements.
1.1. TRACE METALS.
Trace elements are defined by IUPAC (1) as those present at less 
than 100 mg/L. Table 1.1 lists trace metals in order of decreasing 
reported concentrations in human serum or plasma. The data in the 
table are taken from the 1980 review "Normal levels of Trace Elements 
in Human Blood Serum or Plasma." by Versieck and Cornelius (2). The 
original results from the review have been processed to present a 
balanced report free from distortion by a few extreme values. The 
overall means listed for particular metals are the average of the 
reported means after the exclusion of outliers (outliers being defined 
as values outside three standard deviations). Reiteration was carried 
out until the data being processed were free from outliers. The values 
excluded were in all cases high outliers. Furthermore the ranges of the 
processed data for each metal were divided into ten equal intervals and 
the modal decile determined. The median, modal decile (numbered in 
ascending order) and percentages of reported means within the modal 
decile are also presented in table 1.1. Iron was not included in 
Versieck's review, presumably because iron determinations have reached 
a reasonable degree of reliability, and the normal range is no longer 
in dispute. However, iron has been added to the table for comparative 
purposes, the reported values are from "Biochemical Values in Clinical 
Medicine" (3).
The mean normal value reported by different workers should be in
general similar. Clearly data presented for the establishment of 
normal levels should not be taken from isolated ethnic groups, closed 
societies on unusual diets, populations exposed to high environmental 
levels of a particular metal, or other unrepresentative population 
samples. Furthermore homeostatic mechanisms exist for the control of 
essential trace metal concentrations. The tabulated results were all 
reported to be from apparently healthy adults and the number of 
subjects sampled by the majority of contributing analysts was such that 
a small range of values would be confidential/ expected. The wide 
scatter seen for the majority of metals could not be explained by 
biological variation but clearly illustrates the general 
unsatisfactory state of trace metal determinations on human serum and 
plasma. The modes for all trace metals for which adequate data were 
available in Versieck's review, were with one exception, at the lowest 
decile. This markedly skew distribution is consistent with 
contamination of the sample being the major problem.
Two pairs of metals, one pair present in relatively high 
concentrations, the other pair being in the ultratrace region, 
illustrate the influence of element availability for comtamination 
purposes on the ease of an accurate analysis. The first pair to be 
considered are zinc and copper.
Zinc determinations appear to be less satisfactory than would be 
expected from the comparatively high overall mean concentration. The 
reported means vary from 840 to 3090 /ig/L. However 73% of the results 
are between 840 and 1290 ;ug/L. The major problem appears to be 
contamination of the samples. Serum zinc samples are particularly 
susceptible to contamination before separation because of the high zinc 
content of all cells, including thrombocytes. The zinc concentration in 
erythrocytes is 12 times that in plasma, and that in leucocytes is 25 
times that in erythrocytes. Reimold et al (4) investigated 
contaminations interfering with the determination of plasma zinc and 
found polystyrene tubes, vacutainers and glass tubes to be 
unsatisfactory for both sample collection and storage. Polypropylene 
tubes with polythene stoppers were acceptable. Furthermore, the 
non-water wettable plastic surface if used with a suitable 
anticoagulant should help to prevent zinc release from lysed 
thrombocytes. However Reimold did find anticoagulants from some sources 
to have significant zinc concentrations. Furthermore many paper tissues
commonly used for wiping pipette tips were found by Reimold to have a 
high zinc content. The mean normal plasma zinc was found by Reimold to 
be 877 jig/L.
TABLE 1.1.
Ranges of reported means of trace metal concentrations 
in human serum or plasma.
Metal. Concentration u^g/L. Decile % in Mean
Mean. Median. Range. of mode. mode. n.
Zinc. 1285 1965 840 - 3090 1 51 77
Copper. 1130 1131 540 - 1721 5 39 74
Rubidium. 193 221 52 - 390 Insuff. data. 30
Aluminium. 102 202 3.72 - 400 1 62 83
Tin. 57 67 30 - 103 Insuff. data. 124
Arsenic. 39 96 1 .07 - 190 1 71 20
Nickel. 20 32 1 .6 - 621 1 43 41
Chromium. 17 28 0.14 - 55 1 30 61
Molybdenum 13 17 0.58 - 34 Insuff. data. 55
Vanadium. 12 29 0.02 - 57 1 57 43
Cobalt. 11 36 0.00 - 72 1 71 40
Manganese. 11 17 0.54 - 34 1 35 43
Silver. 9.3 13 0.68 - 25 Insuff. data. 45
Mercury. 5.7 7.9 1.8 - 14 1 50 24
Antimony. 2.5 2.9 0.52 - 5.2 Insuff. data. 35
Caesium. 1 .0 1 .0 0.74 - 1 .3 Insuff. data. 47
Iron. 1375 790 - 1960
Note. 1. 'The range quoted for iron is the biological range.
2. Mean n. is the mean number of subjects sampled by the workers 
reporting a normal mean value for a particular trace metal.
The reported normal mean values for serum or plasma copper levels 
are more consistent than the zinc values. The range of reported normal 
means is 850 to 1720 pg/L if a single low value of 540 ;ug/L is omitted, 
and 75% of the means are between 850 and 1200 j^ig/L. Furthermore, in 
contrast to the marked skew distribution of the zinc values with the mode 
at the lowest decile, the reported copper means have a normal 
distribution with the mode at the 5th decile. The inference must be that
there are no serious contamination problems associated with the
collection of samples for serum or plasma copper determinations.
The "ultra-trace" pair of metals selected for discussion are 
caesium and chromium. Caesium has been chosen because it is the only 
metal in this class with reasonably consistent reported means. The risk 
of contamination with caesium during sample collection and storage is
minute, since the element is amongst the least ubiquitous in the 
environment. However the caesium concentration in eryrthrocytes is 
about 6.5 times that in serum (Versieck et al (5)) therefore haemolysis 
or delayed separation of the plasma will produce an elevated result.
The contrasting metal of the second pair is chromium, the trace 
metal of interest in this study. The range of reported means is very 
large, 0.14 to 55 jug/L, and the markedly skew distribution with the
mode at the lowest decile as shown in figure 1.1 indicates that 
contamination is the major problem. Versieck (6) demonstrated that 
gross chromium contamination can result from the use of stainless steel 
needles for sample collection (chromium determinations will be
discussed in detail in chapter III).
Two points emerge from the above discussion. The first is that 
the ratio of a particular metal in the environment, available for 
sample contamination, relative to the normal plasma concentration is 
more important than the latter factor alone, in determining analytical 
difficulties. The second factor is the possibility of contamination 
from the cellular elements where high intracellular analyte 
concentrations are present. However, the data reported for caesium 
confirm that this second factor can be controlled if sufficient care is 
taken. The frequency distribution of Cu, Zn and Cr within the deciles 
are illustrated in figure 1.1. The data from table 1.1 were used for 
this figure and Cs was omitted because insufficient data were 
available. The normal distribution of the Cu values contrast with the 
skew distribution of the levels reported for the other two metals.
1.2. ESSENTIALITY.
Aggett (1) considered the following to be the criteria for trace 
element essentiality. The first is that deficiency is associated with 
reproducible defects which respond to the re-introduction of the 
element. Essential trace elements should be present in relatively 
constant concentrations throughout life. Concentrations of
FIGURE 1.1.
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non-essential trace elements have a skewed distibution within a 
population, whilst those of essential elements follow a normal 
distribution because homeostatic mechanisms exist for essential 
elements.
Essential trace elements must by definition be physiologically 
active at low concentrations. They are constituents or activators of 
enzymes, co-enzymes and hormones, all species which are active at low 
concentrations. The mechanisms by which metals function in enzyme 
systems is listed in table 1.2.
TABLE 1.2.
Mechanism of metal function in enzyme systems.
1. Direct participation in catalysis.
2. Combination with substrate to form an intermediate complex, upon 
which the enzyme acts.
3. Formation of a me tallo enzyme that binds the substrate in an 
enzyme-metal-substrate or enzyme-metal-coenzyme-substrate complex.
4. Combination of metal with a reaction product to alter equilibrium.
5. Maintenance of the quaternary structure of the enzyme.
The relative body burden of an element tends to correspond to 
the environmental availability. Many non-essential elements are in fact 
present in higher concentrations in serum than essential ones. For 
example aluminium, an abundant environmental element not proven to be 
essential, is present at much higher concentrations than chromium, 
which is generally accepted as an essential element. The "spectrum of 
biological effects", figure 1.2, illustates several important points. 
FIGURE 1.2.
The spectrum of biological effects. (Aggett (1)).
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Figure 1.2 illustrates that essential trace elements are potentially 
toxic, and that concentrations of a trace metal modestly above the 
optimal may be beneficial under certain circumstances. For example 
chromium supplementation has been reported to have a beneficial effect 
on lipid metabolism, however other workers have not been able to 
confirm this. Nevertheless there are sound theoretical grounds for a 
beneficial effect if chromium is accepted as an essential component of 
an insulin cofactor. The evidence for beneficial chromium, and the 
toxicity of chromium are both examined in chapter II, section 2.3.
Table 1.3 lists the evidence for essentiality in humans of the 
trace elements for which the concentrations in serum or plasma are 
reported in table 1.1. The possible value to the clinical chemist of 
reliable determinations, assuming these to be available, are also 
indicated. 5eaeftee.n metals are listed, of these seven have importance 
as toxic substances, and five are postulated as possibly being involved 
in trace element deficiency states in human subjects.
TABLE 1.3.
Evidence for essentiality, and value of assays, in humans.
Metal. Evidence for essentiality.
Al. A regulatory mechanism has 
been documented (Versieck 
et al (2)).
Two enzyme systems have been 
shown to be Al dependent :
1. Reaction beween succinate 
dehydrogenase cytochrome-c in 
vitro (Underwood (7)).
2. Al forms chelates with 
pyridoxal amino acid Schiff 
bases which act as model 
transaminases (Schroeder (8)).
Value of assays.
Al is known to be toxic in 
the presence of renal failure. 
Dialysis patients particularly 
at risk. From:
1. Al contaminated dialysis 
solutions.
2. Al compounds given to prevent 
the accumulation of phosphate.
Serum Al greater than 100 ,ug/L 
said to indicate high 
probability of Al deposits in 
bone (Danks et al (9)).
But many workers report normal 
values higher than this.
Sb. No known biological function 
in living organisms.
Antimonials shown to be of value 
in tropical medicine (Versieck 
et al (2)). Sb levels possibly 
of value in therapeutic monitoring.
TABLE 
Metal 
As.
Cs.
Cr.
Co.
Cu.
Fe.
1.3. continued.
Evidence for essentiality. 
Evidence has been presented 
that As may be an essential 
trace element (Versieck et 
al (2)).
No known vital function.
Value of assays.
Toxicology only at the present 
time.
No value.
Evidence for involvement in 
carbohydrate metabolism, as 
an essential component of 
"glucose tolerance factor", 
an insulin cofactor generally 
accepted.
Controversial. Lack of reliable 
reference levels for 
serum/plasma or urine.
Reports of response to a glucose 
challenge even in normal 
subjects also contradictory.
The element serves its 
paramount established 
biological function as a 
component of vitamin B12.
Competitive protein binding 
assays of vitamin B12 using
57 Co are reliable and valuable
Essential, present in many 
enzymes and proteins.
Enzyme activities dependent 
on Cu include:
1. Cytochrome oxidase.
2. Superoxide dismutase 
(cytosolic).
3. Caeruloplasmin (93% of 
plasma Cu on average).
4. Lysil oxidase.
5. Dopamine hydroxylase.
6. Ceramide galactosyl transferase.
7. Ferrioxidase.
Two inherited disorders of Cu 
metabolism occur in humans.
1. Menkes 1 syndrome.
2. Wilson's disease.
Cu determinations on serum 
and urine, and caeruloplasmin 
activities are all valuable.
Essential constituent of the 
respiratory proteins:
1. Haemoglobin, about 75% of 
the total iron.
Iron deficiency is the most 
common disease in the world 
today (Golden and Golden (10) 
Caused by:
TABLE 1.3. continued.
Metal Evidence for essentiality. Value of assays.
Fe. continued.
2. Myoglobin.
3. Cytochromes, minute 
fraction of total iron.
About 25% in storage as:
1. Ferritin, iron core 
surrounded by a protein shell. 
Ferritin circulates in the 
serum and extracellular fluid 
in equilibrium with:
2. Haemosiderin, insoluble 
iron store in the 
reticuloendothelial system.
Transferrins, iron transport 
proteins.
Mn. Hurley (12) states:
1. The skeleton and otoliths 
are susceptible to Mn 
deficiency.
2. Superoxide dismutase 
found in mitochondria 
contains Mn.
3. Mn deficiency results in 
abnormal mucopolysaccharide 
synthesis, alterations in 
the integrity of membranes
and to abnormal brain function.
The enzyme activities 
generally accepted as being 
Mn dependent are:
1. Glyosil transferase.
2. Arginine pyruvate 
carboxylase.
1. Inadequate iron ingestion.
2. Inadequate absorption.
3. Increased iron loss. 
Measurement of serum ferritin 
appears to be the earliest 
indicator of iron depletion. 
Serum iron does not fall until 
later, when iron deficient 
erythropoiesis develops. 
Ferritin determinations also 
give the earliest detection of 
iron overload. Treatment can be 
initiated minimising damage to 
the liver and other organs 
(Halliday (11)).
Only one reliable case of Mn 
deficiency documented.
A subject receiving a purified 
"chemically defined" diet 
designed to establish the adult 
need for vitamin K. The patient 
was unable to correct his 
depressed prothrombin levels 
when given vitamin K until Mn 
was restored to his diet 
(Underwood (13)).
Tanaka (14) and Papavasiliou 
(15) both found whole blood Mn 
levels below normal in about 
one third of children with 
convulsive disorders of unknown 
cause however all the children 
were on anticonvulsant therapy.
TABLE
Metal
Hg.
Mo.
Ni.
Rb.
1.3. continued.
Evidence for essentiality. 
Essentiality for man not 
proven.
Mo is essential as a 
constituent of xanthine 
aldehyde and sulphide oxidases 
(Aggett (1)).
Essentiality for man not 
proven, although deficiency 
states in animals well 
documented Mertz (18)).
A Ni containing 
macroglobulin has been 
found in human serum, 
but function is unknown 
(Sundermann (21)).
No evidence that Rb is 
essential.
Value of assays.
Toxicology purposes only. 
Neutron activation analysis is 
only suitable for the 
determination of total Hg. 
Refined atomic absorption 
methods can distinguish between 
organic and inorganic Hg.
The principal excretory route 
for organic Hg is via the bile 
into the faeces as 
methyl-Hg-cysteine,
(Vallee (16)).
No known deficiency cases in 
man.
In view of the concern about Ni 
toxicology, expressed by 
Sundermann (17), reliable 
reference concentrations are 
needed for the general 
population so that accurate 
determinations on exposed 
subjects can be interpreted.
The close physico-chemical 
relationship of Rb to K has 
stimulated biological interest 
in Rb. Fieve et al (19,20) 
report that there is some 
evidence that Rb has unique 
neurophysical characteristics.
TABLE
Metal
Ag.
Sn.
V.
Zn.
1.3. continued.
Evidence for essentiality.
No evidence that Ag is 
essential for living 
organisms.
Schwartz et al (22) produced 
evidence that Sn was an 
essential element for some 
animals in 1970. No definite 
proof of essentiality in man.
The balance of opinion is 
probably that V is essential, 
but no definite proof. No V 
metalloprotein known.
Golden and Golden (10) state 
that homeostatic control is 
exerted over V, and that the 
metal does not accumulate 
with age.
Cantley et al (23) and Karlish 
et al (24) have produced 
evidence that vanadate 
inhibits the Na pump.
Zn is one of the most 
important trace metals, over 
50 Zn metalloenzymes have 
been identified. All key 
metabolic pathways have 
Zn metalloenzymes.
Williams et al (26) and 
Kirchgessner et al (27), 
both report that when an 
animal dies from Zn deficiency 
the metalloenzymes and the
Value of assays.
Toxicology only but Ag is not 
important in this field.
Toxicology only.
Golden and Golden (10) state 
that the V content of human diet 
appears to be considerably below 
that required by some animals. 
They conclude that the low serum
V concentration in patients with 
nutritional oedema may 
represent a natural human 
deficiency.
Dimond et al (25), reports that
V salts are relatively non 
toxic to man.
Acrodermatitis enteropathica is 
a rare congenital disorder of 
Zn absorption. The disease is 
readily cured by giving Zn 
sulphate. All patients for whom 
data are available have very 
low serum/plasma Zn levels.
The incidence of marginal Zn 
deficiency, and the value of Zn 
determinations for the 
diagnosis of this condition are
11 .
TABLE 1.3. continued.
Metal Evidence for essentiality.
Zn continued.
tissue Zn content have hardly 
changed.
Zn is unique amongst trace 
metals in that there does 
not appear to be a functional 
body store of this essential 
element. Virtually all the Zn 
is locked away in bone or 
protein, this is responsible 
for the rapid onset of 
symptoms on a Zn deficient 
diet.
1.2.1. Regulation.
The metabolism of the essential trace elements is usually 
adjusted by a homeostatic mechanism to maintain body burdens and 
concentrations near the optimum levels. The uptake from food and the 
excretion rate may both be used for control. For example Elinder (29) 
reports that for iron and zinc regulation takes place in the 
gastrointestinal tract, absorption rising under deficiency conditions 
and falling when stores are adequate. The uptake of copper, in 
contrast, is stated by Elinder to be always high, status being 
regulated by an effective and rapid biliary excretion.
The measurement of serum iron and the determination of iron 
status have reached a reasonable degree of reliability. The involvement 
of iron in a single metabolic process, respiration, undoubtedly helps 
in the determination of status. Iron status regulation is therefore a 
useful comparative model for other metals. The factors affecting iron 
absorption are obvio.tisiy relevant to many other metals, despite the 
fact that regulation may not be by absorption. Limited absorption, 
or particularly favourable absorption conditions can clearly ove/Tide 
the homeostatic mechanism, leading to deficiency or overload 
respectively. The conditions resulting from failure of the regulatory 
mechanism are also relevant, because chromium is one of several metals
Value of assays.
both controversial subjects. 
Solomons (28) believes that 
Zn (and Cu) deficiency states 
probably represent an under 
recognised segment of human 
nutrition problems. Solomons 
also states that the simple 
determination of total Zn 
(or Cu) alone is insufficient 
for assessing the metal status 
of an individual.
carried by the iron transport protein transferrin. Furthermore a high 
incidence of diabetes mellitus is seen in one type of iron overload, 
idiopathic haemochromatosis, and Sargeant et al (30) postulated that 
the high saturation of transferrin seen in this condition could result 
in chromium deficiency.
1.2.1.1. Iron status regulation.
The absorption of iron is susceptible to conditions in the
intestinal lumina, particularly to pH and to the presence of oxidising
or reducing agents. A low pH increases absorption because of the higher
solubility of iron, especially Fe(III). the presence of reducing
agents favours absorption because Fe(II) is absorbed about three times 
as efficiently as Fe(III).
Reimold et al (4) gives the following account of iron
absorption. The normal intake of iron averages about 20 mg per day, but 
only a small fraction of this is absorbed, since an adult male 
maintains iron balance on an absorption of about 1 mg per day. However 
females during the reproductive years absorb about 1.5 mg daily to 
balance menstrual losses. The absorptive behaviour of the intestinal 
mucosa changes under conditions of abnormal iron status in an attempt 
to achieve homeostasis. However under deficiency conditions the amount 
of dietary iron that can be absorbed is limited by its bioavailability. 
Absorption rises only to about 4 mg daily under conditions of
depletion, and falls only to 0.5 mg per day in overload states. In
areas where the populations subsist on cereal diets containing little 
ascorbic acid or meat, iron is less available, and the ability to 
increase absorption is even more restricted.
There is a limited loss of iron from the body. In the normal 
adult male the total excretion is from 0.5 to 1.0 mg per day according 
to Moore (31). The bulk of the iron is lost in the faeces where it is 
derived from the intracellular iron of exfoliated epithelial cells and 
erythrocytes. The urinary loss is reported by Dagg et al (32) to be 
less than 0.1 mg daily. When the total body iron content is raised,
iron excretion is somewhat increased. This is mainly due to the fact 
that each desquamated epithelial cell contains slightly more iron. 
Astaldi et al (33) claims that under conditions of iron overload 
macrophages packed with iron pass into the intestine.
1.2.2. Deficiency.
A number of nutritionists consider that absolute deficiencies of
trace elements are unlikely to occur except among subjects who have 
rare inborn errors of metabolism, metabolic alterations secondary to 
protein-energy malnutrition, primary disease or stress, and those 
receiving total parenteral nutrition for prolonged periods. The only 
reasonably convincing cases of Cr deficiency reported are from this 
last category, that is prolonged total parenteral nutrition, and this 
will be discussed in chapter II.
1.2.2.1. Dietary variables.
O'Dell (34) states that there are major discrepancies in the 
literature as regards the definitions of bioavailability, some 
investigators equating bioavailability with absorption. O'Dell defines 
bioavailability as the proportion of nutrient in food which is absorbed 
and utilised. Utilisation is the process of transport, cellular 
assimilation and conversion to a biologically active form or forms. The 
dietary variables affecting the bioavailability of trace elements are 
given in table 1.4 below.
TABLE 1.4.
Dietary variables affecting the bioavailability of trace elements.
A. Extrinsic factors.
1. Age or maturity of food.
2. Processing
3. Dietary components.
i) Protein. Snedeker (35) showed that a high animal protein diet 
significantly increased the apparent absorption of Zn.
ii) Carbohydrate. Fields et al (36) reported that replacement of 
starch by sucrose reduced the hepatic and renal Cu of rats fed on a 
low Cu diet.
iii) Fibre. Davies (37) reviewed the effects of dietary fibre. He 
was unable to draw firm conclusions.
iv) Phytate and oxalate. O'Dell et al (38) demonstrated that 
phytate decreases Zn bioavailability in experimental animals. Kelsay 
(39) showed that foods such as spinach, which are rich in both fibre 
and oxalate decrease Zn balance.
4. Minor dietary components.
Considerable evidence has accumulated that a dietary excess of one 
trace element may have a detrimental effect on the absorption of 
another particularly if the latter is present at a minimal level. 
O'Dell (34) reports the following interferences:
TABLE 1.4. continued.
Fe(II), Pb and possibly Sn reduce Zn.
Zn, Cd, Ag and Mo reduce Cu absorption.
B. Intrinsic factors.
1. Chemical speciation.
McKenzie (40) regards chemical speciation as the more important of 
the two intrinsic factors. Some differences can be explained on the 
basis of aqueous or lipid solubility. As a general rule organics are 
better absorbed than inorganics.
2. Dietary concentration.
Frolich (41) supports the Norwegian policy of having a very 
restrictive fortification policy for foods because of the interactions 
of some elements, and the possibility of overloading some subjects.
Sandstead (42) states: "A factor that probably protects people
in industrialised societies from the occuVfence of greatly distorted 
trace element relationships is the variety of foods consumed from a 
variety of sources. Poor people and members of agrarian societies may 
have less protection in this regard. In the latter instance, food from 
local farms may be the major dietary constituents. When this occurs, 
persons living on the farms may be subjected to undesirable soil/plant 
interactions similar to those affecting livestock."
1.2.2.2. Genetic defects leading to deficiency.
Genetic defects leading to trace element deficiences are 
extremely rare.
1. Menkes' kinky hair syndrome.
This condition was first described in 1962 by Menkes et al (43) 
as an x-linked recessive disorder. Danks et al (9) reported that 
patients with Menkes' syndrome were Cu deficient and that the primary 
defect was probably one of intestinal malabsorption. Nooijen et al (44) 
produced evidence that Cu accumulates in various tissues particularly 
kidney and duodenal mucosa, thus Menkes' syndrome cannot be one of 
simple Cu deficiency. Furthermore, in agreement with the identification 
of the Cu binding protein as a metallothionein, it was found that Zn, 
Cd and Hg were also trapped in these tissues. Table 1.5 compares the Cu 
levels in Menkes' syndrome with normal values (Danks (45)).
TABLE 1.5.
Copper levels in Menkes1 syndrome compared with normal values.
Copper Normal baby Menkes'
Tissue. units. 6 to 12 months. syndrome.
Serum. ;ig/L. 700 to 1525 127 to 381
Liver. jug/g dry wt. 50 to 120 10 to 20
Brain. I 20 to 30 1 to 7
Kidney. ft 10 to 20 240
Duodenum. I 7 to 29 50 to 90
2.Wilson's disease.
Wilson's disease or hepatolenticular degeneration is an 
inherited metabolic disorder that affects Cu metabolism. The 
fundamental disturbances in Wilson's disease are:
i) A gross reduction in the rate of incorporation of Cu into 
caeruloplasmin.
ii) A considerable reduction in the biliary excretion of Cu.
The copper levels in Wilson's disease are compared with normal 
levels in table 1.6 below (Danks (46)).
TABLE 1.6.
Copper levels in Wilson's disease compared with normal.
Normal adult. Wilson's disease.
Serum caeruloplasmin mg/L. 200 to 400 0 to 200
Total serum Cu mg/L. 700 to 1525 191 to 635
Non caeruloplasmin Cu
as a % of total Cu. 5 to 10 > 1 0
Urinary Cu jug/24 hrs. < 40 100 to 1000
3. Achroderma enteropathica.
Achroderma enteropathica is a rare congenital inherited disorder 
of Zn absorption. The disease is readily cured by the administration of 
Zn sulphate. All patients for whom data are available have very low 
serum/plasma Zn levels.
4. Deficiency of transferrin.
A subject with apparent atransferrinaemia was reported by 
Heilmeyer et al in 1961 (47). The subject had severe iron deficiency,
and required regular blood transfusions. However although both parents 
had low transferrin levels they were not iron deficient.
The analytical results reported for the subjects with the known 
inborn errors involving trace metal metabolism illustrate both the need 
to carry out determinations on several types of specimen and the 
potential value of fractionation procedures.
1.2.2.3. Excessive loss.
Excessive trace element loss may follow various conditions. The 
more common ones include burns, kidney disease, cirrhosis, diuresis and 
the therapeutic administration of chelating agents.
The broad spectrum determination of trace element status for 
subjects in this group would clearly be of value. Adequate control of 
status should lead to some improvements in prognosis and quality of 
life, in those cases where significant deficiencies exist.
1.3. DETERMINATION OF TRACE METAL STATUS.
The criteria given by Kirchgessner (27) for the diagnosis of 
trace element deficiency are listed in table 1.7 below.
TABLE 1.7.
Criteria for the diagnosis of trace element deficiency.
1. Characteristic and sensitive for the particular trace element.
2. Indicate latent and early stages of imminent deficiency.
3. Give some clues to the causal factors.
4. Afford easy sampling of the analytical material.
5. Simple and robust analytical methods.
These criteria can be approached for only one trace metal, iron, at the 
present time.
1.3.1. Choice of material for analysis.
Determinations are usually carriec/ out on whole blood,
serum/plasma, urine or hair. The containers used may contaminate any of
these samples with metals. Zn is a particular problem and Reimold et al
(4) reports that the rubber sealing rings used with many sample
containers, especially glass ones are especially troublesome.
1.3.1.1. Blood.
Whole blood, serum or plasma are the samples used for most trace
element determinations, as blood is a convenient readily available 
material. However there are some special problems.
Blood may be contaminated during the sampling procedure. The 
stainless steel needles can contribute Cr, Mo, Fe and Ni. When the 
analyte to be measured is not equally distributed between the blood 
cells and the plasma whole blood results are influenced by the "pack 
cell volume". As mentioned in 1.1 serum/plasma are misleading for 
elements like Zn which are present in much higher concentrations in the 
cells if haemolysis occurs, or if the serum/plasma is not separated 
from the cells without an unreasonable delay. Plasma is superior to 
serum for early separations, but anticoagulants may contain the 
elements to be measured, as discussed earlier with respect to Zn 
determinations. The anticoagulant may react with the metal to be 
measured and this could affect the result. For example, a sample 
collected using EDTA as anticoagulant would be unsuitable for 
determinations after a fractionation procedure, if the original metal 
distribution was disturbed.
The time at which the specimen is taken and the position of the 
patient may be important. For example a patient adopting a recumbent 
position experiences a flow of extracellular fluid into the blood 
vessels leading to a change in many components of the blood plasma. 
Samples taken after a meal may reflect trace element absorption and be 
significantly higher than fasting samples, or a trace element 
containing species may respond to post prandial changes. The last 
factor is especially pertinent to Cr determinations, particularly after 
fractionation procedures because the proposed insulin cofactor 
containing Cr would reasonably be expected to respond to blood glucose 
changes. In addition to the above changes diurnal variations may occur.
1.3.1.2. Urine.
Urine has the advantage of being readily available in relatively 
large volumes, and the collection system can be very simple, especially 
for males, minimising contamination problems. The meaningful parameter 
is the excretion relative to a fixed amount of creatinine. The urinary 
concentration is only useful for the detection of gross toxic states. 
The urine volume and the physical size of the subject under 
investigation must be considered in all other studies.
1.3.1.3. Hair.
Hair trace element levels can provide useful historical
information according to some workers. Mertz (48) suggested that hair 
is a "meaningful and representative" tissue for the analysis of Zn, Cu 
and Cr. Amador et al (49) reported that patients with acrodermatitis 
enteropathica had low concentrations of Zn in their hair. However, 
contamination from the environment, and from applied cosmetic 
preparations, is a major problem. Hildebrand et al (50) concluded that 
because of cosmetic treatment, the effects of which could not be 
eliminated by the commonly used sample preparation procedures, hair 
could not be expected to indicate the concentrations of the intrinsic 
metals. There is general agreement that trace metal determinations on 
hair are of little value in the acute situation.
1.3.1.4. Other materials.
Analysis of soft tissues obtained by biopsy may provide more 
information than can be obtained from blood and urine. However it is 
obvious that good clinical grounds would be necessary to justify the 
collection of such samples. This category of sample has been used 
mainly for the investigation of excessive exposure to toxic metals. 
Sequestering tissues are usually sampled. For example, Ulucci et al 
(51) advocated renal biopsies for Cd studies.
1.3.1.5. Interpretation of results.
The interpretation of results may be difficult for any sample 
type. Thus blood, serum/plasma and urine all give an indirect estimate 
of intracellular trace element content. Plasma carries newly absorbed 
trace elements as well as those being transported to their target 
organs. The concentrations of some elements, or fractions of an element 
may be under tight homeostatic mechanisms and remain virtually 
unchanged until the body reserves are almost exhausted, as indicated in 
table 1.2 for Zn.
1.3.2. Fractionation.
Fractionation to determine the amount of trace element present 
in the form from which it derives its essentiality (usually a 
metalloenzyme, coenzyme or hormone) may help to overcome some of the 
interpretation problems discussed above. However, the extra processing 
involved in such fractionation procedures gives an increased chance of 
loss or gain of the element, and of course greater sensitivity is 
needed. Nevertheless the greater percentage change in a fraction with a 
higher fractional contribution from the essential species could 
compensate for this, giving a more sensitive measurement of status.
Speciation is the ultimate goal, however more modest 
fractionation procedures may be useful. The trace element distribution 
over various binding entities is clearly an important topic. The trace 
elements in plasma are mainly present in three forms. A labile 
exchangeable fraction bound to albumin, a group bound to low molecular 
weight substances such as amino acids, metabolites and drugs, and the 
essential form, which is usually incorporated in specific 
metalloproteins and is usually relatively inert to exchange of the 
trace element component. Table 1.8 lists the fractionation techniques 
used at the present time.
TABLE 1.8.
Fractionation techniques.
Basis. Technique.
1. Molecular weight. i) Gel chromatography.
ii) Ultrafiltration.
2. Complex stability. Addition of a complexing agent followed by
solvent extraction.
3. Solubility. i) Precipitation with chemicals.
eg. The determination of the Zn bound to albumin 
after the precipitation of alpha-2-macroglobulin 
with polyethylene glycol (Giroux et al (52)).
ii) Precipitation with antibodies, 
eg. The determination of the Cu bound to albumin 
after the removal of caeruloplasmin.
4. Indirect methods. i) Determination of a biological property.
eg. Caeruloplasmin measured using its oxidase 
activity. This test is widely used in the 
diagnosis of Wilson's disease (see 1.2.2.2.)
ii) Immunological techniques. 
eg. The Radioimmunoassay measurement of 
ferritin. The best test for the determination of 
iron status, giving early and reliable detection 
of overload or deficiency, as reported earlier 
in table 1.3.
The last category in table 1.8 "indirect methods", is probably the one 
which will be most developed in the future, both the techniques listed
in this category being important.
Williams (53), Fiabane et al (54) and Halstead et al (55) all 
considered the low molecular weight complexes to be important, because 
it is well established that intestinal absorption, reactions in blood 
plasma, deposition into tissues, passage through the blood brain 
barrier, renal and biliary excretion, and even the synthesis of 
metalloproteins, all involve low molecular weight complexes of the 
transition metal ion. The complexing agents are usually amino acids.
For obvious reasons the determination of trace elements after 
fractionation has been applied to the trace elements present in higher 
concentrations, for example Zn, Cu and Fe. The value of the 
fractionation procedures in use at the present time for Cu and Fe have 
been reported in table 1.8. The Zn content of serum is almost entirely 
bound to protein with 50 to 60% bound to albumin and 30 to 40% bound to 
alpha-2-macroglobulin, and a variety of methods have been used to 
separate these two fractions. However the involvement of Zn in nearly 
all organs and metabolic pathways render determinations of total serum 
Zn, and of the Zn present in these two major fractions, of limited 
value.
Danks et al (56) has suggested that the measurement of an 
appropriate metalloprotein before and after the administration of a 
physiological replenishment dose of metal should distinguish low levels 
due to metal deficiency from those due to other mechanisms. Low initial 
levels that do not change after treatment would indicate low apoprotein 
production due to genetic variability or other factors. Defects in the 
absorption of the metal would also prevent a response, eg in Menkes' 
syndrome. The underlying principle is that deficiency of a metal places 
a constraint upon the formation of active holo-metal-enzyme, but a 
moderate excess of metal does not superinduce production of active 
enzymes. Danks states that it seems•logical that this should be true 
for metallo-enzyme, as opposed to metal transport or binding proteins, 
which might be expected to be super inducible.
1.3.4. The Assessment of Chromium Status.
The determinations of total serum Cr, GTF Cr and free GTF Cr are 
clearly the initial targets to aim for.
A chromium analogue of the iron storage substance ferritin could 
exist, and measurements of this by immunoradiometric techniques would 
then probably provide the most reliable guide to chromium status.
1.4. CONCLUSIONS.
1.4.1. Reference Values.
The normal levels of a small minority of trace metals in human 
serum/plasma have been established with reasonable confidence. Two 
principal parameters appear to be relevant to the analytical problems 
when determining a particular trace element level. The first is 
concentration, the second is the availability of the metal in the 
laboratory environment, containers, sampling equipment and process 
materials.
A low concentration exacerbates matrix and contamination 
problems, a high availability factor increases contamination problems.
Metals present in very low concentrations and with high 
availability factors for example chromium and nickel would be expected 
to present special problems in the development of reliable 
determinations. The sampling procedure, which is very difficult for the 
analyst to control for routine samples, presents particular problems 
for these two metals, because of the ubiquitous stainless steel syringe 
needle. The only practical answer to this problem is to develop 
techniques not involving the measurement of the trace element itself, 
for assessing the metal status of subjects, especially in the routine 
clinical chemistry laboratory.
1.4.2. Essentiality.
The characteristics which make a particular trace metal a 
difficult analyte, will also produce problems in essentiality studies. 
A very low plasma concentration implies a very low dietary requirement 
and gross deficiency is then difficult to produce experimentally, if 
there is a relatively high environmental availability. Furthermore, 
natural deficiency is unlikely to occur, except under very exceptional 
conditions.
The demonstration of a metal dependent enzyme system is a 
possible route to proof of essentiality.
The three metals nickel, chromium and vanadium are all present 
in very low concentrations in human plasma, and have relatively high 
environmental availability. Furthermore no enzyme systems dependent on 
any of these three trace elements have been found. Chromium is the only 
one of the three to be virtually universally accepted as essential, 
although there is some support for the other two. Nevertheless the
evidence for chromium as an essential trace metal is perhaps not 
entirely convincing. The evidence for chromium as an essential trace 
metal is discussed in chapter II.
1.4.3. Status.
Trace metal status is clearly easier to define from laboratory 
tests when the metal under consideration is involved in a single 
metabolic process, or where one is markedly predominant. The diagnosis 
of iron status is an example. The only completely reliable indication 
of trace metal deficiency is still the careful observation of the 
clinical response to supplementation of the nutrient under 
investigation, under controlled conditions.
1.4.4. Chromium.
The reference range for serum/plasma chromium is very uncertain, 
and very little work has been carried out on serum chromium 
fractionation. The lack of a consensus value is understandable, given 
the ultratrace concentration and high availability mentioned earlier.
The establishment of reliable reference ranges for serum/plasma 
and urine chromium are necessary for two purposes. The first is for the 
interpretation of accurate determinations on subjects exposed to 
possibly toxic quantities of chromium. The second purpose is for 
investigations into the assessment of chromium status by laboratory 
tests. The fact that chromium essentiality appears to depend only on a 
single molecular species, which acts as an insulin cofactor is an 
advantage. However a chromium analogue of the iron storage protein 
ferritin, if one exists would be the ideal analyte.
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CHAPTER II.
REVIEW OF CHROMIUM AS A TRACE METAL IN HUMAN PHYSIOLOGY.
Chromium is important in human physiology both as an essential 
trace metal and as a serious health hazard to workers in certain 
industries. The toxicity of chromium must be discussed here because of 
its relevance to chromium supplementation.
2.1. TOXICITY OF CHROMIUM.
Cr is used extensively in many industries. Hatherhill (1) 
reports that Cr(VI) is capable of crossing oral and pulmonary membranes 
and perhaps skin as well. Cr(III) is stated to have a markedly reduced 
ability to cross membranes.
2.1.1. Mutagenicity of chromium.
Mutagenic activity by Cr has been demonstrated in both bacteria 
and rodents.
2.1.2. Evidence for mutagenicity.
Hatherhill (1) reports that Cr workers have significantly 
higher incidences of lung cancer, with relatively few reports of cancer
in other tissues, he refers to references (2) and (3).
2.1.2.Mechanism of mutagenic activity.
Levis and Majone (4) tested Cr(III) and Cr(VI) compounds of 
varying solubilities in cell cultures. The observations made in the 
experiments are given in table 2.1.
Table 2.1.
Observations by Levis et al on mutagenicity and carcinogenicity tests.
1. Cr(III) compounds have low activity because of strong binding to 
the cell mebrane, with resultant poor penetration.
2. Highly soluble Cr(VI) compounds such as K or Na dichromate show low 
activity in live animals because of fast spread and rapid
reduction mainly by erythrocytes which are readily penetrated by
Cr(VI).
3. Cr(VI) compounds of moderate solubility such as Ca chromate or Zn
chromate hydroxide, have high mutagenic activity.
4. The cells most at risk are ones which cannot readily reduce Cr(VI)
in the cytoplasm, before contact is made with the nucleus. Cr(III) 
produced by reduction of Cr(VI) in the cytoplasm tends to be
TABLE 2.1. continued.
retained by the cell membrane.
5. Some Cr(III) compounds tested appeared to be active because of 
contamination with Cr(VI).
6. There is probably very little oxidation of Cr(III) to Cr(VI) in 
biological systems.
Jennette (5) reported that the chromate anion mimics the 
sulphate ion and crosses the cell membrane on the sulphate transport 
system.
The mutagenic activity of chromium appears to depend 01 the 
penetration of the cell membrane by Cr(VI) on the sulphate transport 
system. The Cr(VI) must then avoid reduction to Cr(III) by the 
microsomal fraction of the cytoplasm and gain access to the nucleus. 
The Cr(VI) is then reduced at the nucleus and the Cr(III) produced 
interfers with DNA synthesis.
2.1.3. The diagnosis of chromium toxicity.
Toxicological monitoring can be carried out in two complimentary 
ways. The first is environmental monitoring, defined as the direct 
qualitative and quantitative assessment of exposure by measuring the 
harmful agents present in the working environment. The second, 
biological monitoring, is the indirect qualitative and quantitative 
assessment of exposure of a group or of an individual to noxious agents 
present in the workplace.
The objectives and requirements of biological toxicology 
monitoring are given in table 2.2 below.
TABLE 2.2.
Objectives and requirements of biological toxicology monitoring.
1. Determining the presence and extent of human health hazards from
exposure to the toxic metal.
2. Establishing reference base lines of concentration ranges in the
general population for the metal being considered.
3. Establishing dose response relationships.
4. Correlating toxic metal concentrations with sources of contamination 
and determining risks to defined target populations.
5. Determining trends in the toxic metal concentrations in humans.
A consistent picture emerges from the Cr toxicology 
literature. The important points are that contamination of the air in 
the working environment by Cr(VI) can lead to high Cr body levels 
because of the ability of Cr(VI) to cross the membranes lining the 
respiratory tract. Furthermore Cr(VI) compounds of moderate solubility 
appear to be the most dangerous because they can.generate high Cr 
levels at the cell nucleus. However significant Cr(III) absorption 
takes place only via the gastrointestinal tract, about 0.2% of ingested 
inorganic Cr(III) being taken up.
Plasma and urinary total Cr levels appear to have limited value, 
and may be useful only for comparative work on workers exposed to 
similar Cr compounds and under similar conditions.
Lewalter et al (6) investigated the use of Cr levels in 
isolated erythrocytes for toxicological monitoring purposes. The 
authors reported that Cr(VI) taken up by erythrocytes are stored in the 
cells for the rest of the cells' life span. Subjects were found to vary 
in their "plasma reduction capacity" (ability to reduce Cr(VI) in their 
blood plasma) and thus to reduce the intracellular Cr burden. The
interindividual differences observed were considered to be genetically
determined. The conclusions of the author was that the "isolated
erythrocyte" Cr level was a useful biological monitor for exposure to 
highly soluble chromates. However, more work was needed with low 
solubility and insoluble chromates before firm conclusions about these 
could be drawn.
2.1.4. Conclusions, chromium toxicity.
The measurement and strict control of the Cr(VI) concentration 
in the workplace atmosphere appear, to be the primary safety measures
to be undertaken. A biological monitoring technique which takes account 
of individual variations in susceptibility and does not depend on the 
measurement of Cr is needed. The test should be analogous to the 
determination of erythrocyte levels of 5-aminolaevulinic acid 
dehydratase (ALAD) and free protoporhyrin for the detection of lead 
poisoning. Low (ALADj and high free protoporphyrin levels that are not 
due to exposure to Pb are found in some subjects. However this is not a 
disadvantage for "industrial" monitoring purposes as these individuals 
are clearly not suitable for work involving exposure to Pb. The "plasma 
reduction capacity" mentioned earlier could be a useful screen test to 
eliminate individuals who are less suitable for work which exposes them
to Cr.
The conclusion to emerge with respect to Cr supplementation 
from this necessarily brief and limited discussion of Cr toxicology, is 
that ingestion of extremely modest, that is less than 250 ;ug per day of 
Cr(III) for a limited time is acceptable. The tests to be carried out 
over the supplementation period must be of well proven reliability to 
justify the exercise. However the administration of Cr supplements to 
pregnant subjects should be avoided until more information about human 
Cr metabolism is available.
2.2. ESSENTIALITY OF CHROMIUM.
Mertz and Schwartz (7) were the first to produce evidence that 
Cr is an essential trace element. In 1959 they observed that rats fed 
on a diet of Torula yeast, which is deficient in Cr, developed impaired 
glucose tolerance.
Investigations depending wholly on Cr determinations will not be 
presented in this chapter, because chromium measurements on biological 
fluids, appear to be too inconsistent for reliable conclusions to be 
made from them.
2.2.1. Essentiality in Animals.
The evidence that Cr is an essential trace metal for animals 
comes almost entirely from rats maintained• on an artificial low Cr 
diet.
2.2.1.1. Artificial low chromium diet.
Mertz and Schwartz as mentioned above were the first in this 
field. They observed that rats fed on a Torula yeast-sucrose diet 
developed glucose intolerance which was improved by Cr(III) salts 
alone of the 40 elements tested, although, Mn(II) did produce a slight 
benefit.
Schroeder (8) produced similar evidence to Mertz and Schwartz in 
1966. However, by preventing airborne contamination Schroeder 
maintained more strictly controlled conditions producing a greater 
degree of glucose intolerance. Nevertheless he did report a number of 
qualifications on the evidence supporting Cr as an essential trace 
metal. Schroeder acknowledged that a diet free from Cr was not 
available. Therefore a marginal or moderate state of deficiency only 
had been induced in the rats. Furthermore the characteristic renal 
lesions of human diabetes mellitus were not detected on microscopic
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examination of the tissues. Nevertheless a disturbed glucose metabolism 
simulating mild maturity onset diabetes of man was observed. The 
evidence against Cr deficiency as the cause of the glucose intolerance 
is not insubstantial. Schroeder noted that the diet was undoubtedly 
deficient in nutrients other than Cr. And that male rats supplemented 
with vitamin E exhibited glycosuria whether or not Cr was fed, possibly 
as a result of the high sucrose diet.
Davies et al (9) fed rats on a commercial Teklad diet containing 
30% Torula yeast as the sole protein source, plus 60% sucrose with fat, 
minerals and vitamins. The diet was stated by the manufacturers to have 
a Cr content of 0.12 jag /g. However Davies found two batches of the 
Teklad diet to have a Cr levels of about 0.47 and 0.78 ;ug Cr/g. 
Commercial rat cubes contained about 0.82 p.g Cr/g. Nevertheless the 
rats fed on the Torula yeast diet showed growth retardation as reported 
by both Mertz and Schroeder, referred to earlier. Adipocytes were 
isolated by Davies from rats fed on commercial cubes and from rats fed 
on the Teklad diet. However only the adipocytes from the rats fed on 
the Teklad diet showed the responses to yeast fractions in a test with 
suboptimal insulin concentrations that is generally accepted as 
indicating "Cr deficiency". This test is discussed later in the GTF 
section of this chapter. Davies found that Cr supplementation of the 
Teklad diet did not improve the growth rate, or alter the behaviour of 
the adipocytes. Furthermore evidence was produced by Davies indicating 
that the high sucrose content of the Teklad diet was responsible for 
the poor growth and abnormal adipocytes.
2.2.1.2. Rate of absorption of glucose in Channa punctatus.
Sastry and Sunita (10) studied the effects of Cd and Cr on the 
rate of absorption of glucose from the intestine of the snakehead fish, 
Channa punctatus.
All concentrations of Cd decreased the rate of glucose 
transport. However the authors found to their evident suprise that Cr 
increased the glucose absorption rate at all concentrations examined. 
The highest rate of absorption occurring at O.OOImM Cr. Increases above 
this level gradually decreased the absorption rate.
2.2.2. Essentiality in man.
The only real evidence supporting Cr as an essential trace 
metal in man comes from three subjects, all women on long term total 
parenteral nutrition. There is perhaps a very modest support from
investigations into the protein calorie malnutrition of infancy- 
occurring in certain deprived areas and also from certain iron overload 
conditions.
2.2.2.1. Subjects on total parenteral nutrition.
Jeejeebhoy et al (11) thoroughly documented the case history of 
a female aged 40 years who had been receiving total parenteral 
nutrition for five years. The patient showed an unexpected 15% weight 
loss and peripheral neuropathy. An intravenous glucose tolerance test 
showed reduced glucose clearance. Moreover a respiratory quotient of
0.66 indicated that fat was being used as a major energy source. The 
patient showed a limited response to insulin therapy. However 250 ;ug 
of Cr daily as the chloride, added to the infusate restored glucose 
metabolism to normal within two weeks. The glucose intake had to be 
reduced over the next 5 months to prevent the patient becoming 
overweight. A maintenance dose of 20 ,ug Cr per day was sufficient to 
keep the patient well for the next 18 months.
Freund et al (12) reported a second case of apparent severe Cr 
deficiency. The glucose intolerance developed after 5 months of total 
parenteral nutrition following complete bowel resection. The patient a 
woman aged 45 years went into a hyperglycaemic hyperosmolar nonketotic 
coma. Concomitantly a metabolic encephalopathy developed. Insulin 
therapy produced a limited improvement only, with erratic glycosuria. 
However Cr supplementation of 150 ;ug Cr chloride per day was started 
after 7 months. Within a few days insulin was not needed to control the 
blood glucose. Furthermore the encephalopathy cleared completely and 
the patient started to gain weight.
The third case report, by Brown et al (13), was very similar to 
the other two. The patient lost weight on a regimen on which she had 
previously maintained a stable weight as in the other two cases, but 
unlike the earlier subjects this patient did not have clinical evidence 
of neuropathy or encephalopathy. The glucose intolerance began after 
about 7 months of total parenteral nutrition, very similar to the 5 
months reported by Freund et al. Jeejebhoy's patient had been on "TPN" 
for 3.5 years before glucose intolerance developed. However, the 
chromium content of the nutrition regimen received by this patient may 
have changed over this long period, although clearly any change that 
occurred was unplanned. All three patients responded after 3 to 5 days 
of chromium therapy and exogeneous insulin was then no longer required.
The plasma Cr levels reported in the three cases above show the 
usual inconsistencies. Jeejebhoy reported blood levels to be 0.55 ;ug 
Cr/L with a normal range of 4.9 to 9.5 jug/L. Freund reported serum Cr 
levels 50 lig/L for the patient in his report, a normal range of 50 to 
90 )ig/l> was quoted. The plasma Cr level reported on Brown's patient was 
1.0 ,ug/L before treatment, with a reference range of 18 to 38 p.g/h. 
However, the follow-up plasma.Cr levels remained unchanged at 1.0 ;ng/L 
after 1, 3 and 12 months of chromium supplementation, despite the 
subjects return to normal glucose tolerance.
2.2.2.2. Protein-calorie malnutrition of infancy.
Gurson et al (14) reported that a single dose of Cr increased
the glucose removal rate in 9 out of 14 cases of protein-calorie
malnutrition in Turkey.
Hopkins et al (20) reported that Cr deficiency was important
in the development of disorders of carbohydrate metabolism in
protein-calorie malnutrition in both Nigeria and Jordan. Whereas
defective utilization of glucose in protein-calorie malnutrition in 
Egypt could not be attributed to a lack of Cr.
Carter et al (16) also found no evidence of Cr deficiency in
protein-calorie malnutrition in Egypt.
2.2.2.3. Idiopathic haemochromatosis.
Sargent et al (17) postulated that patients with
haemochromatosis had reduced Cr retention due to exclusion of Cr by Fe 
at metabolic binding sites. The iron transport protein transferrin also 
transports Cr, and is highly saturated by Fe in idiopathic
haemochromatosis. The diabetes seen in some haemochromatosis patients 
was postulated by Sargent to be possibly caused by Cr deficiency,
rather than by deposition of Fe as haemosiderin at the sites of insulin 
production in the pancreas. Sargent administered 51Cr(III) to 5 normal 
males and to 11 patients with idiopathic haemochromatosis. The
retention of 51 Cr was measured with a whole body counter for 8 months 
and blood levels measured for 40 to 80 days. Sargent found that the 
zero time intercepts of the slopes of both the whole body retention 
curves, and of the blood clearance curves were significantly different. 
Moreover the data on patients after Fe depletion were not significantly 
different from the data derived from normal subjects.
Lim et al (18) carried out a similar study on 16 subjects, 5 
normals and 11 patients with varying degrees of haemochromatosis. The
clearance of Cr from different body organs, and from the whole body was 
reported to be more rapid in the patients with "fully developed" 
haemochromatosis.
The two papers above are both consistent with the hypothesis 
that Cr absorption and transport, are sensitive to the degree of 
saturation of transferrin by Fe. The iron overload patients showing an 
increased incidence of diabetes mellitus are all of types with a high 
degree of Fe saturation of transferrin. However heavy haemosiderin 
deposits in the pancreas are associated with a high transferrin 
saturation.
Bothwell et al (19) commenting on diabetes and 
haemochromatosis states that it was assumed in the past that the 
diabetes was due to damage to the islets of Langerhans, and low levels 
of insulin have been demonstrated in some patients supporting this
supposition. However it is apparent that other factors unassociated
with tissue damage by Fe deposits are involved. The prevalence of
diabetes among first degree relatives of diabetic patients with 
haemochromatosis is much higher than among the first degree relatives 
of non diabetic haemochromatotics. The diabetes seen in the relatives 
of the diabetic haemochromatotics is of the maturity onset type with 
high levels of circulating insulin. The hepatic damage seen in the type 
of iron overload under discussion may also play a part as cirrhosis is 
associated with both insulin resistance and hyperglucagonaemia.
Heilmeyer et al (20) thoroughly documented the case history of a 
7 year old child with congenital atransferrinaemia. The parents of the 
subject both had reduced serum transferrin levels and the child had 
no detectable transferrin. The subject suffered from severe iron 
deficiency anaemia with iron deposits in many tissues, including the 
pancreas. The iron deposits presumably resulted from the many blood 
transfusions, which had been given at three monthly intervals since 
birth. However the report contained no reference to any disturbance of
glucose metabolism. The regular blood transfusions alone would not 
supply sufficient Cr on the basis of the report on the distribution and 
binding of Cr by Lim et al (18), see table 2.4 in section 2.5. Moreover 
the parents were not reported to have shown any evidence of glucose 
intolerance although, as reported above, they both had low transferrin 
levels. One must conclude that transferrin does not have the same vital 
role in the useful transport of Cr that it has with Fe.
The diabetes seen in idiopathic haemochromatosis is clearly not 
fully understood, perhaps Cr deficiency may be a factor, in a condition 
with a varying spectrum of contributing causal factors.
2.2.2.4. Marginal chromium deficiency.
Investigations into the effects of Cr supplementation on 
subjects with possible marginal Cr deficiency, have usually involved 
groups of elderly individuals with relatively mild glucose intolerance, 
of the non-insulin requiring type. The maturity onset diabetic produces 
normal, or above normal quantities of insulin, and is a popular choice 
as a possible marginal Cr deficiency subject.
A variety of tests have been chosen to determine if a response 
to Cr supplementation has occurred. However tests of glucose tolerance 
are common to all investigations. The change in plasma lipids, and in 
the insulin response to a glucose challenge, have also been monitored 
by some workers. The total cholesterol/high density lipoprotein 
cholesterol ratio together with the glycosylated haemoglobin levels, 
are probably the ideal parameters for objectively assessing if 
supplementation has been of real benefit to the recipient.
Table 2.3 below lists reported responses on subjects with 
possible marginal Cr deficiency to Cr supplementation. It can be seen 
that the reported responses are inconsistent and even contradictory, to 
such an extent that no reliable conclusions are possible.
2.2.2.5. Marginal chromium deficiency in pregnant women.
The glucose intolerance found in pregnancy was first reported by 
Hurwitz et al (27) in 1942, and the possibility that increasing demand 
for Cr by the foetus, could lead to maternal Cr deficiency, on a diet 
of borderline sufficiency, has been a popular hypothesis for the 
glucose intolerance of pregnancy.
Knopp et al (28) reporting on metabolic adjustments in normal 
and diabetic pregnancy, posed the question: whether the foetus acts
solely as a parasite draining fuels from the mother, or whether the 
mother adapts to augment the supply of energy fuels to the foetus? The 
authors concluded that there is a maternal "push", as well as a foetal 
"pull", and the changes in carbohydrate and lipid metabolism seen in 
"normal" pregnancy is adaptive, enabling a greater push of nutrients to 
take place during the peak foetal fuel requirements of the third 
trimester. Clearly completely reliable analytical data on Cr levels 
would be difficult to interpret, even if such data were available.
TABLE 2.3.
Responses of subjects with possible marginal chromium deficiency to 
chromium supplementation.
i) Key to code used.
Subjects.
A. Normal.
B. Intermediate glucose tolerance, in the normal/diabetic border.
C. Maturity onset diabetic, diet controlled.
D. Maturity onset diabetic, taking oral antidiabetc medication.
E. Maturity onset diabetic, on insulin.
F. Juvenile onset diabetic, on insulin.
G. Diabetic, classification not stated.
Supplementation.
Cr. Cr admininstered as Cr chloride.
YB. Brewers' yeast, high GTF content.
YBE. Brewers' yeast extract, low GTF content.
YT. Torula yeast.
Response parameters.
GT. Glucose tolerance.
FBS. Fasting blood sugar.
HbG. Glysolated haemoglobin as fraction of the total haemoglobin.
Glysolation of haemoglobin occurs, in the erythrocyte in the
peripheral circulation during the 120 day life span of the cell. 
HbG is a good indicator of the long term integrated plasma 
glucose level.
IL. Insulin levels following a glucose challenge.Increased
sensitivity to insulin would be a positive response.
FIL. Fasting insulin level.
Cpept. Insulin C-peptide is secreted with insulin in equimolar amounts 
but is cleared from the circulation more slowly. Consequently 
the molar ratio of insulin to Cpept. in plasma changes in
response to the stimulation and suppression of insulin 
secretion. This test is useful in detecting insulin secretion in 
patients on insulin medication.
Choi. Total serum cholesterol.
HDL. High density lipoprotein cholesterol.
C/HDL. Total serum cholesterol/HDL cholesterol ratio. Widely used as a 
risk factor for coronary thrombosis. Low ratios favourable.
TGL. Triglycerides.
TABLE 2.3. continued.
ii) Data.
Reference. Supplementation. Subjects. Response.
Glinsmann 
et al.
(2 1 ).
Cr 60 pg/day.
15 to 120 days, 
24 days.
18 days.
140 days.
73 days.
133 days.
15 days.
F(1 ) 
D(1) 
C(1) 
E (1 ) 
DO) 
D(1)
Levine 
et al.
(22).
Cr 150 pg/day. 
120 days.
B(4)
120 days. B (6) >
Rabinowitz. Cr 150 pg/day.
et al. F(21).
(23). YB 6 pg Cr/day.
C(9).
YBE 18 pg Cr/day.
D (11 ) .
The three above supplements provided about equal 
amounts of Cr after correction for bioavailability. 
Placebo <0.4 pg Cr/day. All subjects received 
3 of the 4 supplements.
Vinson A(6)
et al. Yb 218 pg Cr/day.
(24) B(5)
6 months.
E(7) 
D(5)
GT. No change. 
GT. Improved.
GT. Improved.
GT. No change. 
GT. No change. 
GT. No change.
GT. Improved.
IL. No change.
GT. No change. 
IL. No change.
All categories 
of subjects 
showed no 
significant 
changes in :- 
FBS.
Choi.
TGL.
GT.
FIL.
Cpept.
HbG. No change.
HbG. Improved. 
C/HDL. Improved. 
HbG. No change 
C/HDL. No change 
HbG. No change 
C/HDL. No change
TABLE 2.3. continued.
Reference. Supplementation,
Hunt 
et al 
(25).
YB, YT as control
Martinez 
et al. 
(26).
Cr 200 pg/day.
70 days
Subjects, 
D( 22).
C(17).
B (8).
A( 13).
Response.
Both categories 
showed no 
significant 
change in :- 
FBS.
HbG.
FIL.
Choi.
HDL.
TGL.
GT.
IL.
GT.
IL.
Improved. 
Improved. 
No change, 
No change,
The vast majority of pregnancies are uneventful for both mother 
and child indicating that significant Cr deficiency cannot be common. 
Chromium supplementation in pregnancy could not be encouraged without 
much better evidence than has been produced at the present time.
2.3. BENEFICIAL CHROMIUM.
The normal level of Cr may not be the optimal. Evidence has been
presented by some workers indicating that Cr supplementation of the
diet can have beneficial results in man and in animals.
2.3.1. In Animals.
Abraham et al (29) investigated the effects of Cr 
supplementation on cholesterol induced aortic plaques in rabbits, and 
concluded that Cr supplementation had a significant effect on the
regression of these plaques.
The effects of Cr supplementation on rabbits fed on the very 
high cholesterol diet used by Abraham cannot be accepted as a reliable 
guide to the effects of Cr supplementation on humans on a normal diet. 
However, the results do indicate that Cr may be involved in lipid 
metabolism in mammals
2.3.2. Beneficial Effects in Man.
Atherosclerosis is a major health problem in the western world.
Insulin and hence Cr, if we accept GTF as an insulin cofactor, is very- 
much involved in lipid metabolism. LDL (low density lipoprotein) and 
triglycerides favour the development of atheroscleosis. In contrast HDL 
(high density lipoprotein) exerts a protective effect. Insulin has a 
lipogenic activity and if GTF enhances other effects of insulin but not 
its lipogenic effect then higher GTF levels could be beneficial.
Diabetics tend to have high lipid levels with a consequent increase in 
atherosclerosis.
Riales et al (30) investigated the effect of Cr chloride
supplementation on glucose tolerance and serum lipids including HDL 
cholesterol on a group of healthy adult men. Cr chloride was used 
instead of yeast to eliminate the possibility that any effects could be 
ascribed to some other factor present in yeast. In this controlled 
double blind study of 23 men aged from 31 to 60 years the test group 
ingested 200 ;ug Cr per day, for 5 days of each week, for 12 weeks. The 
Cr supplementation was reported to have resulted in a significant 
increase in HDL cholesterol, a decrease in body weight and a trend 
towards decreased triglycerides. Total cholesterol and LDL cholesterol 
did not change significantly.
Offenbacher et al reported in 1980 (31) an improvement in
glucose tolerance and plasma cholesterol after a supplementation study 
with brewer's yeast. However, a control group given Torula yeast also 
showed significant improvements in plasma cholesterol levels. The 
subjects were a group of healthy elderly individuals in a retirement 
home. Offenbacher et al repeated and extended the study in 1985 (39).
The subjects of this second investigation were from the same area of
New York city, and of similar age, 63 to 93 years, socioeconomic level 
and ethnic origins as the first group. The same health criteria were 
used to select the subjects in both studies. The 23 individuals in 
this second study were randomly assigned into one of three 
supplementation groups:
i) Brewer's yeast, 5 ,ng Cr per day (cf 10.8 ^ ig Cr/day in 1st study).
ii) Cr chloride, 200 ,ug Cr per day.
iii) Placebo.
The authors reported that no significant changes occurred in 
glucose tolerance , insulin, cholesterol or triglycerides in any of the 
three groups in this second study. Three possible explanations were 
considered for the different findings in the two studies :
i) Some substance in the yeast other than Cr was responsible for 
at least part of the improvement in the first study.
ii) Too little yeast Cr was fed in the second study.
iii) The free living group had adequate levels of dietary Cr and 
hence good Cr status at the begining of the study.
A beneficial effect from Cr supplementation has not been 
conclusively demonstrated.
2.4. GLUCOSE TOLERANCE FACTOR (GTF).
Mertz (33) reported the first biologically active compounds 
known to contain Cr in 1957. This compound was considered to be a 
dietary agent required for the maintenance of normal glucose tolerance
in rats, and consequently it was called "Glucose Tolerance Factor"
(GTF).
The term GTF appears to be associated with two characteristics. 
The first to be described was a high dietary availability. Oberleas 
(34) reports that absorption of Cr from a normal diet ranges from 0.5 
to 2%. In contrast absorption of Cr from GTF may rise to 25%. The 
second characteristic of GTF is the ability to enhance the effects of 
suboptimal concentrations of insulin on the oxidation of glucose. 
Adipocytes from the epididymal fat pads of diet induced glucose
intolerant rats are usually used. The stimulation of the rate of carbon 
dioxide production from glucose in a Cr deficient yeast bioassay 
system is also used, and as it is easier to perform it is often used 
for screening purposes.
A number of Cr containing compounds have been reported to have 
one or both the above characteristics. "Substances showing GTF 
activity" appears to be a better term than GTF, to avoid the
implication of a single molecular species. A single molecular species 
may dominate the GTF activity in human plasma, and if this can be
demonstrated the compound could be referred to as "Human GTF".
Toepfer et al (35), and Mirsky et al (36), isolated substances 
with GTF activity from yeast. The former reported that the active 
material contained Cr, nicotinic acid, glycine, glutamic acid and
cysteine, and that reacting these compounds together in vitro produced
a mixture of Cr complexes with GTF activity. Cooper et al (37)
investigated a mixture of the above compounds and also found that the
products showed GTF activity. Cooper and Toepfer concluded that the 
niacin-Cr-niacin axis was important for GTF activity.
Davies et al (9) reported the isolation of two small Cr free 
amino compounds with GTF activity from yeast. These substances, later 
identified as ornithine and a substituted lysine, both increased the 
effect of 10 ;uU of insulin to that of about 200 ;u.U, when 70 pg of
either were added, in the adipocyte test.
2.4.1. Mode of Action of GTF.
Christian et al (38) postulated that the formation of a ternary
complex between Cr, the A chain disulphide of insulin, and membrane
sulpK-ydryl groups facilitates the initiation of the hormone action. In 
support of this Simonoff (39) reported that polarographic studies have 
led to the hypothesis that GTF participates in a ternary complex with 
insulin and a membrane receptor site. Furthermore, Anderson et al (40) 
reported that a Cr containing fraction, isolated from a synthetic GTF 
mixture, was found to bind strongly to porcine insulin.
Mirsky et al (36), however, produced evidence that GTF
influences the transport of sugar to cells. GTF isolated from yeast was
found to increase carbon dioxide production from glucose, fructose, 
mannose and galactose, by several yeast strains, when grown on a Cr 
depleted medium. The increased production from galactose, which is
known to differ from glucose in the initial metabolic steps, together
with the ineffectiveness of GTF on a cell free extract, and the results 
of a Michaelis plot for carbon dioxide production, support the 
hypothesis that GTF influences the transport of sugar to the cells.
Potter et al (41) using the hyperglycaemic clamp technique 
developed by DeFronzo et al (42), reported that Cr supplementation of 
glucose intolerant older people, resulted in improved glucose 
utilisation, and increased beta cell sensitivity to glucose. However 
tissue sensitivity to insulin was not significantly changed, and an 
assay of erythrocyte insulin receptors failed to detect any significant 
change. Potter's findings are consistent with increased glucose 
transport after Cr supplementation.
The increased rate of glucose absorption reported earlier in 
Channa punctatus (10) after exposure to Cr, also supports increased 
transport of glucose as a mode of action of GTF.
The increase in insulin sensitivity reported by some workers 
would favour the hypothesis of an insulin GTF complex. However, many
investigators have found no significant change in insulin levels after 
Cr supplementation, even in subjects who have shown improved glucose 
tolerance.
2.5. DISTRIBUTION AND BINDING OF CHROMIUM.
Lim et al (18) investigated the kinetics of Cr(III) in the human 
body using a whole body scintillation counter. The Cr in the plasma was 
found to be 95% protein bound in equilibrium with 5% unbound or bound 
to small molecules. The plasma Cr was reported to be in equilibrium 
with three clearly defined tissue compartments, with fast, medium and 
slow transfer rates. Each imaged organ appeared to contain varying 
proportions of each compartment. Table 2.4 gives details of the three 
compartments, a plasma level of 0.1 p.g Cr/L was assumed. The slow 
compartment was considered to be a storage compartment, whilst the 
medium compartment could represent a short term borrowing pool. The 
kidney was reported to clear the unbound plasma Cr. A daily excretion 
of about 0.11 ;ag/day was calculated for the derived model.
TABLE 2.4.
The distribution of chromium in the human body.
Compartment. 
Fast.
Medium.
Slow.
Plasma.
Half life.
0.5 to 12 hours.
1 to 14 days.
3 to 12 months.
Tissue.
Adipose 
and muscle.
About equal in 
adipose, muscle 
liver and spleen. 
Liver and spleen.
Total Cr jug, 
0.13
0.8
24
0.3
Graf-Harsanyi et al (43) investigated the distribution of Cr in 
a sample of lyophilised animal serum. The proteins were separated using 
gel-filtration, measured using conventional spectrophotometry at 280 
nm. The Cr concentration was determined using atomic absorption 
spectrophotometry with electrothermal atomisation. Two chromium 
containing fractions were found. One was in the high molecular weight 
range, in the macroglobulin group. The second fraction was found among 
proteins of low molecular weight, such as albumin and transferrin.
2.5.1. Transferrin.
The iron transport protein transferrin has two Fe binding sites, and is
normally maintained at 30% saturation, so that spare sites are 
available. The two sites although similar are not identical. Harris 
(44) reports that the Fe site preference is pH dependent, but only one 
site will bind Cr. Mn and Cu are also bound by transferrin. The release 
of Fe by transferrin is very dependent on pH. Bates et al (45) found 
the half life to be 14 hours at pH 7.5, whereas at pH 4.1 the half 
life was 2 seconds.
Cr in blood plasma appears from the references cited to be 
present in three pools. The smallest pool, in which the Cr is bound to 
small molecules represents about 5% of the total, and is susceptible to 
excretion by the kidney. The other two pools consist of protein-bound 
Cr. In one of these pools the Cr is bound to relatively low molecular 
weight proteins, transferrin predominating. The remaining Cr is bound 
to alpha-2 macroglobulin. The transferrin bound Cr should be readily 
released in acid solutions.
2.6. ASSESSMENT OF CHROMIUM STATUS.
The only conclusive test for Cr deficiency at the present time 
is the response to supplementation using inorganic Cr, and only 
subjects with gross deficiency can be unequivocably diagnosed.
The relative response following a glucose challenge has been 
proposed and investigated by many workers for the establishment of Cr 
status. However this parameter depends on the determination of Cr 
levels in plasma/serum and or urine, and is discussed in detail in 
chapter VIII.
2.7. CONCLUSIONS.
The three cases of gross Cr deficiency in subjects on long term 
parenteral nutrition, represent the only convincing evidence for Cr 
essentiality, certainly in humans and arguably in mammals. The three 
patients appeared to respond to inorganic Cr, and the inadvertent 
co-administration of an identical essential nutrient to all three 
subjects is improbable. The time interval before the development of Cr 
deficiency symptoms is consistent with the data in table 2.4.
The reports on rats maintained on a low Cr diet are not so 
convincing. There is some doubt about the Cr content of the diet, and 
evidence that the unquestionably high sucrose content of the diet may 
have been responsible for the observed glucose intolerance.
The contribution of marginal Cr deficiency as a significant 
factor in glucose intolerance, must be considered as not proven in the 
three classes of subjects, maturity onset diabetics, pregnant women and 
haemochromatotics, investigated.
Maugh (46) reported that insulin levels are normal or high in 
maturity onset diabetics, whereas insulin receptors are reduced. 
Investigations of Cr supplementation to maturity onset diabetics have 
failed to produce consistent reports of increased insulin sensitivity, 
or increased binding of insulin to cell receptors.
The absence of clear evidence that Cr supplementation has a 
remedial action on individuals with mild glucose intolerance does not 
preclude beneficial effects on normal subjects. Clearly a metabolic 
abnormality not due to Cr deficiency, could exert a controlling effect 
not susceptible to Cr supplementation.
The reliable demonstration of a beneficial effect from Cr
supplementation in humans, clearly requires a large scale long term 
clinical trial, and there are possibilities of marginal harmful 
effects. Laboratory tests would have only a minor role in this
investigation. Inorganic Cr, not yeast would have to be used to 
eliminate the effects of other factors present in yeast.
2.8. THE PROPOSED INVESTIGATION.
The determination of Cr in plasma/serum or urine is not an easy 
task, that is clear from the lack of agreement on a normal range. The 
"probable normal range" has been steadily revised downwards and the
true level, is probably near the detection limit attainable at the 
present time, when the matrix problems are taken into account. The 
diagnosis of chromium deficiency even if Cr levels are a reliable 
guide, must depend on the ability to identify values below the normal 
range; a very exacting demand. The response to a glucose challenge of 
the four parameters below may be a more realistic investigation to 
undertake, and a response would itself, be some evidence of an 
involvement by chromium in glucose metabolism. Analytical techniques 
for the determination of these parameters are necessary before their 
value in the establishment of chromium status can be investigated. 
Parameters.
1. Total protein-bound serum chromium.
2. Alpha-2-globulin-bound serum chromium.
Parameters♦ continued.
3. Free serum chromium.
4. Urine chromium, this presumably gives an indirect, time integrated, 
measurement of the free serum chromium level, and is probably a more 
realistic goal, as the free serum chromium level is anticipated to be 
very low.
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CHAPTER III.
REVIEW OF CHROMIUM DETERMINATIONS ON HUMAN SERUM/PLASMA 
AND URINE.
3.1. SERUM AND URINE CHROMIUM CONCENTRATIONS REPORTED IN THE 
LITERATURE.
3.1.1. Serum/Plasma Chromium.
Table 3.1 below lists a selection of the published values for 
serum/plasma chromium, together with the analytical technique used.
TABLE. 3.1 .
Plasma or serum chromium concentration ;ug/L.
YEAR. ANALYTICAL MEAN. RANGE. NOTES. REFERENCE
TECHNIQUE.
1956 Spectrograph. 22 7 to 52 (1).
1956 Spectrograph. 185 82 to 308 (2).
1959 Spectrograph. 25 16 to 39 (3).
1960 Spectrograph. 28 9 to 56 (4).
1962 Spectrograph. 55 10 to 390 (5).
1966 Spectrograph. 171 / (6).
1966 Air/hydrogen 
flame AAS.
28 23 to 34 MIBK extraction 
after wet ashing and 
oxidation to Cr(VI).
(7).
1967 NAA. 0.7 to 3.2 (8).
1967 Air/hydrogen 
flame AAS.
30 11 to 66 MIBK extraction 
after wet ashing and 
oxidation to Cr(VI).
(9).
1968 Air/hydrogen 
flame AAS.
23.2 / Used method directly 
above.
(10).
1969 GC.ECD. 447 40 to 1440 tfacac extraction 
after acid digestion.
(11).
1971 Spectrograph. 28 <10 to 260 (12).
1972 AAS/ETA. 5.1 3.1 to 7.2 Wet ash pretreatment. (13).
1972 NAA. 9.3 / (14).
1972 NAA. 10.3 / (15).
1972 GC.ECD. 13.5 2.7 to 24 tfacac extraction 
after acid digestion
(16).
1972 NAA. 45 14 to 77 (17).
1972 AAS/ETA. 4.7 / Wet ash pretreatment. (18).
Al needles used.
YEAR
1974
1974
1974
1975 
1975
1975
1976 
1978
1978
1978
1978
1979 
1979
1979
1979
1980 
1980
1980
1981
1982
1983
1984
TABLE.3.1. continued.
. ANALYTICAL MEAN.
TECHNIQUE.
AAS/ETA. 1.6
D2 bkgr.
Emission 3.1
argon/silver arc. 
Chemiluminescence. 150
AAS/ETA.
AAS/ETA.
Emission 
Electrical plasma. 
GC.MEED.
NAA.
<0.5
43
12
20.5
RANGE.
/
/
/
/
/
/
/
NOTES.
Direct injection. 
Stds. in dextran.
REFERENCE.
(19).
(20).
Wet ash pretreatment. (21).
(22).
Kansas City, Missouri. (23). 
Kansas City, Kansas.
(24).
AAS/ETA.
WI bkgr. 
NAA. 
NAA. 
NAA. 
AAS/ETA.
WI bkgr.
AAS/ETA.
AAS/ETA.
AAS/ETA.
AAS/ETA.
U he bkgr. 
AAS/ETA.
D2 bkgr. 
AAS/ETA.
D2 bkgr.
NAA.
AAS/ETA.
WI bkgr. 
AAS/ETA.
7.2 3.6 to 9.9 Dry ash, tfacac ext. (25).
0.16 0.04 to 0.35 Samples taken using (26).
polypropylene cannula.
0.14 / Wet digestion in fused (27).
silica tube.
1 .7 
6.0 
0.45 
0.075
(28).
(29).
(30). 
(31 ).Pretreatment- oxidation 
nitric acid/hydrogen peroxide. 
Stainless steel needle used! 
8.2 / (32).
0.7 (serum). Ash pretreatment. (33).
1.0 to 1.5 (Li heparin plasma).
2.9 (whole blood). Direct injection
2.0
4.6
1 .6
1 . 0  
0 .12
3.0
/
4.4 to 6.1
Direct injection 
dil.1/3 Triton X soln. 
Direct injection. 
Method of ref. (19). 
Direct injection 
Method of ref. (19).
(34).
(35).
(36).
(37).
(38).
(39)./ Direct injection.
Plastic catheter for samples, 
(whole blood). Pretreatment- wet (40).
oxidative digestion.
TABLE.3.1. continued.
YEAR. ANALYTICAL 
TECHNIQUE. 
1984 AAS/ETA.
1984 AAS/ETA.
Zeeman bkgr. 
1984 AAS/ETA.
WI bkgr.
MEAN. RANGE. NOTES. REFERENCE.
1984 PIXE.
1985 AAS/ETA.
1985 AAS/ETA.
WI bkgr.
0 .12
0.11
/ Siliconised needle (41).
plus PVC tubing for samples. 
10.6 to 31.8 (42).
/ Pretreatment- dry ash. (43). 
Siliconised needle 
plus PVC tubing for samples. 
8.5 7.6 to 9.4 MIBK extraction (44).
after wet ashing and 
oxidation to Cr(VI).
0.27 0.09 to 0.63 Pretreatment- (45).
partial digestion with bacterial protease. 
Siliconised needle plus PVC tubing for samples. 
0.56 0.012 to 1.0 Direct injection. (46).
Abbreviations.
AAS atomic absorption spectrometry.
ETA electro thermal atomisation.
GC gas chromatography.
ECD electron capture detector.
MEED microwave excited emission detector.
NAA neutron activation analysis.
PIXE proton-induced X-ray emission,
bkgr background correction.
D2 deuterium lamp.
WI tungsten iodide lamp.
MIBK methyl isobutyl ketone.
tfacac 1,1,1-trifluoro-2,4-pentanedione.
3.1.1.1. Discussion.
The obvious trend is towards lower mean values. The mean value 
in the decade starting in 1960 was 126 pg Cr/L, falling to 16 ;ug/L in 
the next decade and to 1.9 in the period from 1980 to 1985. AAS/ETA has
become the most popular technique and the two techniques AAS/ETA and 
NAA are the only ones to have produced reported mean values below 5.0 
)iq Cr/L. In the period from 1980 to 1985 ten of the eleven results 
reported were obtained using AAS/ETA and five of the mean values quoted 
were less than 1 jig Cr/L. Furthermore, three of the five mean values 
below 1 ;ug Cr/L were in the 0.1 to 0.2 jig/L range and one of the other 
two values was only slightly higher at 0.27 ;ug Cr/L.
A major cause of falsely elevated serum/plasma values appears to 
be contamination with extraneous Cr during the sampling procedure, and 
this will be discussed in detail in chapter VII. The published values 
of less than 0.3 u^g Cr/L were, with two exceptions quoted by workers 
who reported taking stringent precautions against sample contamination 
during specimen collection.
Three authors reported mean levels of less than 0.3 jig Cr/L 
prior to 1980, and one (Versieck et al (26)) used a polypropylene 
cannula for sample collection. However Vanderlinde et al (31) stated 
that a conventional stainless steel needle was used for the collection 
of samples which gave a mean serum chromium level of 0.075 ^ ug/L, and 
Kayne et al (27), in default of any specific details for sample
collection presumably also used conventional equipment. Stainless steel 
needles from different sources and even different batches from a
particular source may vary as sources of extraneous chromium: perhaps
Vanderlinde and Kayne were just lucky.
The four workers who reported mean values of less than 0.3 >ug 
Cr/L in the period from 1980 to 1985, avoided contamination at
venepuncture from the conventional stainless steel needle by using a 
plastic cannula, or combination of a short siliconised steel needle 
attached to a length of PVC tubing.
The four authors above, who reported values of less than 0.3 jig 
Cr/L, all used Perkin Elmer 5000 atomic absorption spectrophotometers 
equiped with HGA 500 furnaces. The important characteristic of this 
model appears to be the background correction capability, both tungsten 
iodide and Zeeman facilities are available. Three workers Anderson et 
al (41), Kumpulainen et al (39) and Veillon et al (43), used tungsten 
iodide whilst Offenbacher et al (45) used Zeeman. Kumpulainen used 
direct injection, and background correction must have been obligatory. 
Offenbacher used an unusual pretreatment process, partial digestion 
with proteolyic enzymes derived from bacteria, whilst Veillon used the
more traditional dry ash with magnesium nitrate, however both still 
found background correction was necessary. The last two teams of 
investigators, Offenbaker and Veillon enjoyed the luxury of Class 100 
clean areas for their pretreatment processes. Anderson may have used 
direct injection, he certainly did for urines but no details are given
or referred to for serum samples.
Simonoff et al (44) reported the high reference value of 8.5 ;ug 
Cr/L and claimed that losses of Cr as a volatile component during 
processing, and or the measuring process, was responsible for the lower 
values quoted in the literature. The evidence for and against the
existence of a volatile chromium component in biological materials, and
premature losses during processing and or at the ash stage of the ETA
cycle are discussed in section 3.4.1.
The main conclusions from the discussion above are that blood 
samples must be collected using a plastic cannula, and if AAS/ETA is 
used, then an instrument equipped with tungsten iodide or Zeeman 
correction is probably needed.
3.1.2. Urine Chromium.
Table 3.2 below lists a selection of the published values of 
Cr levels in urine, together with the analytical techniques used.
TABLE.3.2.
Urine chromium concentrations jug/L.
YEAR. ANALYTICAL MEAN. RANGE. NOTES. REFERENCE.
TECHNIQUE.
1969 GC.ECD. 36.5 4 to 196 tfacac extraction (11).
after acid digestion.
1972 AAS/ETA. 5.2 2.6 to 10.6 Wet ash using (13).
perchloric acid.
1973 AAS/ETA. 11.7 3.0 to 38 Direct injection. (47).
1978 AAS/ETA. 0.5 0.2 to 0.7 Continuum source (48).
WM. bkgr. echelle monochromator AAS.
1978 AAS/ETA. 1.1 0.2 to 2.2 Acid digestion. (27).
WI. bkgr.
1979 AAS/ETA. 8.5 / Direct injection. (49).
D2. bkgr.
1979 AAS/ETA. 0.4 / Acid digestion. (31).
WI. bkgr.
1980 AAS/ETA. 0.79 / Hydrogen diffusion (50).
D2. bkgr. flame shield supplement to argon.
TABLE.3.2. continued.
YEAR. ANALYTICAL 
TECHNIQUE. 
1980 AAS/ETA.
MEAN. RANGE. NOTES.
1981 AAS/ETA. 
WI. bkgr,
1982 AAS/ETA.
1983
1983
1983
1983
1984
1984
1985
AAS/ETA. 
D2. bkgr, 
AAS/ETA. 
WI. bkgr. 
ICPES.
AAS/ETA. 
WI. bkgr. 
AAS/ETA. 
D2. bkgr. 
AAS/ETA. 
AAS/ETA. 
WI. bkgr.
0.48
0.15
REFERENCE
(34)Low temp, ash & 
atomisation.
Direct injection. (51)
Values confirmed using 
i) stable isotope GC. MS. ii) CEWM-AAS.
0.72 (20 to 35 yrs.) Direct injection. (52) 
0.39 (47 to 69 yrs.)
0.8 0.2 to 2.4 Low temp. (53)
atomisation.
0.13 / Direct injection. (39)
1 .0
0.11
0.5
/ Selective preconcentration (54) 
using chelating resins.
/ Direct injection. (55)
/ Direct injection. (56)
4.9 / Wet oxidative digestion. (40)
0.31 0 to 0.77 Direct injection. (57)
Abbreviations.
AAS atomic absorption spectroscopy.
ETA electrothermal atomisation.
GC gas chromatography.
ECD. electron capture detector.
WM. wavelength modulation.
WI. tungsten iodide lamp.
D2. deuterium arc lamp,
bkgr. background correction.
MS. mass spectrometry.
CEWM. continuum source echelle monochromator wavelength modulated. 
ICPES. inductively coupled plasma emission spectroscopy.
3.1.2.1. Discussion.
The trend to lower values is not so marked for urine chromium 
levels compared with those for serum/plasma. The averages of the mean 
values from table 3.2. for the inclusive five year periods 71 to 75, 
76 to 80 and 81 to 85 are respectively, 6.2, 2.3 and 1.0 jig Cr/L. 
Chromium determinations on urine have been virtually exclusively by 
AAS/ETA.
Direct injection techniques are clearly more suited to urine 
samples than to serum/plasma specimens, because of the relatively 
simple matrix of the former, and much work has been done to overcome 
background absorption problems . The use of relatively low atomisation 
temperatures, with a carefully controlled ash treatment has been 
claimed to produce satisfactory results, even with deuterium arc 
background correction, by Halls and Fell (53), Routh (50) and Brodie 
and Routh (56).
Nomiyama et al (34), and Ping et al (52) claimed that with 
suitable furnace parameters background correction was not needed. 
Veillon et al (51), Kumpulainen et al (39) and Morris et al (57) used 
a tungsten iodide lamp for background correction. Veillon and 
Kumpulainen appear to have a significantly lower mean than the other 
workers. Anderson et al (55) using the technique developed by Veillon 
et al, also quoted a very low value, however for obvious reasons urine 
values in jug Cr referred to a given creatinine excretion are more 
comparable.
The lack of comparable data, that is jig Cr referred to a given 
creatinine excretion, is a handicap. The work of Veillon et al (51) 
and Anderson et al (55) indicates that urine chromium excretion must 
be less than 2 jig/day. Veillon reported that as only 0.5 to 1 % of
chromium in the diet was absorbed (radiotracer experiments), and as no 
reasonable diets in the U.S. could supply more than 100 p.g Cr/day, 
then urinary excretions above 2 jug/day, certainly on U.S. residents, 
were improbable. Anderson reported a mean excretion of 0.22 jig Cr/day 
and verified the urinary values by three independent AAS/ETA methods 
and by a stable isotope gas chromatography/mass spectrometer 
procedure.
Firm conclusions cannot be made from the above data, but if the 
U.S. dietary figures are correct, then the low values reported by 
Anderson, Kumpulainen and Veillon for urinary Cr are favoured. The
techniques using deuterium arc background correction, even with low 
temperature atomisation, and the direct injection methods with no 
background correction, must then be suspect.
3.2. ANALYTICAL TECHNIQUES USED.
A large number of analytical techniques have been used for the 
measurement of Cr in plasma/serum and urine, but only three have 
demonstrated a low enough detection limit for determinations below 1 
;ug/L. These techniques are atomic absorption with electrothermal 
atomisation (AAS.ETA), neutron activation analysis, (NAA) and stable 
isotope dilution mass spectrometry (IDMS). The most widely used by far 
is AAS.ETA, 85% of reports on plasma/serum, and 91% of reports on 
urine, published since 1980, have used this technique. The .relatively 
low cost and high throughput of AAS/ETA make this the method of 
choice, and it is the technique to be used in this study. The three 
above techniques are discussed below, AAS/ETA in detail the other two 
very briefly, as although the results obtained are of considerable 
significance the equipment used has very limited availability so far 
as the clinical chemist is concerned. The IDMS and NAA methods used 
by Veillon and Versieck respectively included a dry ash preliminary 
step, but both Veillon and Versieck investigated losses of "volatile 
Cr" during ashing procedures, and used conditions they considered to
be acceptable. The work they carried out in this field is included in
section 3.4.1.
3.2.1. Stable Isotope Dilution Mass Spectrometry.
Veillon et al (58) used this method as a reference method for 
the simpler direct injection AAS/ETA technique (51).
Lyophilised urine samples were ashed in an oxygen plasma
discharge and the Cr extracted as the trifluoroacetylacetone chelate. 
Samples were spiked with 50 Cr and the isotope ratio measured by
combining gas chromatography-mass spectrometry, using dual ion 
monitoring. The reported Cr level on a human urine pool was 0.32 ;ug/L, 
with a standard deviation of 0.019 (n = 4). The urine pool was also 
subjected to Cr determination using the novel continuum source, 
echelle monochromator, wavelength-modulated AAS described in section 
3-3.1.1. The results by this later method agreed within experimental 
error, with a mean of 0.34 p.q Cr/L, and a standard deviation of 0.1 
;ug/L.
55.
3.2.2. Neutron Activation Analysis.
Versieck et al (26), reported a mean serum Cr value of 0.16
jug/L, and this was the only mean value below 1 jag Cr/L measured by NAA
reported in the table.
Lyophilised serum samples corresponding to 1 mL of serum were 
irradiated, after dry ashing, in a nuclear reactor for 12 days at a
high neutron flux rate. A decay period of 30 days was followed by a
selective separation of Cr as chromyl chloride. The gamma spectra were
measured using a germanium/lithium detector. The blood samples were
collected using a polypropylene catheter into high purity quartz
tubes, and the latter were used throughout the procedure.
The results obtained are very useful as reference values but 
clearly the method is not one that can be widely used.
3.3. AAS WITH ELECTROTHERMAL ATOMISATION (AAS/ETA).
Flameless AAS is claimed by the leading instrument 
manufacturers to have a sensitivity for Cr of about 1 to 10 pg,
corresponding to 5 to 50 ;uL of a solution containing 0.1 to 1.0 ;ug 
Cr/L. However this is true only for dilute aqueous solutions, but not 
for complex biological matrices.
3.3.1. Matrix effects.
Analytical interferences in AAS/ETA can be severe even for 
elements and matrices that are normally interference free with flame 
AAS. Matrix effects are particularly severe with biological samples 
because of their complexity. Background effects constitute a major 
source of error, but other interference effects can cause problems. 
Physical effects can affect the "spread1 of the injected material 
within the graphite tube, and this will influence the analytical 
response. Matrix dependent chemical effects may cause an apparent 
enhancement or depression of the response, these may be classified as 
stable compound effects, volatile compound effects and vapour phase 
interferences.
3.3.1.1. Background correction.
Salt particles and smoke are particularly troublesome for 
chromium measurements on biological samples. Background absorption is 
much greater in the UV range and background correction is rarely 
required above 430 nm. The most sensitive resonance line for Cr 
measurements is 357.9 nm, low enough for significant interference by
background absorption and too high a wavelength for a deuterium arc, 
the usual background correction source to provide adequate intensity.
Guthrie et al (58) conclusively demonstrated in 1978, that 
AAS/ETA instruments in use at that time were simply measuring 
background absorption of urinary components. Deuterium lamps were used 
as the background correction continuum source, and these had 
insufficient intensity at the wavelength used to measure Cr in both 
plasma and urine. The Cr lamp must be run at a low intensity to 
balance the deuterium arc and a high gain setting is then needed. 
Halls and Fell (53) stated that the magnitude of the interference was 
increased with increasing gain used on the spectrometer, thus the use 
of background correction could increase the interference. However 
Halls and Fell found that reducing the atomisation temperature to 2400 
0 C completely eliminated the problem providing the urine was diluted 
with an equal volume of water before sampling. Routh (50) also claimed 
to have successfully used a deuterium arc for background correction in 
urine Cr determinations. Routh also used a low atomisation 
temperature, 2300 0 C. However he further reduced the background 
absorption, by using a hydrogen diffusion flame as a supplement to the 
inert gas flow through the graphite furnace. Routh claimed to have 
reduced the background absorbance to 1/3rd of its original value using 
this technique. However, as reported earlier, there is some evidence 
that these low temperature atomisation methods are not satisfactory.
A number of instrument modifications have been developed to 
overcome the inadequacies of the deuterium arc system.
Kayne et al (27) used a quartz-halogen lamp to give greater 
intensity at the Cr resonance line. Commercial instruments are now 
available with quartz-halogen lamps built in for background 
correction in the visible region.
Thompson (35) used the 358.5nm line of a uranium hollow cathode 
lamp as the background -correction source for plasma Cr measurements.
Guthrie et al (59) used the novel continuum source, echelle 
monochromator wavelength-modulated AAS developed by Harnly et al (60). 
This system is claimed to have the benefits of double beam and
background correction with a much simpler optical system.
Zeeman and Smith-Hiefjte background correction systems are 
available on commercial instruments. The currently available
background systems all give reduced sensitivity, but differ in other
characteristics.
3.3.1.1.1. Comparison of background correction systems.
Broad comparisons only are possible, as the different 
background correction systems have not been used under identical 
conditions. However continuum source background correction systems 
which use two lamps will give optimum performance only when both lamps 
are carefully aligned.
i) Sensitivity.
All background correction systems give reduced sensitivity. 
Continuum source (deuterium arc or tungsten iodide) correction 
requires a beam splitter and suffers an attendant 50% light loss, 
nevertheless this system has the highest sensitivity of any background 
correction system. The Zeeman system gives reduced sensitivity due to 
the light loss at the polarizer and because splitting is not usually 
complete, so that there is some analyte absorption included in the 
background measurement. The reduction in sensitivity using 
Smith-Hieftje correction is caused by some analyte atomic absorption 
occurring during the high current pulse. Zeeman and Smith-Hieftje 
are probably similar in terms of sensitivity. Intensity of the source 
is the limiting factor in the continuum source echelle monochromator 
wavelength-modulated AAS. The xenon source used by Harnly et al, has 
low intensity in the UV region and maximium output at 480nm. The 
sensitivity using this instrument for Cr appears from Harnly's report 
to be better than that given by the Zeeman system, but lower than that 
found with conventional AAS using a tungsten iodide correction source.
ii) Ability to handle high background absorbance.
The continuum source echelle monochromator wavelength-modulated 
AAS developed by Harnly et al is reported to be capable of handling a 
background absorbance of 3.0 units. Sotera and Kahn (61) report that 
the deuterium arc system can correct for background absorbances as 
high as 1.5 units at the Cr 357.9nm line in instruments of good 
optical design. Perkin Elmer claim that their Zeeman 5000 system can 
correct for up to 2 units of background absorbance, and 
Instrumentation Laboratory state that the Smith-Hieftje system on 
their IL Video 11 and IL Video 22 instruments can handle up to 3 units 
of background absorbance.
iii) Structured background.
The continuum source system (deuterium arc or tungsten iodide)
cannot cope with structured background. The other systems discussed 
above are reported by their principal protagonists to be able to 
correct for structured background.
iv) Spectral overlap.
Spectral interferences are rare in AAS, but the absorption band 
of some other element can overlap the emission line of the hollow 
cathode lamp characteristic of the analyte in some cases. The 
continuum source echelle monochromator wavelength-modulated AAS has 
the best reported performance in this field. Zander et al (62) 
claimed correction for spectral overlaps with differences as small as 
0.003 nm. Perkin Elmer report satisfactory correction with lines 0.02 
nm apart for their Zeeman 5000 system, whilst Instumentation 
Laboratory can only manage 0.05 nm for their Smith-Hieftje equipment. 
Deuterium arc and tungsten iodide systems are of course unable to cope 
with spectral overlap.
v) Linearity of the corrected curve.
The Zeeman system is the poor performer in this field, because 
as the concentration of the analyte increases, the sidebands broaden 
and begin to absorb progressively more of the perpendicular component 
of the source radiation. This analyte absorbance is seen as background 
by the correction system, and is subtracted, causing the working curve 
to bend over and eventually to reverse direction, according to 
Fernandez et al (63). The usable range is therefore limited to about 
0.5 absorbance units, which is ample for Cr determinations on 
serum/plasma or urine.
The calculation of absorbance for the wavelength modulated 
system is not easy, but Harnly et al (60) claimed to have developed a 
circuit.
vi) Cost.
The continuum source echelle monochromator wavelength-modulated 
AAS is probably the most expensive, as the monochromator must be of 
very high quality, and the electronics are complicated. The high 
production costs are presumably responsible for the absence of a 
commercial instrument of this type. The Zeeman system is also 
expensive. However the Smith-Hieftje equipment is even cheaper than a 
deuterium arc.
vii) Conclusion.
The important characteristics for Cr determinations on
biological fluids are probably sensitivity and ability to handle high 
background absorbances, because of the low analyte concentrations and 
smoke generating properties of the samples. The data in tables 3.1 and 
3.2 indicates that the tungsten iodide system is probably the most 
suitable, assuming that serum and urine Cr levels are below 0.3 ,ug/L.
3.3.2. Chemical Effects.
The depressed response by Cr in the presence of chlorides, 
which is attributed by some workers to the loss of Cr as the volatile 
halide, is discussed and investigated in chapter V, section 5.3.3.
3.4. PRETREATMENT PROCESSES.
The 5 techniques listed in table 3.1 which report values of 
less than 0.3 ;ug Cr/L for serum samples, include two by direct 
injection, one partial digestion using bacterial proteolytic enzymes, 
one dry ash and one wet ash. The reported urine levels below 0.3/ig 
Cr/L in table 3.2 are all derived from direct injection techniques.
The main controvery in the pretreatment field appears to be 
concerned with the loss of a volatile chromium fraction.
3.4.1. Volatility Losses.
Simonoff et al (44), found that dry ashing at 500 0 C resulted 
in apparent loss of up to 50% of the original Cr, but conceded that 
the lost Cr could be retained in acid insoluble residues.
Shapcott et al (64) reported in 1977 that losses of Cr occurred
from serum, liver , kidney and muscle when ashed at temperatures 
greater than 750 0 C. However no losses of exogenous 51 Cr added to
control tissues were found. The volatile Cr was attributed to "glucose
tolerance factor". In contradiction to this Shapcott (65) stated in 
1979 that no loss of 51 Cr from spiked urine and serum heated to 
1000 0 C occurred. The contradiction is that Shapcott in the later 
report appears to be accepting the 51 Cr spike as a reliable guide to 
losses of the native Cr.
Jones et al (66) reported no losses of 51Cr from endogenously 
labelled brewers yeast with oven drying, lyophilisation, or wet 
digestion even with high levels of chloride at up to 800 0 C.
Versieck et al (26) investigated the volatilization during dry 
ashing rigorously, in the dry ashing stage of the serum Cr 
determination procedure using NAA which produced a mean value of 0.16 
;ug Cr/L. No losses of radioactive Cr were recorded from serum dry
ashed at up to 450 0 C. The serum was from patients who had received 
51 Cr intravenously, and from rats fed for one week with 51Cr(III) 
and 51Cr(VI). Versieck also dry ashed organic material from the 
National Bureau of Standards (NBS). NBS bowens kale, orchard leaves 
and bovine liver were reported to show no losses after dry ashing at 
450° C. Finally, NBS brewer's yeast showed no losses when dry ashed 
at 800 0 C.
Simonoff et al considered that the tests carried out by 
Versieck were not conclusive as : "inorganic Cr is only slowly 
converted to a volatile (organic) form, the loss of which would not be 
detected by the foregoing, short term tests."
The tests carried out by Versieck appear to be reliable and the 
evidence for the structure of "GTF" certainly does not suggest a 
volatile compound, particularly in the presence of available oxygen. 
The loss of volatile Cr at the ash stage of the ETA cycle, which is 
discussed and investigated in chapter V, section 5.3.3., under 
conditions in which volatilization is more probable, appears not to 
take place.
3.4.2. Effectiveness of the Pretreatment Process.
The two aims of the pretreatment process for Cr determinations 
by AAS/ETA on serum or urine are to produce a solution in which the Cr 
is concentrated, relative to the original sample, and is suitable for 
measurement without the need for background correction, using ideally, 
primary standards for calibration.
The two methods for serum Cr determinations giving values below
0.3 pg Cr/L in which a pretreatment process was used, Veillon et al 
(43) and Offenbacher et al (45) both required background correction at 
the AAS/ETA stage. The process used by Offenbacher et al resulted in a 
dilution (1/2) of the original sample, and the method of additions 
was required for calibration. Veillon et al did not specify the volume 
of solvent used to dissolve the ash residue, and hence no 
concentration factor can be deduced. Veillion used bovine serum for 
the calibration standards.
3.5. DETECTION LIMIT.
There is no universally accepted definition of the "detection 
limit" of an analytical process, and many workers do not quote one, or 
give sufficient data for a relative value to be calculated by applying 
a standard formula. However, the 4 techniques for serum/plasma Cr
determinations giving mean values of <0.3 jig Cr/L, referred to below, 
gave broadly similar data as listed in table 3.3.
TABLE 3.3.
Data from four serum/plasma Cr techniques.
Reference. Serum/plasma Cr l^g/L. Blank Cr }ig/L. Detection
Mean. Range. Mean. Range. limit
(26). 0.16 0.04 to 0.35 0.048 0.03 to 0.07 /
(39). 0.12 / / / 0.05
(43). 0.11 <0.05 to 0.29 0.02 / 0.05
(45). 0.27 0.09 to 0.63 0.04 / /
It can be seen that the relationship between the detection 
limit and the normal range is in all cases, unfavourable for the 
confident identification of samples with levels below normal.
3.6. CONCLUSIONS.
The wide scatter of reported means for chromium levels in 
serum/plasma and urine confirm that severe problems are associated 
with these determinations.
The ability to confidently identify chromium levels 
significantly below the lower limit of the reference range requires 
that considerable improvements in the detection limit are made. The 
considerable advances that have been made in background correction 
systems have clearly contributed to published work in the last few 
years and have certainly narrowed the uncertainty around the normal 
range. However no background correction system is entirely 
satisfactory at the present time.
A major cause of falsely elevated serum/plasma values appears 
to be contamination with extraneous chromium during the sampling 
procedure. The published values of less than 0.3 ;ug Cr/L were, with 
two exceptions, quoted by workers who reported stringent precautions 
against sample contamination during specimen collection.
The available evidence indicates that the mean serum/plasma 
chromium level is certainly less than 0.3 and probably close to
0.15 )ig Cr/L.
The lack of comparable data for urines, that is _pg Cr referred 
to a given creatinine excretion is a handicap. The work of Veillon et
al (51) and Anderson et al (55) referred to earlier, indicated that
urine chromium excretion must be less than 2 jig/day.
3.7. THE PROPOSED INVESTIGATION.
The information derived from the topics discussed in this
chapter for the proposed investigation indicates that both serum and 
urine Cr levels are probably very low, <0.3 jug Cr/L for the former and 
a probable excretion of less than 1 jig/day for the latter. The methods 
developed, besides having the appropriate detection limit and 
sensitivity for the above low levels, should be such that loss of Cr
as a volatile component of the original samples, cannot a cc cj K
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CHAPTER IV.
THE DEVELOPMENT OF A METHOD FOR THE DETERMINATION OF 
CHROMIUM IN PLASMA/SERUM.
4.1. THE GENERAL DESIGN OF THE METHOD.
The principal features governing the design of the method are 
the very low concentration of chromium anticipated, and the extreme 
complexity of the matrix. A highly selective extraction producing a 
concentrated final solution with the minimum contamination by other 
serum constituents is required. The minimum number of stages and 
reagents should be used , and the ratio of sample volume to reagent 
volume must be as large as possible, to minimise the addition of 
extraneous chromium. The reagents used should be available with very 
low chromium levels, and be suitable for purification by relatively 
simple techniques. The final solution must be suitable for graphite 
furnace AAS without background correction. Simple pretreatments must be 
developed to separate the protein-bound chromium from the unbound, and 
to remove the transferrin-bound fraction from the total protein-bound 
metal.
The most promising technique to achieve a large selective 
concentration step is solvent extraction, using ideally an alkane or as 
second choice an arene. The vast majority of the constituents of human 
serum are too hydrophilic to be extracted by petroleum spirit. 
Cholesterol is the only major serum component that is soluble in this 
solvent, but it is virtually non-extractable unless the lipoproteins 
are severely denatured (Abell et al (1)). The vast majority of drugs 
are too polar to be extracted by petroleum spirit alone. The addition 
of a small amount of a more polar solvent such as hexanol is needed to 
extract the majority of the drugs commonly measured in the clinical 
chemistry laboratory. Fatty acids are extracted from acidified serum by 
alkanes but under the acid conditions used to remove the transferrin 
bound chromium the fatty acids are removed to waste at this preliminary 
stage. A second advantage of petroleum spirit is the low concentration 
of chromium in this solvent.
The two beta diketones 1,1,1-trifluoropenta-2,4-dione (tfacac) 
and 1,1,1,5,5,5-hexafluoropenta-2,4-dione (hfacac) have been used for 
chromium determinations on serum as reported in chapter III, and
although the chromium levels found using these materials appear to be 
too high, these beta-diketones are the obvious choice to produce alkane- 
soluble complexes from ultra low concentrations of Cr(III). The best 
path to isolate the chromium in a form suitable for AAS/ETA is probably 
by back extraction from a high boiling point petroleum spirit, using a 
volatile acid or base to minimise the solute concentration. 
Hydrochloric acid ; and ammonia are obvious choices as acid and base 
respectively, as both these are readily volatilised from the extract 
and are relatively easy to purify.
The protein precipitation pretreatment can be combined with the 
dehydration needed prior to the reaction with hfacac by using 
propan-2-ol. The dehydration step is required with hfacac because this 
reagent reacts with water to form a hydrate which is a weak complexing 
agent compared with the parent beta-diketone. The decantation and 
subsequent evaporation of the supernatant provides a simple separation 
of the non protein-bound chromium.
The ease with which iron can be removed from transferrin by 
dilute acid has been reported earlier (2.53). The transferrin — bound 
chromium, together with the non protein-bound chromium, can probably 
therefore be removed by precipitating the serum proteins under dilute 
acid conditions.
The experimental work in this and subsequent chapters is 
outlined in the main text and reported in more detail in an 
experimental section under references with the prefix "E" at the end 
of the appropriate chapter, which is denoted by the first digit of the 
reference number, for example, the details of procedure CDI are 
recorded in E401, at the begining of the experimental section of this 
chapter. The experimental details are, for the sake of brevity, 
recorded as ’’standard procedures" wherever possible. For example the 
serum chromium determination pretreatment processes have been recorded 
as CDI, CDII and CDIII, representing the procedures used at three main 
stages in the continuous development of the adopted method which is 
CDIII. The between main stage experiments are reported in terms of 
deviations from the appropriate standard procedure.
4.2. MONITORING THE RECOVERY OF THE CHROMIUM.
The obvious choice for monitoring the recovery of the Cr(III) 
present in the sample is 51Cr(III). A demonstration that the added
chromium exchanges with the native element is essential, and ideally 
the added chromium should represent less than 1% and certainly less 
than 10% of the native metal.
The first experiment demonstrated that added Cr(III) readily 
exchanged with the native element at 60° C, and rather slowly at 37° C. 
In this experiment radioactive chromium as both chromium chloride (0.38 
jag Cr/L) and crude GTF (preparation, Toepfer et al,(2)) (0.48 pg Cr/L) 
was added to two aliquots of a human serum pool. The percentage of 
radioactive chromium precipitated by propan-2-ol and by 0.6M 
perchloric acid from the two pools using procedure CD1 (E401) was
measured both before and after heat treatment at 3 7 0 C and 60° C. The
0 ' 037 C pool was sampled after 24 and 72 hours and the 60 C pool after
1 hour. The propan-2-ol precipitates from all samples contained 98%- 1
of the radioactive chromium. However the perchloric acid precipitated
widely disparate amounts from the "cold" chloride and GTF pools, but
increasing heat treatment brought these fractions together as the
radioactive chromium was redistributed. The redistribution of the
radioactive chromium is illustrated in figure 4.1.
The two cold labelled serum pools were subjected to
electrophoresis using the standard electrophoresis conditions described
in the experimental section (E404). The fractions of the radioactive
chromium extracted by the perchloric acid closely matched the
percentages bound by the beta-globulins, presumably by the transferrin
component of this serum protein fraction. The results are given in
table 4.1 below.
TABLE 4.1.
Fraction of 51 Cr extracted by perchloric acid compared with 
that bound by the beta-globulins.
Perchloric acid Beta-globulin
extracted. bound,
n. Mean. RSD. Mean. RSD.
Chromium
chloride spike. 4 74% 3.3% 76% 5.1%
Crude GTF spike. 4 28% 1.8% 27% 6.6%
t tests confirm no significant difference between 
perchloric acid extracted and beta-globulin-bound fractions.
A human serum pool was spiked with radioactive Cr(III) chloride 
at three different concentrations in a third experiment. Aliquots of 
the three labelled pools were then heated at 600 C for 30 minutes to 
speed up the equilibration process. Samples of the three pools both 
before and after the heat treatment were then subjected to 
electrophoresis using the standard conditions (E404). The results are 
illustrated in figure 4.2. A substantial fraction of the radioactive 
chromium bound to beta-globulin in the cold aliquot, migrated on 
heating to the alpha-2-globulin fraction, in the pool with the lowest 
concentration of added chromium. However no significant changes 
occurred on heating the pools with the higher concentrations of 
radioactive chromium.
The three experiments described above confirm that added 
chromium rapidly exchanges with the native element at 60° C. This 
ready exchange indicates that added radioactive chromium can give a 
meaningful guide to the recovery of the native element during the 
processing preceding the AAS chromium determinations. The size of the 
spike to be added in the final recovery checks must be decided in the 
light of the chromium levels found in the test samples. The agreement 
between the percentage of chromium extracted by 0.6M perchloric acid 
and that bound by the beta-globulin fraction supports the 
susceptibility of transferrin— bound chromium to removal by dilute 
acids. However this is reported in more detail in the section on 
protein precipitation.
4.2.1. The Distribution of Chromium in Human Serum Protein Fractions.
The chromium distribution results from the electrophoresis 
experiments described above are given in table 4.2 below.
The three major chromium containing fractions were albumin, 
alpha-2-globulin and beta-globulin. The chromium binding species in the 
beta-globulin fraction is presumably transferrin. The agreement between 
perchloric acid extractable and beta-globulin-bound percentages, and 
the capacity of this relatively small fraction to accept 80% of the 38 
jig Cr/L spike, as reported in table 4.2 above, support this.
The marked differences shown by the "cold" and "hot" aliquots of 
pool A were not reflected in the other two chromium chloride spiked 
pools. The redistribution from beta-globulin to alpha-2-globulin, and 
to a lesser extent to albumin, presumably cannot take place on a 
similar percentage basis at the higher chromium levels because a
FIGURE 4.1.
Comparison of the percentage 1 Cr precipitated by 0.6M perchloric 
acid before and after equilibration.
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limited number of binding sites are available. The crude GTF added to 
the serum at a similar chromium level to that in pool A showed 
relatively high binding to albumin and especially to alpha-2-globulin, 
without equilibration.
TABLE 4.2.
Distribution of 51 Cr in Human Serum Protein Fractions.
Chromium chloride spikes. GTF spike.
jag Cr/L. (A) 0.38 (B) 3.8 (C) 38 0.48
Cold. Hot. Cold. Hot. Cold. Hot. Cold.
Albumin. 1% 16% 5% 7% 8% 10% 30%
Globulins.
Alpha-1. 10% <1% 2% 2% 1% 2% <1%
Alpha-2. 3% 52% 14% 14% 9% 8% 43%
Beta. 86% 27% 78% 74% 79% 77% 27%
Gamma. 1% 5% 1% 2% 2% 3% <1%
Cold = no heat treatment.
Hot = heat equilibration (60 0 C for 1 hour).
The above observations provide some evidence that
alpha-2-globulin and or albumin may have some functional binding sites 
for human GTF and Kallee (3) reported that alpha-2-macroglobulin binds 
insulin and is probably responsible for the physiological transport of 
this hormone, with which "GTF" is often associated.
The observation by Graf-Harsanyi et al (4) discussed in chapter 
II that the protein-bound chromium in animal serum is mainly present in 
two protein fractions , namely transferrin and alpha-2-globulin is in 
general supported by the electrophoresis results above. The chromium 
precipitated under dilute acid conditions has been labelled 
"alpha-2-globulin— bound chromium" in this work, as this appears to be 
the major chromium containing component of the precipitate.
4.3. FLOW CHARTS.
Two flow charts have been introduced at this early stage to 
ensure that both the sample pretreatment process and the development of 
this process can be easily followed.
4.3.1. Flow Chart of the Pretreatment Process Developed.
Figure 4.3 is a flow chart for procedure CDIII, the method used
for the serum chromium determinations the results of which are reported 
and discussed in chapter VIII.
4.3.2. Development Flow Chart.
The development process outlined in figure 4.4 is the theme of 
this chapter. The extended description of the development process has 
been broken down into the same stages and follows the same order as 
given in the flow chart. The actual development process followed a 
reiterative pattern of course, and included contamination control and 
developments in the AAS/ETA area. Contamination control and AAS/ETA 
optimisation are described in later chapters.
4.4. SPECIMEN VOLUME.
The sample volume was progressively increased from 250 jjlL 
through 1000 ^ 1 to 5000 )iL as evidence for the very low concentration 
of chromium in human serum accumulated. The volumes of the reagents 
used were not increased in proportion and a steady increase in the 
sample derived Cr to reagent blank was achieved. A fall in Cr extracted 
from the surfaces of the containers used, relative to the sample Cr 
should also theoretically result from the increase in sample volume. 
All volumes used were finally reduced by 20% to increase the pipette 
"freeboard" to help in contamination control, enabling pipettes to be 
used at 80% of their maximimum capacity, an acceptable compromise 
between precision and contamination goals. The large sample volume is 
clearly a disadvantage, but is put into perspective by the problems 
associated with obtaining an uncontaminated blood specimen which 
involves discarding, for chromium determination purposes the first 30 
mL of blood after venepuncture with a stainless steel needle.
4.5. PROTEIN PRECIPITATION.
A reagent miscible with both petroleum spirit and water, and 
capable of precipitating the serum proteins, was required for the 
determination of the total protein-bound chromium. The miscibility with 
petroleum spirit was necessary for the penetration of the precipitated 
protein mass by the hydrophobic solvent. Propan-2-ol was an obvious 
choice and was found to be suitable both for total protein-bound 
chromium determinations and, plus 0.5M hydrochloric acid for 
alpha-2-globulin-bound chromium measure
Perchloric acid was initially used as the protein precipitant
FIGURE 4.3.
Method CDIII flow chart.
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1. Protein precipitation, 
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i) propan-2-ol for total 
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ii) 0.5M HC1 in propan-2-ol 
for alpha-2-globulin-bound 
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Roller mixer 15 min.
2. Wash,
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7 5 0 C overnight.
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Roller mixer 4 hrs.
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2.2M K HFO .
Roller mixer 1 hr.
7. Wash, 
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8.Back extraction, 
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Roller mixer overnight.
9. Evaporation, 
of NH.^  and water.
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10. Dissolve Cr(EDTA), 
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of unwanted Cr fractions 
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Cr(hfacac >3 .
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neutralisation of NH^ by 
phosphate.
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FIGURE 4.4.
Development flow chart (sheet 1).
1. Specimen volume (4.4
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ii) 1000 ul.
iii) 5000 yUL.
iv) 4000 jiL.
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2. Protein precipitation (4.5).
ii
TOTAL CHROMIUM 
Methanol. 
Propan-2-ol.
Very bulky precipitate, not 
easily washed, and only 851 
Cr pptd. Propan-2-ol ppt. 
superior, 981 Cr pptd.
b) "GTF" CHROMIUM.
i) 0 . 6M perchloric acid.
ii) 0.5M HC1 in propanol.
0.5M HC1 in propanol gives 
better recovery, dehydrates 
and precipitates, easier to 
purify.
hfacac gives higher recovery, 
and is easier to purify.
.3 . Complexing agent (4.6).
i) tfacac.
ii) hfacac.
4.Conditions for complex formation (4.7).
i) Dried ppt. plus toluene.
ii) Ppt. in propanol plus toluene. Development tohigher and more
iii) Ppt. washed free from propanol reliable recoveries.Increasingly robust 
with toluene. method.
iv) Toluene plus acetic acid 
containing 7.51 v.v. sulphuric 
acid.
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FIGURE 4.4. continued.
Development flow chart (sheet 2).
5. Extraction of Cr(hfacac) from the protein mass (4.8) .
i) Toluene.
ii) Petroleum spirit hot. Specificity improved.
iii) Petroleum spirit cold.
6. Removal of excess hfacac (4.9
i) Water only.
ii) 1M K2HF04 .
iii) 1M K2HF04 then water.
iv) 2.2M K^HPO ^ moderated by
acetic/sulphuric acid added 
earlier, then water.
Improved efficiency of 
excess hfacac 
extraction,
no significant increase 
in the loss of Cr.
7. The back extraction process (4.10).
i) NH^ then solution in Improved solubility
Q.001M perchloric acid after evap. after evaporation.
ii) NH plus EDTA, then dissolve
in 0.1M acetic acid after evaporation.
iii) NH^ plus EDTA, then dissolve Improved AAS/ETA
in 0.5M NH , 0 . 7M acetic acid characteristies.
after evaporation.
in. frGvt. alpha-2-globulin-bound chromium series but was found to give 
variable recoveries. Dilute (0.5M) hydrochloric acid in propan-2-ol was 
substituted, and only one wash in propan-2-ol was then required because 
of the concurrent precipitation and dehydration then possible.
The suitability of 0.5M hydrochloric acid in propan-2-ol was 
demonstrated using an equilibrated human serum pool spiked with 0.074 
pg/L of radioactive chromium. The changes in the fraction of chromium 
precipitated was investigated with respect to the mixing time before 
separating, the concentration of hydrochloric acid and the relative 
volume of reagent volume to sample. Aliquots of the pool were subjected 
to precipitation with 0.6M perchloric acid and to electrophoresis for 
comparative purposes. The losses during three washes with propan-2-ol 
after protein precipitation with propan-2-ol and 0.5M vr-» ^^panoQ-
Method CDII (E402) was followed except for the tests 
with perchloric acid, with this reagent procedure CDI (E401) was used. 
The results of these experiments are summarised in table 4.3.
TABLE 4.3.
i) Mixing time of precipitation varied, 0.5M HC1 in propanol.
Time. Mean. S.D.
15 min. 75.8 3.01
Overnight. 73.7 2.01
n = 4
t test indicates no significant difference.
ii) Three washes with propan-2-ol.
Percentage radioactive Cr removed. 
Precipitant. Precipitation. Wash 1. Wash 2. Wash 3.
Propan-2-ol. 3.3 0.4 0.4 0.3
0.5M HC1 in propan-2-ol. 18.8 5.4 2.0 0.7
n = 4
iii) Four concentrations of HC1 in propan-2-ol.
Percentage of radioactive Cr precipitated.
0.1M 0.2M 0.5M 1 .0M
Mean. 86.6 83.8 75.8 73.5
RSD. 0.7 1.1 1.3 1 .8
n = 4
78.
TABLE 4.3. continued.
iv) Comparison of % 51 Cr extracted by 0.5M HC1 in propanol 
with that extracted by 0.6M perchloric acid and with 
the % 51 Cr bound to beta-globulin.
Percentage radioactive chromium. 
0.5M HC1. Perchloric. Beta-globulin. 
Mean. 24 29 25
RSD. 4.1 4.9 2.0
n = 4
t tests confirm no significant difference between 
the three means.
4.5.1. Protein Fractions Precipitated by 0.5M Hydrochloric Acid in
Propan-2-ol.
A number of human serum samples were processed using method 
CDIII (E403) and the supernatants, from the precipitation stage with
0.5M hydrochloric acid in propan-2-ol, were subjected to total protein 
and albumin determinations. The methods used for the measurements of 
these two parameters are given in the experimental section under 
reference E407. The total protein and albumin concentrations of the 
original serum samples were also determined. A total of eight samples 
were tested.
The total protein and albumin determinations both confirmed that 
precipitation with 0.5M hydrochloric acid in propan-2-ol is selective 
in precipitating globulins, leaving albumin in solution. The albumin 
present in the supernatants was compared with that in the original 
serum samples, and the mean ratio was 95%, confirming that little 
albumin was precipitated. The total protein content of the supernatant 
fluids as a percentage of that in the original sample was compared with 
the original serum albumin concentration, expressed as a percentage of 
the total protein. The mean figure was found to be 97%, indicating that 
virtually all the protein not precipitated under the conditions used 
belongs to the albumin fraction.
4.5.2. Iron Concentrations in the Supernatants.
The iron concentrations of the supernatant fluids after the 
precipitation of the alpha-2-globulin-bound chromium using method CDIII 
(E403) was also determined.
The supernatants were diluted with 0.1M acetic acid (1:11) and
the iron concentrations measured using AAS/ETA as described in the 
experimental section (E408). The iron levels in the serum samples were 
measured by a standard spectrophotometric procedure using a centrifugal 
analyzer: this method is outlined in E408. Twelve human serum samples 
were tested and the data were subjected to a t test which indicated 
that there was no significant difference between the two means.
4.5.3. Protein Precipitation, Summary.
In summary, propan-2-ol and 0.5M hydrochloric acid in 
propan-2-ol appear to be useful protein precipitation reagents for the 
determination of total protein-bound serum chromium and 
alpha-2-globulin-bound chromium respectively. The treatment with 0.5M 
hydrochloric acid in propan-2-ol appears to be selective for 
precipitating the alpha-2-globulin-bound chromium. The other two major 
chromium binding protein fractions, albumin and beta-globulin make no 
contribution to the precipitate, as albumin is not precipitated and the 
metal bound to beta-globulin is eluted into the supernatant. Relative 
volumes of reagent to sample of 2:1 followed by a single wash with 
propan-2-ol gives reproducible precipitates sufficiently dehydrated to 
allow penetration of the protein mass by a hydrocarbon solvent. The 
propan-2-ol wash continues both the dehydration process and the removal 
of unwanted chromium fractions initiated in the protein precipitation 
step. The wash of the alpha-2-globulin-bound chromium precipitate also 
completes the removal of fatty acids released by the acid precipitant. 
The fatty acids if not removed at this stage are extracted by the 
hydrocarbon solvent leading to emulsion formation and interference at 
the wash and back extraction stages.
The total protein-bound chromium appears to represent about 96% 
of the total element, which agrees with the value quoted by Lim et al 
(4) of 95%, referred to in chapter II.
The modest change in the percentage chromium extracted by 
hydrochloric acid in propan-2-ol over the acid concentration range 0.1 
to 1.0M supports the precipitation of a species fundamentally different 
from that which bound the extracted metal in the untreated serum. The 
agreement noted earlier between the fraction of chromium bound to the 
beta-globulin as measured after electrophoretic separation and the 
chromium extracted by 0.6M perchloric acid was demonstrated again, and 
found to be not significantly different from that extracted by 0.5M 
hydrochloric acid in propan-2-ol. These observations are consistent
with the extraction of transferrin-bound chromium by 0.5M hydrochloric 
acid in propan-2-ol, and the use of this reagent for a simple 
separation of the alpha-2-globulin-bound chromium from the transferrin 
bound element.
4.6. COMPLEXING AGENT.
The two beta-diketones 1,1,1-trifluoropenta-2,4-dione (tfacac) 
and 1,1,1,5,5,5-hexafluoropenta-2,4-dione (hfacac) have been
successfully used to extract chromium from biological fluids, as 
reported earlier.
Savory et al (5,6) reported that it was necessary to 
completely destroy all organic compounds present in the sample before 
quantitative isolation of the chromium in serum using tfacac could be 
achieved.
An experiment using serum diluted 1 in 4 with phosphate buffer 
at p H  6.5 confirmed Savory's observation that serum components 
interfered, at least in aqueous solution. Negligible recoveries were 
given by the diluted serum although good recoveries were recorded on 
the phosphate buffer in the absence of serum, even with high Fe(III) 
concentrations (4 times that in normal serum).
The technique of precipitating the protein-bound chromium with
propan-2-ol, followed by drying the isolated precipitate involves the
minimum pretreatment. The two beta-diketones were compared in recovery
tests on the dried propan-2-ol precipitates from 250 jiL of serum spiked
with radioactive chromium as the chloride at a concentration of 0.6
/ig/L. The volume of propan-2-ol used was 2.5 mL and the precipitates owere dried at 95 C for 1 hour. The reagents added and the results 
obtained are listed in table 4.4 below. The tubes were thoroughly 
vortexed after adding the reagents and then heated for 24 hours at 
95 0 C. The tubes were then cooled to minus 20° C, then 1000 jaL of 
petroleum spirit was added and the chromium extracted on a roller mixer 
for 2 hours. The radioactive chromium was determined as described in 
E405 in the experimental section.
The results clearly demonstrated the superiority of hfacac: this 
diketone produced recoveries approximately double those recorded for 
tfacac under similar conditions.
81 .
TABLE 4.4.
Comparison of recoveries using two beta-diketones.
% Cr recovered. 
Beta-diketone. hfacac. tfacac.
1. 150 dichloromethane
plus 150 p.L diketone. 84 46
2. 250 xuL diketone. 88 /
3. 500 i^L diketone. / 33
4. 1000 jaL diketone. / 35
4.6.1. The volatility of chromium as the hfacac complex.
Si-Jung Yeh and Chin-Nan Ke (7) reported that the volatility of 
chromium as the hfacac complex was responsible for the poor precision 
recorded when using hfacac for chromium determinations. The possibility 
of variable losses occuring during the analytical process because of 
the volatile nature of the chromium, complex was therefore investigated, 
in a manner relevant to the process under development.
The chromium complex is only exposed to evaporation in solution
in petroleum spirit and at ambient temperature. The experiment carried
out was therefore designed to measure chromium losses under these
conditions. Radioactive chromium as the hfacac complex was dissolvedoin petroleum spirit (120 to 160 C b.pt.). Aliquots, of 2000 >iL 
volume were then distributed into 12 x 75 mm polypropylene tubes. Four 
tubes were capped as reference tubes, and four tubes were left uncapped 
in a fume cupboard with the fan operating for 24 hours. The radioactive 
chromium was then determined (E405). The test series of tubes were then 
left for a further 24 hours uncapped in the fume cupboard as before.
The petroleum spirit in the test series was then made up to the
original volume of 2000 pL before measuring the radioactive chromium. 
The results are given in table 4.5 below.
The volatility of the chromium complex when dissolved in
petroleum spirit appeared to be relatively low and this observation led
to an experiment to purify hfacac by distillation from petroleum 
spirit. The purification process is given in detail in chapter VII and 
demonstrated that only 0.28% of the added radioactive chromium was 
present in the distilled hfacac.
Table 4.5.
Retention of Cr hfacac complex In pet, spirit at ambient temps.
Retained radioactive chromium as a % of the mean reference value.
24 hours. 48 hours.
Mean. 101.8 99.13
SD. 0.9574 2.425
The mean count was 75352, and the mean background was 351. 
Statistical count RSD 0.36%.
The results discussed above confirm that reasonable handling at 
ambient temperatures should not result in significant evaporative 
losses of chromium, as the hfacac complex from solutions in petroleum 
spirit.
4.7. CONDITIONS FOR COMPLEX FORMATION.
The early experiments on serum used dried protein precipitates,
and the temperature used at the drying stage was investigated using
aliquots of a human serum pool spiked with either chromium chloride or
crude GTF, at radioactive chromium concentrations of 1.36 or 0.48 jag
Cr/L respectively. The samples were processed using method CDI (E401)
except that one series were dried at 37 0 C and a duplicate series were odried at 78 C. The procedure was terminated after extracting the 
chromium beta-diketone complex into petroleum spirit and the 
radioactive chromium recovery determined at this stage. The results of 
the experiment are listed in table 4.6 below. The results of the 
experiments clearly demonstrated that the lower temperature drying was 
superior, especially for the perchloric acid precipitates, as charring 
occurred with these at the higher temperature.
TABLE 4.6.
Chromium recoveries on dried protein precipitates.
Percentage radioactive chromium.
Propan-2-ol. 0.6M perchloric acid.
Precipitated. Recovered. Precipitated. Recovered.
37 0 C. 78° C. 37 0 C. 78° C.
Chromium chloride. 99 98 73 25 98 3
Crude GTF. 98 74 10 49 99 6
The optimum temperature for the complex formation step was 
investigated in a similar experiment to the one above, but only the 
chromium chloride spiked serum was used and the precipitates were all 
dried at 37 0 C. The recoveries were compared over the temperature 
range 80 through 100 and 120 to 140 0 C, at the complex formation stage. 
The protein precipitates after extraction of the beta-diketone Cr 
complex with petroleum spirit were dried and dissolved in 1000 p!L of 
5M sodium hydroxide to determine the percentage chromium not converted 
to the acetylacetonate. The radioactive chromium in the sodium 
hydroxide solution was determined using the usual technique (E405). The 
results of this experiment are summarised in table 4.7 below.
TABLE 4.7.
Optimisation of the complex formation temperature.
% 51 Cr retained in the protein precipitate. 
Temperature 0 C. Propan-2-ol. 0.6M perchloric acid.
i. ii. i. ii.
2 2 1 2
3 2 2 3
19 10 19 58
30 9 69 66
The results clearly demonstrated that the lower temperatures 
were much superior. The poor performance at the higher temperatures 
may be due to increased leakage of the volatile beta-diketone at higher 
vapour pressures, and this would also be consistent with the poor 
precision. The greatly increased charring of the organic material at 
the higher temperatures is possibly an important factor for the 
alpha-2-globulin-bound chromium recoveries.
The avoidance of the drying stage with the associated 
possibilities for contamination of the open vessels, and the inevitable 
time delay, especially at lower temperatures was seen as a clear 
advantage. The experiment described below was carried out to determine 
the minimum amount of hfacac that would give acceptable recoveries with 
a sample volume of 1000 jih. However "wet" precipitates were used and
0.5M hydrochloric acid in propan-2-ol was used as the protein 
precipitant for the alpha-2-globulin-bound chromium, and therefore a 
number of developmental changes are illustrated. The method used was
essentially CDII (E402) except that only 1000 pL of sample was 
processed, and the wash to remove the excess beta-diketone was with 5 
ml of water for 1 hour, and no phosphate buffer solution was used. The 
volumes of hfacac were 50 through 100 to 250 ;uL, and 1000 ;uL of toluene 
without acetic acid were added with the diketone. The residual protein 
masses were dissolved in IOOO.^uL of 5M sodium hydroxide solution and 
1000 ;uL of both petroleum spirit and the water wash solution were 
reserved to determine the chromium distribution. The results are 
summarised below in table 4.8. The sample used was a human serum pool 
spiked with chromium chloride at 1.0 ^ ug Cr/L and equilibrated at 60 0 C 
for 30 minutes.
TABLE 4.8.
Distribution of chromium, "wet” precipitates processed.
i) Radioactive chromium precipitated.
Propan-2-ol. 0.5M HCl/propanol.
Initial precipitate. 96.1% 50.5%
After propan-2-ol wash. 95.9% 42.0%
ii) Distribution of radioactive Cr as a % of that precipitated.
a) Propan-2-ol precipitates (total protein-bound Cr).
Vol. hfacac. Residue. Water wash. Pet. spirit. Ammonia. Total.
1. 50 pL 60% 11% <1% 23% 94%
2. 100 ^L 22% 8% 2% 56% 88%
3. 250 ;iL 2% 5% 4% 84% 95%
b) 0.5M HC1 in propan-2-ol (alpha-2-globulin-bound Cr).
Vol. hfacac. Residue. Water wash. Pet. spirit. Ammonia. Total.
1. 50 jiL 2% 7% 1% 68% 78%
2. 100 pL 3% 5% 2% 65% 75%
3. 250 pL 2% 5% 1% 68% 76%
The minimum quantity of hfacac needed for the total protein-bound 
chromium stream appeared to be 250 ;uL. However the conversion to the 
acetylacetonate was satisfactory in the alpha-2-globulin-bound series 
even with 50 ,ul of beta-diketone. The addition of a toluen soluble 
acid to the precipitates from the total protein— bound chromium series 
with the hfacac, appeared to be a possible way to improve the 
recoveries obtained with small volumes of diketone. The high conversion 
to acetylacetonate in the alpha-2-globulin-bound chromium stream was
presumed to be due to the lower pH in this series. Acetic acid was 
chosen as the toluene soluble acid, and improvements in the conversion 
of chromium to the beta-diketone derivative in the total protein-bound 
chromium series were seen. The addition of sulphuric acid (7.5 % v.v.) 
to the acetic acid resulted in further improvements. Sulphuric acid was 
added because it is a strong acid, free from water, and is miscible 
with a toluene, acetic acid mixture of the composition used.
The "missing" chromium in the alpha-2-globulin-bound stream was 
due to the poor separation of the aqueous and organic phases in this 
series, this in turn was caused by the failure of the water wash to 
remove the acidic substances, probably fatty acids generated during the 
processing of this series.
4.8. THE EXTRACTION OF THE CHROMIUM COMPLEX FROM THE PROTEIN MASS.
The precipitates in the total protein-bound chromium stream are 
in the form of leathery discs which are less readily penetrated by 
solvent than the loosely aggregated particulate precipitates produced 
by the 0.5M hydrochloric acid in propanol. The former were therefore 
used for investigations into the extraction of the chromium 
acetylacetonate from the protein mass.
A human serum pool was spiked with radioactive chromium at a 
concentration of 0.56 p.g Cr/L. Aliquots of the serum pool were then 
processed for total protein-bound chromium using standard method CDII 
(E402) up to and including step 4. The chromium hfacac complex was 
then extracted with 10 mis of either toluene or petroleum spirit (140 
to 160° C b.pt.), the details of the extraction conditions and results 
are listed in table 4.9 below.
TABLE 4.9.
Comparison of toluene and pet, spirit as extraction solvents.
Percentage 51 Cr extracted.
Roller mixer. Oven 75 0 C.
Ambient T,, 4 hrs. 1 hr. 2 hrs. 4 hrs. Overnight.
Toluene. (mean). 79.0 78.5 79.3 79.5 85.5
(S.D.) 1 .7 1 .9 2.4 1 .7 1 .2
Pet. spirit. (mean). 87.0 81 .3 82.8 81 .6 85.0
0.7 1 .7 1 .3 2.1 1 .4
n Statistical count RSD = 0.6%.
The recoveries were measured using technique E405 on 1000 ;uL samples of 
the solvents. Petroleum spirit at ambient temperature was chosen, on 
the basis that less extraction of unwanted material should
theoretically result.
4.9. REMOVAL OF EXCESS BETA-DIKETONE.
The removal of excess beta-diketone , which would tend to 
accompany the chromium analyte through the process, was initially 
recognised as a necessary stage in the procedure.
4.9.1. Problems caused by excess hfacac.
Two problems were anticipated, interference with the back 
extraction, by neutralisation of the base used, and interference at 
the electrothermal atomisation stage by smoke production. However an 
unexpected interference causing gross diminution of the chromium signal 
at the electrothermal atomisation stage was found. The interference 
proved difficult to eradicate as even a 3% retention of the excess 
hfacac resulted in severe interference.
4.9.2. Water wash.
The suitability of a water wash for the removal of the excess
beta-diketone was investigated using 250 juL of hfacac in a mixture of 8
mL of petroleum spirit and 1 mL of toluene. Aliquots of the solution 
were washed with 4 mL of water on a roller mixer for a variable length 
of time ranging from 5 to 120 minutes. A second experiment was carried 
out in which an aliquot of the solution was subjected to three 24 hour 
sequential washes with 4 mL of water. The hfacac extracted was 
determined by titration with M sodium hydroxide using phenolthalein as 
indicator. The 100 % reference was 250 jiL of hfacac in 4 mL of water.
The results are listed in table 4.10 below.
TABLE 4.10.
Percentage hfacac extracted by water washes.
A) Variable wash time. B) Three sequential 24 hr washes.
Time. % hfacac in water wash. Wash. % hfacac in water.
5 min. 46% 1. 97%.
10 min. 55% 2. 2.6%
30 min. 88% 3. 0.6%
60 min. 95%
120 min. 97%
A practical water wash of 60 minutes duration was observed to 
remove 95% of the hfacac from a petroleum spirit toluene mixture 
containing no other acids. The unexpected interference referred to 
above became apparent when, as the individual stages appeared to be at 
a suitable development level , a trial run of standards were carried 
through the full process. Three standards containing radioactive 
chromium equivalent to 1 jag Cr/L in a 1 mL serum sample were processed 
using method CDI, except that a 60 minute wash with 4 mL of water was 
used to remove the excess hfacac. The standard AAS/ETA conditions 
described in E406 were used with coated profile graphite tubes, and two 
25 ;uL injections were made from each sample. The radiometric recoveries 
were measured using the usual method (E405). Aliquots of the 
radioactive chromium solution used were evaporated and dissolved in 100 
u^L of 0.025M diammonium EDTA solution and used as reference solutions 
for radiometric recovery checks and AAS measurements. The results are 
summarised in table 4.11 below.
TABLE 4.11.
AAS/ETA and radiometric recoveries on standards compared.
Tube. Atomisation peak height mm. Radiometric recovery.
i. ii. Mean.
Blank. 13 13 13
Stds.
1. 15 16 16 75%
2. 24 36 30 73%
3. 67 13 40 77%
Reference. 67 62 65 100%
The processed standards were seen to show extremely poor 
reproducibility for both replicate injections from individual tubes and 
between similarly processed tubes, and severe interference was 
obviously occurring at the AAS/ETA stage. An experiment to confirm that 
a 3% retention of hfacac would produce a significant suppression of the 
chromium signal was carried out. Standard solutions of Cr(III) in
0.005M perchloric acid were prepared together with a duplicate set 
containing hfacac equivalent to a 3% retention of the usual 250 ^ iL 
added to each sample in process CDI. The solutions were left for 24
hours at ambient temperature to ensure that hydration of the hfacac, a 
slow reaction in acid solutions, was complete in the aliquots 
containing the beta-diketone. Standard AAS/ETA conditions (E406) were 
used, and duplicate 25 ;iL injections were made from each solution. 
Coated profile graphite tubes were fitted. The results are listed in 
table 4.12 below.
TABLE 4.12.
Comparison of atomisation peak heights, with and without hfacac.
Atomisation Peak Height mm.
Reference soln. Soln. plus hfacac.
Cr(III) ;ig/L. i. ii. Mean. i. ii. Mean.
Zero. 1 1 2 18 19 19
2.5 18 18 18 22 7 15
5.0 32 34 33 8 12 10
10.0 64 68 66 27 26 27
20.0 121 128 125 42 52 47
The above results demonstrated that a 3% retention of hfacac 
produced severe interference, and also that the hfacac used contained a 
high concentration of chromium. The conclusion was that if a single 
wash was to be used then a weakly basic buffer solution was needed, and 
dipotassium hydrogen phosphate appeared to have the appropriate 
characteristics.
4.9.3. 1M dipotassium hydrogen phosphate wash.
The suitability of 1M dipotassium hydrogen phosphate as a wash 
solution was investigated using standards equivalent to 2.8 jig Cr/L in 
a 1000 pl> sample. Standard method CDI was followed except for the wash 
stage. Aliquots of the standard were washed with water for 60 minutes 
or with 1M dipotassium phosphate for 15, 30 or 60 minutes. A wash
reagent volume of 5 mL was used for all tubes. Radioactive chromium was 
used for the standards and the distribution of the chromium in the wash 
solutions, petroleum spirit and ammonia solutions used for the back 
extractions was determined using the usual conditions (E405). The 
radioactive chromium left in the tubes used for the evaporation of the 
ammonia was also measured. The AAS/ETA determination was carried out 
using standard conditions (E406) with coated profile tubes. Three 
injections were made from each test solution. The results are
summarised in table 4.13 below.
TABLE 4.13.
1M dipotassium phosphate as a wash solution.
A. Tube identification.
Tube. Wash solution. Wash time, minutes.
1. water. 60
2. 1M phosphate. 15
3. 1M phosphate. 30
4. 1M phosphate. 60
B. Distribution of the radioactive chromium.
Tube. Wash solution. Pet. spirit. Ammonia soln Evap. tubes.
1. 0.4% 6.8% 93% 1.2%
2. 7.4% 6.6% 86% 1 .5%
3. 9.2% 7.9% 83% 1 .5%
4. 15.5% 13.2% 71% 1.5%
C) AAS/ETA chromium measurements.
Atomisation Peak Height mmi. AAS/ETA AAS/ETA recovery ai
Tube. Mean. RSD. recovery. % of radiometric.
Blank. 53 1% / /
1 . 62 43% 24% 26%
2. 137 26% 52% 61%
3. 122 14% 47% 57%
4. 174 0.6% 69% 98%
Reference. 198 0.7% / /
Note, The blank value in the table above refers to sample 4. The blan]
values used for the calculation of the AAS/ETA recoveries for the other 
samples were derived from this result, assuming similar recoveries and 
relative responses for blanks and tests, when processed in an identical 
manner.
The anticipated results of high radiometric recovery but severe 
interference at the AAS/ETA stage for the water wash sample, and 
increasing AAS/ETA relative response at the expense of higher losses of 
chromium at the wash stage were illustrated in the results above. 
However the failure of the phosphate wash to improve the back 
extraction efficiency was unexpected. A repeat experiment demonstrated 
that the introduction of a water wash after the phosphate buffer
treatment was effective, and consistent back extraction efficiencies of 
greater than 95% were recorded.
4.9.4. 2.2M Dipotassium phosphate wash.
The addition of the acetic acid containing 7.5 % sulphuric acid 
with the hfacac improved the conversion of chromium to the 
hexafluoroacetylacetonate, particularly in the total protein-bound 
chromium series as reported earlier. However a more concentrated 
phosphate buffer was required to compensate for the extra acidity of 
the petroleum spirit extracts. The suitability of 2.2M dipotassium 
hydrogen phosphate was investigated using a solution of radioactive 
chromium, as the hexafluoroacetylacetonate at a concentration of 1.0 jug 
Cr/L in petroleum spirit. Two 9 mL aliquots of the petroleum spirit 
solution were labelled A and B, 250 ;llL of acetic acid was added to A 
and 250 ;aL of hfacac to both. The aliquots were then washed with 4 mL 
of the 2.2M phosphate solution on a roller mixer for 24 hours. The 
aliquots were both subsampled (250 ;uL) at intervals, and the 
radioactive chromium content of the subsamples measured in the usual 
way (E405). The final pH values of the wash solutions were measured 
and compared with 4 mL aliquots of water and phosphate buffer 
containing 250 ,uL of hfacac and treated similarly. The results of the 
experiment are given in table 4.14 below.
TABLE 4.14.
i) Chromium retention during a 2.2M phosphate wash.
Percentage chromium remaining.
Wash time. A (plus acetic acid). B
1 min. 95 85
10 min. 91 79
15 min. 90 80
30 min. 94 75
60 min. 94 70
24 hrs. 90 36
ii) pH values of the wash solutions. 
Solution. pH.
Phosphate buffer (untreated) 9.1
A after 24 hrs. 6.8
B after 24 hrs. 7.9
Phosphate buffer plus hfacac (24 hr. mix). 7.9
Water plus hfacac (24 hr. mix). 2.2
The acetic acid (plus 7.5 % v.v. sulphuric acid) moderated the 
effects of the phosphate buffer as expected. The chromium lost in a 24 
hour wash was reduced from 64% to 10%.
The effectiveness of the 2.2M phosphate wash for removing the 
excess hfacac was investigated by washing twelve tubes containing 9 mL 
of petroleum spirit plus 250 ;uL of hfacac and 250 jiL of acetic acid
with 4 mL of 2.2M phosphate buffer for 15, 30, 60 minutes and
overnight. Tests were carried out in triplicate. The petroleum spirit 
from all tubes was washed with 4 mL of water for 60 minutes after the 
phosphate buffer wash. A solution containing 0.1 jig Cr/L in 4.25M 
ammonia, 0.005M EDTA was prepared and 500 jjlL of this solution was added 
to duplicate tubes from each wash series. The third tube was used as a 
blank and ammonia/EDTA solution containing zero chromium was added to 
these tubes. All tubes were then placed on a roller mixer and left
overnight. The ammonia/EDTA solutions were then removed to small
polypropylene tubes and evaporated in a desiccator at 80 0 C over
sulphuric acid and 5 tubes containing 500 )iL of the chromium solution
were similarly treated. The residues were all dissolved in 100 jjL of
0.1M acetic acid at 800 C on a vortex mixer for 5 minutes. The chromium 
concentrations of the 0.1M acetic acid solutions were then determined
using standard AAS/ETA conditions (E406) with uncoated profile graphite
tubes. Duplicate 25 ;iL injections were made from each solution. The 
results of this experiment are summarised in table 4.15 below.
TABLE 4.15.
AAS/ETA results on processed standards after 2.2M phosphate wash.
Wash time 
minutes.
15 min.
30 min.
60 min.
16 hr. 
Reference.
Mean peak height 
test - blank.
26
27
23
30
29
Relative 
std. deviation. 
8.3%
31 .4%
6 .1%
14.1%
7.1%
% of reference 
standard.
88%
93%
80%
104%
100%
The mean peak heights of the processed standards were compared 
with the reference mean using Student's t test, and only the value from 
the samples washed for 60 minutes was found to be significantly 
different.
The conclusion was that the results confirm that significant 
signal suppression does not occur after the treatment outlined above, 
and that even a 15 minute wash with 2.2M phosphate buffer was 
acceptable.
4.10. THE BACK EXTRACTION PROCESS.
The initial stage of the back extraction process is the removal 
of the chromium from the petroleum spirit to form a stable solution in 
the aqueous extraction phase. The chromium must then be concentrated by 
evaporation and redissolved to form a stable solution suitable for the 
AAS/ETA stage.
4.10.1. Extraction from the Petroleum Spirit.
The back extraction depends on efficient removal of acids at the 
earlier wash stage, as discussed earlier. The rate of removal of 
chromium from a petroleum spirit solution containing hfacac and acetic 
acid by 4.3 M ammonia solution containing 0.005M EDTA was investigated. 
Radioactive chromium as the hfacac complex was added to the petroleum 
spirit to produce a concentration equivalent to that produced by the 
complete extraction into 9 ml of solvent of the chromium from 4 ml of 
sample containing 0.1 ;ug Cr/L. The 9 ml aliquots of petroleum spirit 
also contained 250 ^ 1 of both hfacac and acetic acid. The solutions 
were washed sequentially with 4 ml of 2.2 M dipotassium hydrogen 
phosphate and then 4 ml of water, each wash was of 60 minutes duration 
on a roller mixer. The petroleum spirit aliquots were then extracted 
with 500 jiL of the ammonia/EDTA solution for from 15 minutes to 16 
hours. The radioactive chromium in the ammonia solutions was measured 
using the usual method (E405). The results of the experiment are 
summarised in table 4.16 below, and the aliquots were processed in 
duplicate.
TABLE 4.16.
The rate of removal of 51 Cr by ammonia soln. from pet, spirit.
% Cr extracted. % Cr extracted.
Time. i. ii. Time. i. ii.
15 min. 40 73 120 min. 94 96
30 min. 51 79 150 min. 95 98
60 min. 73 96 16 hours. >99 >99
The conclusion was that ammonia solution can, under the above 
conditions give acceptable back extraction recoveries. The extractions 
should be carried out for at least two hours and ideally overnight.
The stability of trace concentrations of chromium in ammonia 
solution was demonstrated using radioactive chromium at a concentration 
of 0.69 ,ug Cr/L, equivalent to 0.108 p.g/h in a serum sample processed 
using method CDIII, and assuming a recovery of 80%. Four 500 ,uL 
aliquots of the 51 Cr solution were pipetted into small polypropylene 
tubes for reference values and the bulk was stored in a screw cap 
polypropylene tube of the type used for the back extraction stage in 
the chromium determination process. After 24 hours storage at ambient 
temperature four 500 ;uL aliquots were pipetted into small polypropylene 
tubes without prior mixing. The radioactive concentration of the two 
sets of tubes were then compared using the usual method (E405). The 
mean chromium concentration of the test series as a percentage of the 
mean level in the reference tubes was 101.2%, with a standard deviation 
of 0.69%. The statistical radioactivity RSD was 0.5%.
The conclusion was that Cr(III) solutions in 4.3M ammonia are 
stable for at least 24 hours in the concentration range expected in the 
standard procedure.
4.10.2. Redissolving the chromium after the evaporation step.
The solution of radioactive chromium equivalent to 0.108 ^ ug Cr/L 
in a specimen referred to above (4.10.1) was used in an experiment to 
investigate the redissolving of the chromium after the evaporation 
step. Sixteen 500 jiL aliquots were pipetted into polypropylene tubes of 
the type used for the evaporation stage in method CDIII. The contents 
of 13 to 16 were evaporated after the addition of 50 jiL of 0.025M EDTA. 
The evaporations were carried out at 80 0 C in a desiccator. The 
solution of the residues was attempted in 100 ;uL of various solvents at
80 0 C on a vortex evaporator for 5 minutes, after capping. The tubesowere then centrifuged at 3000 rpm at 20 C for 10 minutes and then all 
fluid was removed using a water pump and fine pipette. The empty tubes 
were then subjected to radioactive chromium determinations in the usual 
manner (E405). The four remaining aliquots of the original solution 
were used for reference values. The results are summarised in table 
4.17 below.
The results clearly indicated that EDTA must be added to the 
ammonia before evaporation, for the chromium in the residue to be
readily dissolved.
TABLE 4.17.
Comparison of solvents for redissolving residual chromium.
Tube No. Solvent. Percentage 51 Cr remain:
i) EDTA not added before evaporation. i. ii. Me<
1 and 2. 0.025M EDTA. 38 32 35
3 and 4. 0.050M EDTA. 32 32 32
5 and 6. 0.025M EDTA in 0.1M acetic acid. 30 25 28
7 and 8. 0.05M hydrochloric acid. 23 20 22
9 and 10. 0.1M hydrochloric acid. 18 17 18
11 and 12. 0.01M perchloric acid. 29 22 26
ii) EDTA added before evaporation.
13 and 14. Water. <0.1 <0.1 <0
15 and 16. 0.1M acetic acid. <0.1 <0.1 <0
4.11. INTERFERENCE BY IRON.
The trace metal with the highest probability of producing 
significant interference in chromium determinations on biological 
specimens is clearly iron, principally because of the relatively 
high concentration of iron relative to other trace metals. The ability 
of both Fe(II) and Fe(III) to form complexes with beta-diketones 
together with the iron:chromium ratio of about 150:1 in normal human 
serum indicates that significant competition from iron for hfacac could 
take place, particularly in samples with high iron concentrations. The 
presence of a considerable excess of the beta-diketone to drive the 
complexation reaction in the forward direction in the presence of very 
low concentrations of chromium is clearly an important factor in 
obtaining a high recovery. The removal of virtually all the serum iron 
together with the transferrin-bound chromium at the protein 
precipitation stage of the alpha-2-globulin-bound chromium 
determination stream should ensure that interference from this source 
does not occur with this parameter.
4.11.1. Effect of High Serum Iron Levels.
An experiment was carried out to investigate the effects of high 
serum iron levels on method CDIII. Aliquots of a human serum pool 
derived from samples taken with precautions to avoid contamination with
chromium were spiked with radioactive chromium to provide a range of 
values from 0.086 to 0.69 jag Cr/L. One aliquot was also spiked with 
Fe(III). The samples were then processed using method CDIII (E403) for 
both total protein-bound and alpha-2-globulin-bound chromium. Standards 
equivalent to 0.69 jig Cr/L were also processed, and quarter scale 
precipitation and wash experiments were performed to measure the 
fraction of 51 Cr precipitated as alpha-2-globulin-bound chromium. The 
recoveries of 5 Cr were determined using the usual technique (E405) 
and are summarised in table 4.18 below. The table also gives details of
the Cr and Fe(III) spikes.
TABLE 4.18.
Comparison of the Cr recoveries on aliquots of a human
serum pool with and without added Fe(III)
Pool. n. Spike. Percentage recovery.
51 Cr jig/L. Fe mg/L. Total Cr. GTF Cr.
Mean. RSD. Mean. RSD.
A. 4 0.69 / 73 2.1 83 3.2
B. 1 0.345 / 73 86
C. 1 0.173 / 76 85
D. 1 0.086 / 70 85
E. 4 0.69 125 59 6.1 85 1.7
Std. 4 0.69 / 75 2.3
Student 1 s t test confirmed that there was a highly significant
difference between the recoveries from pool E compared with those
recorded from pool A.
The conclusion was that iron at a concentration about sixty 
times the normal level does not significantly reduce the recovery of 
alpha-2-globulin— bound serum chromium (GTF Cr in the table above). 
However the total protein-bound chromium (Total Cr in the above table) 
is significantly reduced.
4.11.2. Recovery of Fe(III) using method CDIII.
A second experiment similar to the one described in 4.11.1 above 
was carried out except that the chromium and iron levels were 
determined using AAS/ETA and the total protein—  bound chromium protocol 
only was followed. Standard AAS/ETA conditions (E406) with an uncoated 
"Profile" tube, and no background correction were used. The iron
measurements were carried out under identical conditions except that an 
iron hollow cathode lamp was used at 248 nm. The spike details and the 
results are given in table 4.19 below. The chromium in the ferric 
nitrate used for spiking the serum pool was determined by preparing a 
solution in 0.1M acetic acid. A solution of chromic nitrate in the same 
solvent was used as a standard.
TABLE 4.19.
i ) Iron recovery on a spiked serum sample using method CDIII.
Pool. n. Spike. AAS/ETA results.
51 Cr ^ pg/L. Fe mg/L. Cr ^ jig/L. Fe jig/L.
F. 4 / / 0.074 /
G. 4 0.86 / 0.93 /
H. 4 / 200 37.0 8
ii) Chromium content of ferric nitrate.
35.39 mg Fe/L. 38.4
Cr as a percentage of Fe in the spike solution = 0.109%. 
Recovery of chromium in the Fe spiked solution = 18%.
The recovery of the added iron was extremely low (0.004%). The 
red Fe(III) hfacac complex was observed to be lost from the petroleum 
spirit at the phosphate wash stage. The relatively high chromium 
content of the added iron (0.109%) was noted and clearly implied that 
the interference by iron was more serious than originally concluded 
from the earlier experiment. The iron/ chromium ratio in the iron 
spiked serum used in 4.11.1 was, in the light of the high chromium 
content of the iron, very different from that prevailing in a specimen 
with a 60 times elevated iron but normal chromium level, as originally 
envisaged.
4.12. THE EFFECT OF HAEMOLYSIS ON CHROMIUM RECOVERY.
A specimen of blood taken without anticoagulants and with the 
precautions against contamination with chromium discussed in chapter 
VII, was lysed by repeated freeze-thawing. The haemoglobin stained 
serum was then added to unhaemolysed serum taken at the same 
venepuncture. Two haemolysed specimens were prepared equivalent to 20% 
and 2% of a whole blood containing 140 g haemoglobin/L. The total iron 
contaminations resulting from the haemolysis were about 94 and 9.4 mg
Fe/L respectively. Radioactive chromium was added to the haemolysed and 
to non haemolysed samples to produce a final concentration of 0.18 p.g 
Cr/L. The serum samples were then processed using method CDIII (E403) 
for both total protein-bound chromium and alpha-2-globulin— bound 
chromium. A summary of the recovery results is given in table 4.20
below. The radioactive chromium determinations were carried out using 
the usual method (E405).
TABLE 4.20.
Chromium recoveries on haemolysed serum samples.
A. Total Protein-Bound Chromium.
Sample. Mean Recovery,
No haemolyis. 70.5
20% haemolysis. 28.3
2% haemolysis. 69.0
B. Alpha-2-globulin-Bound Chromium.
Sample. Mean Recovery. Standard Deviation.
No haemolysis. 80.1 2.1
20% haemolysis. 80.5 2.0
Standard Deviation. 
2.1 
4.8 
1 .4
Number. 
4 
4 
4
Number. 
4 
4
Student's t test was applied to the recoveries from the total 
protein-bound chromium process. The recovery from the specimen with 20% 
haemolysis showed a highly significant reduction compared with the 
sample free from haemolysis. However the recovery from the sample with 
2% haemolysis was not significantly different from the haemolysis free 
base serum.
The alpha-2-globulin-bound chromium determination process was 
clearly much less susceptible to haemolysis and showed no reduction in 
recovery even with 20% haemolysis.
4.12.1. Conversion of "haemoglobin iron" to the hfacac complex.
The interference only in the total protein-bound chromium series 
indicates that iron derived from haemoglobin is not responsible. The 
haematin iron cannot be extracted under the conditions used for 
precipitating the alpha-2-globulin-bound Cr, and the iron content of 
the precipitates in the two series must be broadly similar.
The percentages of the total iron content of the 20% haemolysed 
sample present in the supernatants of the two alternative protein 
precipitation procedures were compared. The supernatants were diluted
with 0.1M acetic acid 1:20 and the iron concentrations determined as 
described in E408. The specimen was diluted with 0.1M acetic acid to 
give solutions corresponding to 12.5, 25, 50 and 100% of the total iron 
and aliquots of these solutions were used to establish a standard 
curve. Appropriate blanks were deducted from the readings of the test 
solutions. The results are summarised in table 4.21 below.
TABLE 4.21.
Percentage of total iron in supernatants.
n. Mean. Standard deviation.
Total protein-bound Cr. 3 3.9 0.2
Alpha-2-globulin-bound Cr. 3 14.4 0.5
The results confirm that although rather less of the haemoglobin 
derived iron is precipitated in the alpha-2-globulin-bound series, the 
major fraction is present in the precipitate.
The fraction of the haemoglobin iron that was converted to the 
hfacac complex in a specimen with 20% haemolysis was determined for 
both the total protein-bound Cr and the alpha-2-globulin - bound Cr 
series. A serum sample containing erythrocytes equivalent to a 20% 
contamination with whole blood was processed in duplicate using method 
CDIII, except for the modifications described below.
The standard procedure was followed up to and including the 
extraction with petroleum spirit. The washes with phosphate buffer and 
water were omitted and the petroleum spirit extracts were subjected to 
back extraction with 500 ;uL of a 50:50 mixture of 6M hydrochloric acid 
and propan-2-ol, overnight on a roller mixer. The aqueous phase was
then evaporated at 75 0 C in a small desiccator with the tap open. The
extracted hfacac and the hydrated derivative readily evaporate under 
these acidic conditions, and unlike Cr(III), Fe(III) is extracted into 
acidified water/propan-2-ol solutions. The residues were dissolved in 
500 pL of 0.1M acetic acid, 0.005M EDTA on a vortex mixer at 75 0 C for 
30 minutes. The extracts were then diluted 1 in 100 with 0.05M acetic 
acid. Blanks were put through the procedure and the original
"haemolysed serum" sample was diluted 1 in 800, 1 in 1600 and 1 in 3200
in 0.05M acetic acid for comparative purposes. The iron concentrations 
were then compared as described in E408B. The results are listed in 
table 4.22 below. The recoveries are of the total iron precipitated,
of which about 99% is derived from haemoglobin.
TABLE 4.22.
"Haemoglobin iron" recoveries from a specimen with 20% haemolysis.
1 . 2. Mean.
Alpha-2-globulin-bound Cr. 24.4% 24.4% 24.4%
Total Protein-bound Cr. 14.9% 14.8% 14.9%
The experiment was repeated to confirm that a higher hfacac/iron 
ratio would result in a higher conversion of haemoglobin derived iron 
to the beta-diketone complex. A serum sample with added erythrocytes 
equivalent to 2.5% haemolysis was processed using the total protein 
bound Cr stream of standard method CDIII. The modifications described 
above were again used and a 67% recovery of the haemoglobin derived 
iron was recorded.
4.12.2. Interference by Copper, Iron and Zinc.
The poor recovery recorded for the total protein-bound stream
for the 20% haemolysed sample was considered to be a result of the 
combined competition given by a number of metals present in relatively 
high concentration in the erythrocyte. The precipitates produced in the 
alpha-2-globulin stream would contain substantially lower amounts of 
these metals.
The effects of these metals on the Cr recovery at a
concentration about 10 times the upper limit of the normal range were 
therefore investigated. The recoveries with and without the individual 
metals was determined on a standard Cr solution containing 51 Cr 
equivalent to a sample containing 0.1 jig Cr/L. The standard method 
CDIII was used, and the metals were added in 50 ^ L  of acetic acid,
except for Fe(II) which was added in hfacac/acetic acid because of the
low solubility of Fe(II) sulphate in acetic acid. The bright red Fe(II) 
complex was observed to change to the orange/red Fe(III) complex on 
heating. The residues from the back extraction were dissolved in 1000 
juL of 0.05M acetic acid and the 51 Cr recoveries measured as described 
in E405. The concentrations of Cu, Fe and Zn in the extracts were 
determined using the AAS/ETA conditions recommended by the instrument 
manufacturer, using the original acetic acid solutions diluted 1 in 500 
with 0.05M acetic acid as standards. The Fe(III) standard solution was 
used for both Fe tests. The normal ranges for the metals were taken
from reference (9), and the results are given in table 4.23 below. The
51recoveries are relative to the unspiked Cr solution processed at the 
same time.
TABLE 4.23.
Effects of Cu, Fe and Zn on 51 Cr recovery from a standard.
Metal. mg/L in a spec. Recovery 51 Cr. Recovery metal.
Cu(II). 14.3 97.0% <0.1%
Fe(II). 19.6 100.7% 0.3%
Fe(III). 19.6 103.2% 0.6%
Zn. 10.0 99.4% <0.1%
n = 2.
S.D. 2.5%. (Stat.RSD. 0.57%).
A series of paired t tests confirmed that there were no significant 
differences between the recoveries of 51 Cr with the above spikes, 
compared with the Cr standard.
4.12.3. Conclusions, effects of haemolysis.
Haemoglobin iron is accepted as being firmly bound. Ruben et al 
(10) have shown, using 53Fe, that there is no exchange between
haematin iron and ionic iron. Nevertheless experiments in this section 
have indicated that a high recovery of haemoglobin iron could be 
achieved with a hfacac/Fe ratio similar to the hfacac/Cr ratio in a 
"normal" test sample. This observation provides good evidence that the 
presence of a native Cr(III) compound inert to extraction as the hfacac 
complex is improbable.
The poor recovery recorded for total protein—  bound Cr
determinations on samples with 20% haemolysis is puzzling, in view of 
the resistance to recovery interference shown by the standards spiked 
individually with Cu, Fe and Zn. However extra Cr was undoubtedly added 
with the spike solutions, and this may have increased the Cr
recoveries. A sample with 20% haemolysis would in any case be normally
rejected for the determination of serum components.
The resistance of the alpha-2-globulin— bound Cr series to 
recovery interferences is noteworthy.
4.13. THE CHARACTERISTICS OF THE TOTAL PROCESS.
The characteristics of method CDIII are discussed below.
101 .
4.13.1. Recovery.
The recoveries and the chromium distribution throughout the 
analytical processes are summarised in table 4.24 below. The data is 
from three batches processed using method CDIII.
TABLE 4.24.
Recoveries and Cr distribution.
A. Recoveries, 
i) Standards. 
Batch. Mean,
1 . 
2. 
3.
ii)
76%
73%
75%
RSD.
8.8%
2 .1%
2.3%
Total Protein-Bound Chromium.- 
Batch. Mean. RSD.
1. 74% 3.0%
2. 73% 0.8%
3. 73% 2.1%
iii) Alpha-2-globulin-Bound Chromium. 
Batch. Mean. RSD.
1. 79% 5.1%
2. 82% 0.6%
Between batch distribution 
of means.
Mean 74.7%, RSD 2.0%
Between batch distribution 
of means.
Mean 73.3%. RSD 0.8%
Between batch distribution 
of means.
Mean 80.5%, RSD 2.6%
B. Chromium Distribution in Tests.
Total Protein-Bound. Alpha-2-globulin
Solution. Cr% SD. Cr% SD.
Phosphate buffer. 7.0 2.2 2.4 0.5
Water wash. 2.4 0.3 2.1 0.3
Petroleum spirit. 1 .5 1 .2 2.5 1 .3
Ammonia EDTA. 73.3 2.2 80.5 2.9
Protein mass. 12 6.3 5.3 1 .0
Total. 96.2 / 92.8 /
Cr unaccounted for. 3.8 / 7.2 /
The standard pretreatment process CDIII gave recoveries of 73% 
for the total protein-bound chromium and 81% for the 
alpha-2-globulin-bound chromium. The major identified location of
unrecovered chromium is the protein mass in both cases. However the 
chromium left in the less penetrable precipitates from the total 
protein-bound chromium series at 12% is slightly more than twice the 
amount left in the alpha-2-globulin-bound precipitates at 5%. The 
chromium loss in the phosphate buffer wash is also higher in the total 
protein-bound series, presumably due to the higher acidity of the 
petroleum spirit extract from the alpha-2-globulin-bound stream. The 
higher value of the "lost" chromium in the alpha-2-globulin-bound 
process is due to the less well demarcated petroleum spirit/aqueous 
phase boundaries at the wash stages leading to less complete transfer 
of .the organic phase, particularly from the wide diameter tuftainers. 
Haemolysis and high serum iron levels can both reduce the recovery with 
the total protein-bound chromium process.
4.13.2. AAS/ETA. Relative Response.
The AAS/ETA conditions are discussed in the next chapter,however 
the relative signals given by chromium in the processed materials 
compared with unprocessed material are relevant to the pretreatment 
process, as discussed in the section on excess hfacac.
The AAS/ETA relative response is defined as :-
Peak height x 100 / Expected peak height.
Expected peak height is the peak height given by an equal concentration 
of chromium in unprocessed ammonia/EDTA/acetic acid solution. The 
concentrations of chromium in the solution derived from processed 
samples were calculated from radiometric recoveries. Incremental peak 
height values were used for the relative responses. The reference 
values for the increments were reagent blanks and unspiked serum values 
respectively for determinations on standards and serum samples. Spike 
values were equivalent to 0.125 p.g Cr/L in a specimen.
Standard AAS/ETA conditions as described in E494 were used, with 
uncoated profile graphite tubes and 25 /iL injections. A summary of the 
results is given in table 4.25 below.
TABLE 4.25.
Relative Responses, Processed and Unprocessed Materials.
i) Unprocessed standards. iij Processed standards.
Response 100%, RSD 4.5%, n=4 Response 94%, RSD 3.9%, n=12
iii) Total Protein-Bound Serum Cr. iv) Alpha-2-globulin-Bound Cr.
Response 99.5%, RSD 3.5%, n=12 Response 82%, RSD 6.5%, n=7
The relative responses of processed material on AAS/ETA compared with 
unprocessed standards was subjected to Student's t test. The material 
from the total protein-bound chromium process did not differ 
significantly from the unprocessed material (95% confidence). However 
the processed standards and the alpha-2-globulin-bound chromium 
material both showed significantly different responses from unprocessed 
material, the confidence limits being 95% and 99% respectively.
4.13.3. Matrix Simplification Achieved.
The weight of the residue from 4 mL of serum processed for total 
protein-bound chromium using method CDIII was compared with the weight 
of the total dried solids from 4 mL of the same human serum pool. The 
mean weight of the processed material was 2.9 mg representing only
0.82% of the solids in the original specimen.
The chromium concentration factors are 24 and 27 for the total 
protein-bound chromium and alpha-2-globulin-bound chromium processes 
respectively.
The matrix simplification factor is 3.7 based on 8.8% dried 
solids in the human pool serum tested compared with 2.4% serum derived 
solids in the solution for AAS/ETA. However the chromium concentration 
factor multiplied by the matrix simplification factor is (27 X 3.7) = 
1 0 0.
Metals other than those present at an oxidation stage capable of 
forming "inert" complexes will be eliminated at the phosphate wash 
stage as shown by the recoveries of Cu, Fe and Zn, all well below 1%. 
Iron and nickel are the only metals forming "inert" complexes which are 
probably normally present in human serum at levels higher than 1 .0 
,ug/L. However the serum iron is present as Fe(III) (Lemberg et al (8)), 
and observation has indicated that the possibly inert Fe(II) complex is 
oxidised to the Fe(III) at the heating stage. The serum nickel is 
probably less than 5 pg/L and problems due to the presence of metals 
other than Cr in the test extracts are extremely improbable.
4.13.4. Detection Limit.
The detection limit is clearly governed in this method by the 
precision of the blank. A gross signal > blank + (4 x blank SD) , can 
be detected with 95% confidence. Thus a sample chromium level equal to 
4 x the blank standard deviation in pg Cr/L equals the detection limit. 
Table 4.26 below lists the blanks and detection limits of four batches.
TABLE 4.26.
Blank values, and derived Detection Limits.
Blank jig Cr/L. Detection Limit.
Batch. Mean. Standard Deviation. >ug Cr/L.
I. 0.08 0.0076 0.030
II. 0.08 0.0078 0.031
III. 0.05 0.0086 0.034
IV. 0.09 0.0088 0.035
Means. 0.075 0.0082 0.033
4.13.5. Summary.
A pretreatment has been developed that will extract and 
concentrate 75% of the total protein— bound chromium, or 80% of the 
alpha-2-globulin— bound chromium into 120 jiL of final solution 
containing less than 1% of the solids present in the original sample. 
The final solution appears to be suitable for the determination of 
chromium by conventional AAS/ETA without background correction. The 
detection limit using a sample volume of 4 mL is about 0.033 /ig Cr/L. 
However individual specimens need to have a radioactive chromium spiked 
aliquot processed in parallel to monitor the recovery matrix
modified AAS/ETA response.
The batch of tests cannot be processed in under three days, and 
the maximum number of tests in a batch is probably 24, representing 
duplicate determinations for both serum Cr parameters from a single 
glucose tolerance test. The radioactive chromium is not expensive, the 
hfacac is easily the most costly consumable.
EXPERIMENTAL SECTION CHAPTER IV.
E401. Serum chromium determination, standard method CPI.
METHOD.
1. 1000 pL of serum was pipetted into a Tuftainer and 10 mL of protein 
precipitant added. The serum suspensions were then mixed on a roller 
mixer for 15 minutes and then centrifuged at 3000 rpm for 15 minutes. 
The protein precipitants were propan-2-ol for the total protein-bound 
chromium and 0.6M perchloric acid for the alpha-2-globulin-bound metal.
2. The precipitates were dried after the removal of the supernatants,
at 37° C for 24 hours.
3. 250 pL of toluene and 250 pL of hfacac were added to the
precipitates followed by vigorous mixing on a vortex mixer.
Standards were set up as follows
i) Zero. ( toluene, propan-2-ol, 9 : 1 )
ii) 1.25 pg/L. ( 5 ug Cr/L, as the chloride, in toluene/propanol ).
iii) 2.50 pg/L. (10 pg Cr/L, as the chloride, in toluene/propanol ).
250 pL of the standard solutions were then taken and 250 pL of hfacac
added, followed by vigorous mixing on a vortex mixer.
Tests and standards were then treated in an identical manner.
4. All Tuftainers were then heated at 100 0 C for 24 hours.
5. The Tuftainers were cooled in a freezer at -20° C for at least 30
minutes. 5 mL of cold petroleum spirit ( 4° C ) was then added, and the
Tuftainers were heated at 75 0 C for 4 hours.
6. 2.5 mL of 1M disodium hydrogen phosphate was then added and the
Tuftainer contents mixed on a roller mixer for 15 minutes.
7. The petroleum spirit was removed to a screw cap polypropylene tube
containing 2.5 mL of water and the tubes were then placed on a roller 
mixer for 15 minutes.
8. The petroleum spirit was then extracted with 250 pL of 9M ammonia 
solution in a similar polypropylene tube on a roller mixer for 24 
hours.
9. The ammonia solutions were evaporated on a vortex evaporator at 75°
C under reduced pressure in 12 x 75 mm polypropylene tubes and the 
residues dissolved in 100 pL of 0.025M EDTA.
E402. Serum chromium determination, standard method CPU.
METHOD.
1. 5 mL of serum was pipetted into a Tuftainer and 10 mL of protein 
precipitant added. The serum supensions were then mixed on a roller 
mixer for 15 minutes and then centrifuged at 3000 rpm for 15 minutes. 
The protein precipitants were propan-2-ol for the total protein-bound 
serum chromium and 0.5M hydrochloric acid in propan-2-ol for the 
alpha-2-globulin-bound chromium.
2. The protein precipitates were then washed x 2 with 10 mL of 
propan-2-ol using the above mixing and centrifuging procedure, and then 
with 10 mL of toluene substituting heating at 75° C in a hot air oven 
for the roller mixing step.
3. 500 pL of toluene and 250 pL of hfacac were added to the 
precipitates and the Tuftainer contents thoroughly mixed on a vortex 
mixer.
Standards were set up as follows
500 pL of toluene (plus 50 pL acetic acid per 15 mL of toluene). 
50 pL of propan-2-ol containing the chromium as the chloride.
250 pL of hfacac.
Thoroughly mixed, and then treated in an identical manner to the 
tests.
4. All the Tuftainers were then heated at 75 0 C overnight and then 
cooled at -20° C for 1 hour.
5. 8 mL of petroleum spirit was then added and the Tuftainers were
placed on a roller mixer for 4 hours.
6. 4 mL of 1M dipotassium hydrogen phosphate was then added and the 
Tuftainers replaced on the roller mixer for a further 30 minutes.
7. The petroleum spirit was then removed and added to screw cap 
polypropylene tubes containing 4 mL of pure water. The tubes were then 
roller mixed for a further 2 hours.
8. The petroleum spirit was then extracted with 500 pL of 3.5M ammonia,
0.005M EDTA in similar polypropylene tubes on a roller mixer for 90 
minutes.
9. The ammonia solution was removed into 12 x 75 mm polypropylene tubes 
and evaporated at 75 ° C under reduced pressure on a vortex evaporator.
The residues were dissolved in 100 pL of water at 750 C for 5 minutes
on a vortex mixer.
RESULTS.
Mean radiometric recovery. Relative standard deviation.
Standards. 74% 3.6%
Serum samples.
Total protein-bound. 
Alpha-2-glob.-bound.
73%
84%
6.0%
4.6%
E403. Serum chromium determination, standard method CDIII.
METHOD.
1. 8 mL of propan-2-ol (resin treated) was added to each Tuftainer. 750 
ju.L of 6M hydrochloric acid (purified by distillation) was added to the 
propan-2-ol in the Tuftainers for the alpha-2-globulin-bound serum 
chromium determinations only. The two series were then treated in an 
identical manner.
2. 4 mL of serum was added slowly to the 8 mL of protein precipitant in 
the Tuftainer.
3. The Tuftainers were placed on a roller mixer for 15 minutes.
4. Tuftainers centrifuged for 15 minutes at 3000 rpm.
5. The supernatants were carefully removed and discarded.
6. 8 mL of propan-2-ol were added, and the Tuftainers shaken vigorously 
to resuspend the precipitates.
7. Tuftainers centrifuged for 15 minutes at 3000 rpm.
8. The supernatants were removed and discarded, l ojr resin treated
toluene was added and the Tuftainers heated at 75 c C for 15 minutes 
after a vigorous shake to resuspend the precipitates.
9. Tuftainers were centrifuged at 3000 rpm for 15 minutes.
10. Supernatants were removed and discarded.
11. The treatment with toluene was repeated.
12. 200 ,uL of acetic acid (purified by ion-exchange resin treatment) 
containing 7.5% v.v. Aristar sulphuric acid was added.
13. 200 jil of hfacac double distilled from petroleum spirit was added.
14. The Tuftainers were firmly capped and the contents viqorously mixed 
on a vortex mixer.
15. Standards.
Tuftainers were washed x 2 with 4 mL of propan-2-ol and x 2 with 
4 mL of toluene.
1000 „uL of toluene and 200 ;iL of acetic acid containing 7.5% 
v.v. sulphuric acid and chromium (as the nitrate) at X 20 the nominal 
value was then added to the Tuftainer, followed by 200 ;uL of hfacac.
The containers were then firmly capped and vigorously mixed on a vortex 
mixer.
16. All further treatment refers to both tests and standards.
All Tuftainers were heated at 75 <• C in an oven (fan assisted ovens may 
give contamination problems) and the container caps were carefully 
checked for tightness after 15 minutes.
17. The Tuftainers were cooled in a freezer at -20° C for 1 hour.
18. 8 ml of petroleum spirit were added to all Tuftainers.
19. Tuftainer contents thoroughly mixed on a roller mixer for 4 hours
after a vigorous shake to detach the precipitates from the container.
20. 4 mL of 2.2M dipotassium hydrogen phosphate, 0.01M EDTA was added 
to all Tuftainers.
21. Containers placed on a roller mixer for 1 hour.
22. Tuftainers centrifuged at 3000 rpm for 15 minutes and then the 
petroleum spirit extracts were removed and added to 13 mL screw cap 
polypropylene tubes containing 4 mL of pure water.
23. The petroleum spirit extracts were then washed for 1 hour with the 
water on a roller mixer.
24. The petroleum spirit was then removed and extracted with 500j iL of 
5.0M ammonia, 0.005M EDTA in a similar polypropylene tube overnight on 
a roller mixer. The ammonia had been distilled under isothermal 
conditions and the EDTA was the di-ammonium salt.
25. The ammonia/EDTA solutions were removed and evaporated in 12 x 75 
mm polypropylene tubes in a desiccator over concentrated sulphuric acid 
at 80 5 C.
26. 120 yiL of 0.5M ammonia, 0.7M acetic acid was added to the residues. 
The tubes were capped and then vortexed at 80 0 C for 10 minutes.
27. The tubes were then centrifuged at 3000 rpm for 10 minutes to 
return any evaporated water which had condensed on the upper walls of 
the tubes to the base.
E404. Electrophoresis conditions.
Electrophoresis was carried out on cellulose acetate strips, at 
pH 8.6 in a 0.05M barbitone buffer. The proteins were fixed in 
propan-2-ol and stained with 0.2% bromphenol blue in propan-2-ol.
E405. Radioactive chromium measurements.
A Nuclear Enterprises 1600 gamma counter was used at the
cobalt-57 setting. The two diagonally opposing wells 1 and 16 were used
to minimise interference. The efficiencies were 2.44 and 2.40% for 
wells 1 and 16 respectively. The changes in efficiency with respect to 
the volume of the test material were not significantly different for
the two wells and the same correction curve was used for both.
Volume jiL. 
250 
500 
1000 
2000 
4000
Relative efficiency. 
100%
99%
94%
76%
47%
E406. AAS/ETA Standard conditions.
A. Electrothermal Atomisation Settings.
Stage.
Dry.
Ash.
Delay.
Atomisation.
Delay.
Tube clean. 
Delay.
Tube blank. 
Water flow 
Argon flow
Time seconds. 
20 
40 
10 
5 
10 
5 
10 
5
0.5 litres/minute. 
3.0 litres/minute.
Temperature C.
240
1400
/
2900
/
3000
/
2900
B. Atomic Absorption Spectrophotometer Settings.
Chromium lamp current 7 mA.
Wavelength 357.9 nm.
Bandpass 0.4 nm.
Direct absorbance signal to recorder. Recorder set at 10mV fsd. 
Recorder variab control used to give scale expansion.
Pen deflections corresponding to a change in absorbance of 0.1 were: 
Minimum setting. 26mm.
Mid-point setting. 75mm.
Maximum setting. 100mm.
E407. Total Protein and Albumin Determinations.
The test specimens were the supernatants from the preliminary 
precipitation stages of the total protein-bound chromium or 
alpha-2-globulin-bound chromium determination processes. The human 
serum pool used for these experiments was diluted 1 in 3 with water and 
10% increments from zero to 100% prepared from this primary dilution 
for comparative purposes. A standard human albumin solution was also 
tested to determine the albumin in the serum pool as a percentage of 
the total protein.
A. Total protein. (Relative standard deviation 2.83%).
1. 50 pL of sample was diluted to 1000 pL with water.
2. 4 mL of 3% trichloroacetic acid was added and mixed by repeated 
inversion.
3.The absorbance was measured at 450 nm.
B. Albumin♦ (Relative standard deviation 2.26%).
1. 35 pL of specimen was added to 3 mL of dye reagent.
2. 35 pL of water, propan-2-ol or 0.5M hydrochloric acid in propan-2-ol
was added as appropriate to correct for differences between tests
and standards.
3. Mixed by repeated inversions.
4. Allowed to stand at ambient temperature for 10 minutes.
5. The absorbance was measured at 630 nm .
Dye reagent :
Bromcresol green 0.15 mmol/L.
Succinate buffer 0.075 mol/L.
E408. Iron determinations.
A. Spectrophotometric method.
In an acidic medium Fe(III) is released from the transferrin 
complex. Ascorbic acid reduces the Fe(III) to Fe(II), and the divalent 
iron then reacts with "ferrozine" to form a coloured complex which is 
measured spectrophotometrically at 580 nm. Under the conditions of the 
test the serum proteins remain in solution.
Ferrozine :
3-(2-pyridyl)-5,6-bis(4-phenylsulphonic acid)-1,2,4-triazine.
The serum iron determinations were carried out using a standard method 
on a Rotochem CFA 2000 centrifugal analyzer using a primary iron 
standard. The same standard was used for the iron determinations by
1 1 1.
AAS/ETA on the supernatents from precipitation with 0.5M hydrochloric 
acid in propan-2-ol.
B. AAS/ETA.
1. Iron determinations on the supernatant fluids from the preliminary 
precipitation stage of the alpha-2-globulin-bound chromium 
determinations were diluted 1 in 11 with 0.1M acetic acid. The diluted 
supernatants were then analyzed directly.
All injection volumes were 25 pL.
2. AAS/ETA Standard conditions.
i). Electrothermal Atomisation Settings.
Stage. Time seconds. Temperature (nominal) C.
Dry. 20 240
Ash. 40 1400
Delay. 10 /
Atomisation • 5 2900
Delay. 10 /
Tube clean. 5 3000
Delay. 10 /
Tube blank. 5 2900
Water flow 0.5 litres/minute.
Argon flow 3.0 litres/minute.
ii). Atomic Absorption Spectrophotometer Settings.
Iron lamp current about 15 mA.
Wavelength 248.3 nm.
Bandpass 0.4 nm.
Background correction used. The deuterium lamp emission was reduced 
using the stepwise variable aperture control to achieve a rough 
balance.
Fine balance was made by adjusting the iron lamp current.
Direct absorbance signal to recorder. Recorder set at 10mV fsd.
Recorder variab control used to give scale expansion.
Pen deflections corresponding to a change in absorbance of 0.1 were:- 
Minimum setting. 26mm.
Mid-point setting. 75mm.
Maximum setting. 100mm.
C. Results.
Twelve specimens of serum with iron concentrations from 4.1 to
40.2 ^ jimol/L were tested.
Method. Mean ^ mol/L.
Spectrophotometric. 18.9
AAS/ETA. 21.8
Relative Standard Deviation. 
2.6%
9.6%
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CHAPTER V.
THE OPTIMISATION OF AAS/ETA CONDITIONS.
The SP 9-01 digital flameless atomiser has controls only for the 
voltage applied to the graphite tube and for the duration of time it is 
applied for. A complete cycle has five heating periods designated :- 
dry, ash, atomise, tube clean and tube blank. Three delay periods, 
with time control only, separate the atomise, tube clean and tube blank 
segments.
5.1. DRY,ASH AND ATOMISATION SETTINGS.
The dry and ash settings are the two phases in the furnace 
program which must be carefully tailored to optimally suit the analyte 
and sample type to be investigated. The aim of the ash stage is to 
remove all matrix components producing chemical interference or 
background signal at the atomisation step, with . rcO loss of
analyte. The drying stage must produce a dry residue of material at the 
injection point which is in the hottest region of the tube. Spitting, 
either during the drying stage or at the start of the ash phase will 
lead to particles of the injected material being redistributed to 
cooler parts of the tube, and hence to reduced efficiency of both the 
ash and atomisation processes. A reduction in the efficiency of the ash 
process may produce increased background signal at the atomisation 
step, and hence poor analytical precision, which is also an inevitable 
result of reduced atomisation efficiency.
Presumptive conditions, which were confirmed later using 
processed materials, were found using chromium in ammonium EDTA 
solutions as this was anticipated to be the major matrix component in 
the injection solution derived from the process under development. The 
role of EDTA in maintaining chromium in a soluble form has been 
discussed in chapter IV, section 4.10.1., and ammonium salts of low 
volatility had been found to be useful for controlling the interference 
by fluorine derived from the excess hfacac, this will be discussed 
later in this chapter (section 5.3.3.).
5.1.1. Drying Stage.
The drying step was optimised using a small mirror to view the 
behaviour of the droplet in the graphite tube over the drying and ash 
segments of the electrothermal atomisation cycle. Illumination by .the
neon 352 nm line was found to be useful for this purpose.
A relatively high drying temperature (nominally 240 0 C) was 
found to be necessary to prevent spitting at the ash stage. A minimal 
amount of frothing was unavoidable using the steep temperature rise 
produced by voltage control. A temperature ramp would be an advantage. 
5.12. Ash and Atomisation Settings.
The ash and atomisation conditions were selected in the 
conventional manner using ash/atomisation curves and plots of 
atomisation peak heights versus notional atomisation temperature. The 
drying stage settings were confirmed by precision determinations at 
various drying temperatures using optimum ash and atomisation 
conditions, and monitoring background absorbance at the neon 352 nm 
line. The nominal temperatures listed are those quoted by the 
instrument manufacturer for the settings given. However under voltage 
control conditions, the only ones available with the equipment used, 
reproducibility of temperature depends on graphite tube uniformity, as 
reported by Veillon, et al (1). In practice drying and ash conditions 
must be checked for each tube. Modest differences from the standard 
conditions quoted' were necessary for some tubes to obtain similar 
performance characteristics.
The ETA standard conditions listed in table 5.1 below were used 
in all experiments except where other details are given, or where only 
slightly different settings were required.
TABLE 5.1.
STANDARD AAS/ETA CONDITIONS.
Electrothermal Atomisation Settings.
Cycle segment.
DRY.
ASH.
DELAY.
ATOMISATION.
DELAY.
TUBE CLEAN. 
DELAY.
TUBE BLANK.
Time.
(seconds) 
20 
40 
10 
5 
10 
5 
10 
5
Temperature. 
Setting. Nominal (0 C ).
25
50
/
88
/
92
/
88
240
1400
/
2900
/
3000
/
2900
Between cycle delay increased from 40 to 55 sec. to prevent partial 
sample loss due to pressure increase in pipette barrel.
Argon flow 3.0 litres/min. Water flow 0.5 litres/min.
TABLE 5.1. continued.
Atomic Absorption Spectrometer Settings.
Wavelength 357.9 nm. Bandpass 0.4 nm. Chromium lamp 7 mA.
Direct absorbance signal to recorder (10 mv full scale deflection). 
Recorder variab control used to give scale expansion, pen deflections 
corresponding to a change in absorbance of 0.1 were 26mm to 100mm.
Background correction was not used unless stated, and when used the 
chromium lamp current was adjusted to balance the unattenuated emission 
of the deuterium lamp, a reduction to between 5 and 6 mA was 
satisfactory.
Ash conditions were investigated using a solution of chromium in 
0.05M EDTA, about double the concentration used in method CDIII. The 
higher concentration was used to ensure that settings able to cope with 
the EDTA, which produces smoke at the atomisation stage with inadequate 
ash temperatures, were attained. A solution of chromium in 0.0025M EDTA 
was then injected to confirm that significant losses of chromium did 
not occur at the 1400 n C ash temperature selected. The results are 
illustrated in figure 5.1 below.
FIGURE 5.1.
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Ash, atomise plot.
Atomisation, peak height mm. 5n
600 800 1000 1200 1400 1600 1800
Nominal ash temperature °C.
Red 0.05M EDTA. Blue 0.0025M EDTA.
The tests were repeated using chromium solutions in 0.1 and 0.5M 
hydrochloric acid and significant losses of chromium were not recorded 
using the selected ash temperature. Atomisation temperature was 
investigated using chromium in 0.025 EDTA solution. The results are 
given in figure 5.2 below, and show that atomisation peak height does 
not level off for chromium even up to the maximum temperature.
FIGURE 5.2.
Response relative to temperature.
Atomisation peak height mm. n = 5.
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Nominal atomisation temperature 9C .
5.2. INJECTION VOLUME.
Three solutions containing 25, 12.5 and 6.25 ;ug Cr/L were
prepared in 0.05M EDTA. The relatively high chromium concentrations 
were selected so that good precision was possible from the five 
replicate injections made from each of the test solutions. The volumes 
of the aliquots injected were 12.5, 25 and 50 u^L respectively, such
that 0.313 ng of chromium was injected each time. The results are 
summarised in table 5.2 below.
The 25 jjL injections showed improved precision (95% confidence) 
over the 50 jfL series when calculated in terms of chromium 
concentration. However there was no significant difference in precision 
between the 25 ,uL and 12.5 injections. The detection limit is
defined by precision not relative peak height and for this reason the 
convenient injection volume of 25 pL was selected.
TABLE 5.2.
Comparison of response in relation to injection volume.
jnq Cr/L. 6.25 12.5 25
Injection volume ^ uL. 50 25 12.5
Atomisation peak height mm.
Mean. 23.8 46 57.5
Standard deviation. 1.7 1.4 2.1
Relative S.D. n = 5. 7.2% 3.1% 3.6%
5.3. COMPARISON OF PYROLYTICALLY COATED AND UNCOATED TUBES.
A series of experiments were carried out to compare the 
sensitivity, precision, carryover and peak shape characteristics of 
coated and uncoated profile graphite tubes.
5.3.1. Precision and Carryover characteristics.
The above parameters were compared by injecting three 
concentrations of chromium: zero, 20 and 5 jig/L in 0.1M acetic
acid/0.05M EDTA. Five consecutive 25 pL injections of each solution in 
the order above were made at three stages in the lives of coated and 
uncoated profile graphite tubes. The tubes were tested at zero, 100 and 
200 firings. Carryover was assessed by measuring the displacement of 
the first injection of a solution from the mean for that solution 
series in terms of SD's. A summary of the results is given in table 5.3 
below.
TABLE 5.3.
Comparison of coated and uncoated tubes.
Uncoated tube. Coated tube.
Chromium ^ jig/L. 5. 20. 5. 20.
Atomisation peak height mm.
Zero firings.
Mean. 10.4 34.8 27.4 105.4
R.S.D.%. 5.2 13.5 2.0 7.7
1st inj. displacement SD's. + 1 .1 -1 .2 + 1.1 -1 .2
TABLE 5.3. continued.
100 firings.
Mean. 9.1 31.9 20.6 79
R.S.D.% 6.8 1.3 19.6 10.6
1st inj. displacement SD's. +5.3 +0.2 +0.3 +0.4
200 firings.
Mean. 8.6 29.8 17.6 68
R.S.D.%. 15.6 1.9 9.5 2.8
1st inj. displacement SD's. +11 +1.1 -1.6 0.0
Figure 5.3 below illustrates the difference in sensitivity of 
the two tube types and the changes with use.
FIGURE 5.3.
Comparison of sensitivity with uncoated and coated graphite 
tubes, and changes in this parameter over 200 firings.
Absorbance. n = 5.
4
3
2
1
0
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Number of firings.
Coated tube - — 5 jig/L , —  20 ^ ug/L .
Uncoated tube,--------5 jig/L,-------- — 20 jiq/L.
The linear relationship between atomisation peak height and 
chromium concentration is shown for new tubes in table 5.4 below.
TABLE 5.4.
Response linearity.
n = 5 Uncoated profile tube. Coated profile tube,
jag Cr/L. Peak absorbance. Sensitivity. Peak absorbance. Sensitivity. 
Zero. <0.0040 / <0.0040 /
5. 0.0400 0.32 0.1054 0.84
Range. 0.038 to 0.042 0.31 to 0.34 0.103 to 0.108 0.82 to 0.86
20. 0.1338 0.27 0.4054 0.81
Range. 0.116 to 0.152 0.23 to 0.31 0.374 to 0.437 0.75 to 0.87
Sensitivity is defined here as the absorbance change per ng Cr with an 
injection volume of 25 jiL. Range is over 95% confidence limits.
The coated tubes were superior in terms of sensitivity. However 
although sensitivity decreased with use for both types of tube the fall 
was much steeper for the coated tubes. The sensitivity ratio fell from 
3.03 to 2.28 over 200 firings as the pyrolytic layer became thinner, as 
illustrated in figure 5.3.
The only significant carryover demonstrated was with the 
uncoated tube. Positive carryover from the 20 Jig/L solution to the 5 
jug/L standard was significant after 100 firings, and further
deterioration was evident after 200 firings.
The only significant difference in precision was at 100 firings 
with the 20 jig/L standard. A highly significant advantage in favour of 
the uncoated tube was recorded.
The linearity of the.signal response to the chromium dose was 
superior for the coated tubes. A response of less than 1mm was recorded 
for the zero standard prior to injecting aliquots of the 20 jig/L 
solution in all series for both tubes. The mean value of the 5 jig/L 
standard was calculated from the appropriate mean peak height of the 20 
jig/L solution, assuming a linear response and a zero reading of 1mm. 
The overall values were 4.99 jug/L for the coated tube and 5.36 for the 
uncoated. The mean. joferx/a-icS deviations over the three stages of
tube life were 1.2% and 3.3% for coated and uncoated tubes
respectively.
The conclusions are that the coated tubes are superior in terms 
of sensitivity and memory effects. However uncoated tubes appear to 
show minimal and steady changes in sensitivity over their useful life,
121 .
in contrast to the marked changes, particularly over the first one 
hundred firings recorded for the pyrolytically coated tubes. The poor 
precision observed at the mid life series for the coated tube was 
recorded after the injection of processed material and later 
experiments demonstrated that this was significant.
5.3.2. Comparison of peak area/height ratios.
The above results relate to unprocessed chromium solutions in 
0.1M acetic acid/0.05M EDTA. A series of experiments were carried out 
comparing processed and unprocessed materials in both types of graphite 
tube. Peak heights and areas were measured, the latter using a DP 
101 computing integrator. Ideally peak area/height ratios should be 
identical for all types of processed materials of similar chromium 
values, that is for standards, serum samples and urines. The ratio 
should also be very similar to that recorded for unprocessed chromium 
solutions in the solvent used for dissolving the processed extracts.
5.3.2.1. Peak area/height ratios in 0.1M acetic acid/0.0125M EDTA.
The peak area/height ratios of processed materials, both 
standards and serum samples were compared with unprocessed chromium 
solutions using both pyroly.tically coated and uncoated graphite tubes. 
The standard CDIII process for alpha-2-globulin— bound chromium was 
used except that the residues were dissolved in 0.1M acetic acid. Three 
injections of each solution were made. The integrator peak width 
half-height parameter was evaluated by injecting representative 
solutions with the recorder chart speed at 300 mm per minute. The 
default values were used for all other integration parameters.
A. Pyrolytically Coated Tubes.
Table 5.5 below summarises the results obtained with coated
tubes.
The absorbance at the 520 nm neon line was monitored, and a very 
small peak (height < 5 mm) was recorded for all solutions injected, 
including 0.1M acetic acid/0.0125M EDTA, with and without background 
correction.
The very poor precision for replicate injections reported in 
table 5.5 below clearly prohibits the use of coated profile tubes under 
these conditions, and a discussion of the peak area/height ratios is of 
little value.
TABLE 5.5.
Peak area/height ratios, coated profile tubes.
n = 3.
Mean.
i) No bkgr. correction. 
Unprocessed stds.
5 jig/L. 50
10 jig/L. 09
Processed stds.
I. 17
II. 59
Processed tests.
I. 73
II. 61
III. 71
IV. 63
ii) Bkgr. correction. 
Unprocessed stds.
5 jig/L. 59
10 jig/L. 111
Processed tests.
V. 62
VI. 110
VII. 91
Peak Height.
mm.
RSD %.
Peak Area. 
jiV sec.
Mean. RSD %.
Area/Height. 
pV sec./mm. 
Mean. RSD %,
23
27
13
6
17
45
33
20
2
27
37
21
6
1507
3232
446
2377
2273
2119
2503
2150
1801
3316
1786
3107
2697
25
26
17
12
14
34
20
9
1
25
33
21
6
30.1
30.3
27.0
40.6
31 .5 
36.5
36.4
34.4
30.6 
30.0
29.3
28.2
29.7
2.6 
1 .6
3.9
5.7
8.5 
10 .0  
11 .0 
10 .0
3.5 
2 . 1
4.5 
0.5 
1 .9
B. Uncoated Tubes.
Table 5.6 below summarises the results obtained with uncoated 
tubes. Absorbance monitoring at the 520 nm neon line did not produce 
any peaks therefore no tests were carried out using background 
correction.
The precisions of the chromium signals from replicate injections 
were compared for processed standards and tests with coated (no 
background correction), and uncoated tubes. The differences were 
significant for four (highly significant for one) of the six pairs 
tested.
TABLE 5.6.
Peak area/height ratios, uncoated profile tubes.
n = 3.
Peak Height.
mm.
Peak Area 
jiV sec.
Area/Height. 
>iV sec./mm.
Mean. RSD %. Mean. RSD %. Mean. RSD
Unprocessed stds.
8.6 i^g/L. 73 3.2 1830 4.2 25.2 3.5
17.2 ^ g/L. 139 3.2 3895 5.6 27.9 2.6
Processed stds.
I. 25 3.1 754 5.4 29.5 3.6
II. ‘ 
Processed tests.
100 3.8 2860 5.2 28.8 1 .2
I. 63 4.5 1357 3.6 21 .6 8.5
II. 135 4.2 3735 3.2 27.4 6.7
III. . 46 6.1 984 6.3 21 .6 0.3
IV. 33 11 886 16 27.0 6.5
V. 35 36 835 15 24.8 22
VI. 35 0 917 0.5 26.2 0.5
The mean peak area/height ratios of processed standards, test 
serum samples and unprocessed chromium solutions using both coated and 
uncoated graphite tubes, the former with and without background 
correction, are listed in table 5.7 below. The data for processed 
standards using coated tubes has been omitted because of the large 
difference beween the values found for the two samples tested, and in 
view of the very poor precision recorded with this type of tube repeat 
tests were not carried out.
TABLE 5.7.
Comparison of peak area/height ratios.
Uncoated tube. Coated tube. Coated tube (BC).
sec. /mm. ^uV sec./mm. juV sec./mm.
n. Mean . SD. n. Mean . SD. n. Mean. SD.
Unproc. Sol. 9 26.2 1 .43 6 29.8 0.57 6 30.3 0.8
Proc. Std. 14 29.2 0.89 / / / / / /
Test serum. 18 24.8 3.2 12 34.4 3.5 9 29.1 0.99
A series of t tests were carried out to assess the significance 
of the differences in peak area/height recorded above. The values 
reported for uncoated tubes were significantly different (99% 
confidence) for both processed standards versus unprocessed chromium 
solutions and processed standards versus serum samples, whilst no 
significant difference was found between serum samples and 
unprocessed chromium solutions. In contrast the ratios found for 
serum samples and unprocessed chromium solutions using coated graphite 
tubes were significantly different using background correction and 
highly significant without it.
The conclusions from the above tests are that uncoated tubes 
appear to be superior under the conditions used. Pyrolytically coated 
tubes appear to be unsuitable and will not be discussed further.
The material from serum samples has similar peak area/height 
ratios to the unprocessed chromium solutions but processed standards 
have higher peak area/height ratios indicating some matrix differences. 
A tentative explanation is that slightly higher levels of derivatives 
from the beta-diketone are present in the processed standards compared 
with serum samples. The extracts from processed standards probably 
contain higher concentrations of excess beta-diketone because of lower 
consumption in side reactions compared with serum samples. The serum 
samples were processed by the alpha-2-globulin-bound Cr method in the 
experiments reported in this section, because the higher acidity of the 
protein precipitates produced could result in a less efficient removal 
of the excess hfacac compared with the total protein-bound Cr process. 
The addition of EDTA as the di-ammonium salt had been observed to 
reduce the interference caused by fluoride derived from the diketone, 
but produced smoke at the atomisation step at other than low 
concentrations. The removal of fluorine as volatile ammonium fluoride 
at the ash stage was considered to be a possible mechanism•for the. 
beneficial effect, and ammonium acetate was therefore investigated as a 
matrix modifier.
5.3.2.2. Peak area/height ratios in ammonium acetate solutions.
An excess of acetic acid was added to prevent ammonia vapour 
from interfering with the.pipetting characteristics of the solution. 
Volatile material can cause an increase in pressure in the pipette 
barrel as the warmer environment near the graphite furnace is entered, 
and a partial loss of sample dose can result. The delay between
cycles had been increased to 55 seconds as described in the standard 
AAS/ETA conditions as a precaution against this, after observing it to 
occur with a number of solutions. The excess acetic acid also prevents 
premature loss of the ammonia at the dry stage of the cycle. Table 5.8 
below records the results obtained on a series of solutions containing 
10 ^ug Cr/L and a range of ammonium acetate concentrations using a 
coated profile tube.
TABLE 5.8.
Ammonium acetate solutions in a coated profile graphite tube.
Atomisation Peak Height mm.
Mean RSD %.
0.1M acetic acid, 0.0025M EDTA. 107 2.9
0.125M ammonia, 0.325M acetic acid. 77 69
1.0M ammonia, 1.8M acetic acid. 34 37
Ammonium acetate solutions are clearly not suitable for use with 
pyrolytically coated graphite tubes. The above experiment was repeated 
with an uncoated graphite tube. The results are given in table 5.9 
below.
TABLE 5.9.
Ammonium acetate solutions in an uncoated profile graphite tube.
Atomisation Peak Height mm.
Mean. RSD
0.1M acetic acid, 0.0025M EDTA. 57 to to
0.125M ammonia, 0.325M acetic acid. 59 COCN
0.25M ammonia, 0.60M acetic acid. 58 2.5
0.50M ammonia, 1.4M acetic acid. 58 1 .2
1.00M ammonia, 2.8M acetic acid. 40 1 .4
It can be seen that uncoated graphite tubes tolerate ammonium 
acetate/acetic acid up to 0.5M ammonia, 1.4M acetic acid.
An experiment was carried out to check that the standard ash 
temperature setting (nominally 1400 0 C) of the electrothermal 
atomisation cycle was suitable for ammonium acetate solutions. Ten 
aliquots of a serum pool were processed using standard method CDIII. 
The dried extracts were dissolved in 1.0M ammonia/1.75M acetic acid and
pooled. Five aliquots of the pooled extract were then injected at each 
setting of the AAS/ETA conditions. The ash temperature was varied from 
800 to 1650 0 C, and the absorbance was monitored at the neon 352 nm 
line and at the 357.9 nm emission from the chromium lamp. The results 
are given in table 5.10 below.
TABLE 5.10.
Check on ash temperature with ammonium acetate solution.
Ash temperature C. 
800 
900 
1000 
1100
1400 (standard) 
1650
Atomisation Peak Height mm. (mean). 
Neon 352 nm. Chromium 357.9 nm.
41
14
zero
zero
zero
zero
/
/
35
35
36 
27
The conclusion was that the standard ash setting was suitable 
for use with ammonium acetate solutions.
The effects of hfacac derivatives on the peak area/height ratio 
was investigated using aliquots of a solution of the beta diketone 
converted to the hydrated derivative in ammonia solution. The aliquots 
were evaporated to dryness over sulphuric acid in a sealed desiccator 
at 75 0 C. Solutions containing 10 jig Cr/L but with a range of 
hydrated beta-diketone concentrations corresponding to retentions from 
0, through 0.5, 1.0, 2.0 to 4% of the hfacac used in the standard
process (CDIII) were prepared. Three sets of these solutions were
prepared, one in 0.02M EDTA (diammonium salt), another in 0.02M EDTA 
plus 0.5M ammonia and the third in 0.02M EDTA with both 0.5M ammonia 
and 0.7M acetic acid. A summary of the results is given in table 5.11 
below. All solutions were injected five times.
The experimental results confirm that traces of hfacac 
derivatives in 0.02M EDTA produce a highly significant reduction in
atomisation peak height at the 0.5 % retention level, and a highly
significant deterioration in precision at the 1% hfacac retention 
level. The reduction in peak area was less pronounced than that 
recorded for peak height. The result of this was an increase in the 
peak area/height ratio which was significant at the 2% hfacac retention 
level.
TABLE 5.10.
Comparison of peak area/height ratios in three solutions.
Solution. hfacac Mean Peak Height. Area/Height ratio.
n = 5. Retention %. % of reference. RSD%. Mean. RSD%
1. 0.02M EDTA.
Zero 100 4.1 37.9 8.3
0.5 76 4.2 40.1 8.4
1 .0 79 19 40.4 4.4
2.0 57 19 43.4 15
2. 0.02M EDTA, 0.5M ammonia. 
1.0 65 8.2 48.6 7.
3. 0.02M EDTA, 0. 5M ammonia, 
Zero
0.7M acetic 
100
acid.
2.8 35.1 6.
0.5 98 2.8 38.4 10
1 .0 105 7.5 36.0 7.
2.0 100 6.5 37.3 5.
4.0 82 8.0 35.6 5.
The addition of ammonium acetate clearly reduces the 
interference by hfacac derivatives. The peak area/height ratio was 
not significantly changed even with 4% hfacac retention, and although a 
highly significant reduction in peak height was seen at this level no 
significant changes in this important parameter were recorded up to 
and including 2% hfacac retention. The precision was however adversely 
affected by hfacac levels equivalent to 1% retention or more. The
addition of ammonia alone did not appear to be effective, presumably 
because it is volatilised too early in the electrothermal atomisation 
cycle.
A batch of tests were processed using method CDIII to compare
the peak area/height ratios of serum samples and standards as earlier
(5.32.1), but this time with ammonium acetate added. A serum pool from 
samples taken with the necessary precautions was processed in duplicate 
for both total protein — bound chromium and alpha-2-globulin — bound 
chromium. A serum sample taken with no special precautions was
processed for alpha-2-globulin-bound Cr only. Standards equivalent to
zero and 0.2 jig Cr/L were also processed, the former in triplicate the 
latter in duplicate. The solutions from each individual source were 
pooled to obtain volumes of sufficient size for a statistically 
significant number of injections to be made. The unprocessed standard 
chromium solutions were prepared in the 0.5M ammonia, 0.7M acetic acid,
0.0125M EDTA used for the processed material, as specified in method 
CDIII.
The results are listed in table 5.12 below. Pool I was derived 
from samples taken with special precautions to reduce contamination 
with exogeneous chromium and pool II was from samples taken in the 
routine manner.
TABLE 5.12.
Peak area/height ratios for serum samples and standards 
in ammonium acetate solution.
Peak Heights. Peak Areas. Area/Height ratio.
n. Mean. RSD%. Mean. RSD%. Mean. SD.
Unprocessed Std.
1 . 2.5 ;ug Cr/L. 5 24 2.9 882 12 36.8 14.5
2. 5.0 p.g Cr/L. 5 41 2.8 1461 9.1 35.1 6.2
3. 10.0 pg Cr/L. 5 76 2.7 2582 4.6 33.8 2.9
4. 20.0 p.g Cr/L. 5 144 1 .0 4530 3.1 31 .4 3.0
5. 30.0 ^g Cr/L. 5 210 0.86 5885 1.5 28.0 1 .6
Processed Std. 
1. "Zero". 9 20.4 13 703 13.3 34.5 2.4
2. "0.2 STD". 6 60.3 0.96 1666 7.7 27.7 1.5
Serum samples.
A. Alpha-2-globulin-bound Cr. 
1. Pool I. 6 36.0 8.6 1294 7.6 35.9 2.8
2. Pool II. 6 201 4.5 5514 7.0 27.4 1 .2
B. Total protein- 
1. Pool I.
bound 
6.
chromium. 
39.3 5.3 1422 7.5 36.2 0.8:
The peak area/height ratios for the unprocessed standard 
solutions show a steady decrease with increasing chromium 
concentration. However the values found for both processed standards 
and test samples were not significantly different from those of
unprocessed standards of similar peak height. The relative standard 
deviations of the peak height measurements were smaller than those of 
the peak areas, significantly so for two standards and highly 
significant at the 2.5 „ug Cr/L level. The linearity of the peak height 
measurements was also superior as illustrated in figures 5.4 and 5.5. 
The reproducibility of the transient signal peak heights at the 20 >ug 
Cr/L level (equivalent to about 0.75 ^ug Cr/L in a sample) is 
demonstrated by the recorder trace reproduced in figure 5.6.
5.3.2.3. Peak profiles in ammonium acetate solution.
A number of serum samples were processed for total protein-bound 
chromium and others for alpha-2-globulin—  bound chromium using the 
adopted standard method CDIII. The profiles of the atomisation peaks 
were recorded under conditions such that 100 mm of pen deflection 
corresponded to an absorbance change of 0.1, and at a chart speed of 
300 mm/second. A selection of peak profiles representing a range of 
sample chromium concentrations are illustrated in figure 5.7, together 
with processed standards corresponding to zero, 0.10, 0.35 and 0.50 ^ g 
Cr/L. A similar range of profiles from urine samples processed using 
the standard method adopted for urines, which is described in chapter 
VI, are also included, plus a number of relevant peak profiles 
recorded at the neon 352 nm line and "no injection" profiles at both 
wavebands. The c o m &*-<*• (*-jc- £ 5 r  jsiajndoAclf 
solutions in ammonium acetate/EDTA range from 0.6125 to 30 jig/L, 
equivalent to 0.03 and 1.25 i^g Cr/L respectively in a test sample. The 
characteristics of the peak profiles are summarised in table 5.13. 
W.h/2 is the half height peak width (sec.).
TABLE 5.13.
Peak profile characteristics.
Unproc . stds. Proc. stds. Total .P.B.Cr. Alpha.Glb.Cr. Urine Cr.
Abs. W.h/2. Abs. W.h/2. Abs. W.h/2. Abs. W .h/2. Abs. W.h/2
0.011 3.6 0.012 3.6 0.020 3.6 0.016 3.6 0.021 3.6
0.015 3.6 0.031 3.4
0.024 3.4 0.036 3.5 0.027 3.4 0.032 3.4
0.041 3.4 0.063 3.4 0.037 3.4 0.056 3.8
0.076 3.3 0.086 3.4 0.090 3.4 0.104 3.6
0.144 3.3 0.100 3.3 0.138 3.5
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FIGURE 5.4.
Plot of peak height versus chromium concentration.
Peak height mm.
20
00
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Cr >ig/L.
FIGURE 5.5.
Plot of peak area versus chromium concentration.
qq Peak area ;iV sec.
5000
4000
3000
2000
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0 302010
Cr /ig/L.
Blue line = linear regression (least squares).
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FIGURE 5.6.
Reproducibility at the 20 ,ug Cr/L level.
* Chromium peak.
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FIGURE 5.7.
Peak profiles in ammonium acetate.1. At the neon 352 nm line.
a) No injection, b) Ammonium acetate, c) Serum.
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d ) Urine.
2. At the chromium 357.9 nm line. 
a) and b) No injection. c) and d) Ammonium acetate.,
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j a), b), c) and d) Unprocessed standards 0.6125 ;ig Cr/L.
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4. At the chromium 357.9 nm line.
a), b), c) and d) Unprocessed standards 1.25 pg Cr/L.
Time scale 300 mm/min. Peak height scale 100 mm/0.1 absorbance.
FIGURE 5.7. continued.
Peak profiles in ammonium acetate.
1, 2, 3, and 4. Unprocessed standards at the 357.9 nm chromium line. 
a), b), c) 2.5 jig Cr/L.
J
i a) and b) 5.0 jig Cr/L.
10.0 jig Cr/L.
20.0 jig Cr/L.
'HIL1PS PM 5920/00
Time scale 300 mm/min. Peak height scale 100 mm/0.1 absorbance.
rx»jUK£. o./. continuea.
Peak profiles in ammonium acetate*
1,2, 3, and 4. Processed standards at the 357.9 nm chromium line,
a) and b) Zero standards
10
0.10 ^ ig Cr/La) and b) Standards equivalent to
a) and b) Standards equivalent to 0.35 ;ug Cr/L
Standard equivalent to 0.50 ^ ig Cr/L
Time scale 300 mm/min. Peak height scale 100 mm/0.1 absorbance.
FIGURE 5.7. continued.
Peak profiles in ammonium acetate.
1, 2, 3, and 4. Serum total protein-bound Chromium
at-the Cr 357.9 nm linear- ,
I*
a) and b) 0.05 p g  Cr/L.
a) 0.10 jig Cr/L.r  > u k i r n v i b) 0.07 p g  Cr/L
0.53 jig Cr/L
0.60 ^ jig Cr/L.
13
_i
Time scale 300 mm/min. Peak height scale 100 mn/0.1 absorbance.
FIGURE 5.7. continued.
Peak profiles in ammonium acetate.
1, 2, 3, and 4. Serum alpha-2-globulin-bound chromium 
at the Cr 357.9 nm line.
a) and b) below detection limit
PHlupi PM 9920/|)0 :
a) 0.12 ;ug Cr/L. b) 0.11 jig Cr/L.
a) 0.15 ^ ug Cr/L. b) 0.14 ;ug Cr/L.
a) 0.16 jig Cr/L. i b) 0.17 ;ig Cr/L.i
Peak height scale 100 mm/0.1 absorbanceTime scale 300 mm/min
1 3 7.
FIGURE 5.7. continued.
Peak profiles in ammonium acetate.
1, 2, 3, and 4. Urine chromium at the 357.9 nm line.
a) below detection limit. b) 0.05 ,ug Cr/L.
a) 0.31 Cr/L. b) 0.31 jag Cr/L.
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The peak profiles tend to confirm the conclusions drawn from the 
peak area/height ratio experiments. The steady decrease with increasing 
chromium concentration of the peak area/height ratio and the similar 
profiles seen in processed and unprocessed materials producing similar 
absorbances can be clearly seen.
The "no injection" peaks have a similar profile to the peaks 
recorded at the neon 352 nm line, by all classes of material. The peak 
absorbance in all these traces occurs later in the peak profile than 
the maximum chromium absorbance and appears to be largely responsible 
for the increase in peak area/height ratio seen at low absorbances. 
Background correction does not appear to be required.
5.4. INVESTIGATION OF THE INTERFERENCE MECHANISM.
The mechanism of the hfacac derivative based interference was 
tentatively investigated by comparing the effects of adding ammonium 
acetate either before, or after, an ash step. This was to test the 
hypothesis that: if the interference was caused by the partial loss of
chromium as a volatile compound at the ash stage, then the addition of 
ammonium acetate after this step would be demonstrably less effective. 
The standard AAS/ETA conditions were used, but the dry and ash stages 
were duplicated, to allow for the introduction of ammonium acetate 
between the two dry ash cycles in one series. The base solution 
contained 10 jig Cr/L in 0.05M EDTA, and for the interference tests beta 
diketone derivatives equivalent to a retention of 0.5% hfacac, through 
the wash stages of the standard process, were added. The results of the 
investigation are summarised below in table 5.14. The injection volumes 
were 25 ;uL for both chromium and ammonium acetate solutions.
TABLE 5.14.
Comparison of results with ammonium acetate additions 
before or after ash stage.
n = 5. Mean peak height mm. RSD %.
10 jig Cr/L in 0.05M EDTA.
A. Single dry and ash steps.
1. No hfacac. 52.6 3.5
2. Plus hfacac. 27.6 25
B. Double dry and ash steps.
3. Plus hfacac. 27.3 8.9
4. Ammonium acetate after 1st ash. 44.4 14.4
5. Ammonium acetate after 1st dry. 42.8 24
The ammonium acetate appears to be equally effective, when added 
either before or after the ash step. The mean peak heights produced by 
the solution containing the beta-diketone derivatives are virtually 
identical for the two series with single and.double ash steps. These 
two observations taken together are inconsistent with major losses of 
chromium through volatilization at the ash stage. The reduction of 
chromium signal by halides was reported to be expected on theoretical 
grounds by L'vov (2), and negative interference has been observed in 
the presence of chloride by several workers and has been attributed to 
volatile compound formation by Segar et al (3), Aggett et al (4) and 
Fuller (5). However a vapour phase process was considered to be 
responsible for the interference by Persson et al (6), Freeh et al (7) 
and Czobik et al (8), whilst analyte occlusion in the matrix was 
considered to be the cause by Cruz et al (9), Churella et al (10) and 
Krasowski et al (11). Goodfellow et al (12) worked on the determination 
of chromium in sodium chloride solutions and found that both EDTA and 
ammonia enhanced the absorbance of Cr(III) from that recorded in the 
presence of sodium chloride alone. The EDTA was considered to enhance 
the chromium signal by preferentially forming the stable transition 
metal complex so that decomposition to the metal oxide occurred at the 
ashing stage with minimal formation and subsequent loss of the volatile 
chloride. Ammonia was found to be more effective than EDTA (1M ammonia 
cf 0.02M EDTA) but both caused a decrease in precision offsetting any 
gain in sensitivity. Matsusaki et al (13) investigated the removal of 
chloride interference in the determination of chromium by AAS/ETA and 
reported that the presence of cations which form chlorides with high 
vaporization temperatures such as Ca(II), Sr(II), Ba(II), Cu(II) and 
Fe(III) caused severe interference, whilst cations forming more 
volatile chlorides produced less interference. Tetra-ammonium EDTA and 
acetate ions were both found to be effective in reducing the 
interference. The acetate ions were assumed to form kinetically inert 
Cr(III) complexes that are not attacked by chloride, whilst readily 
volatile ammonium chloride was considered to be produced from the EDTA 
salt. Matsusaki produced evidence that the interference is not due to 
loss of chromium at the ash stage, but is due to chromium salts 
remaining at the atomisation stage. The formation of monochlorochromium 
(III) ions at the atomisation step was suggested as the source of the 
reduced signal.
The demonstrated effectiveness of ammonium acetate and of
tetra-ammonium EDTA in reducing the interference produced by the 
fluoride derived from the hfacac is in agreement with the observations 
on chloride interference in the references cited above. The failure to 
correct the poor precision agrees with the observations of Goodfellow 
et al (12) on the ammonia and EDTA treated materials. The correction of 
the fluoride based interference by ammonium acetate added after an ash 
step is consistent with vapour-phase interference by fluoride similar 
to that suggested by Matsusaki et al (13) for chloride.
5.5. CHARACTERISTICS OF THE AAS/ETA CONDITIONS.
The signal linearity, precision and sensitivity for the 
AAS/ETA conditions developed are summarized in table 5.15 below. The 
chromium solutions were in the standard ammonium acetate, EDTA solution 
and the injection volume was 25 /iL. The peak height was taken as the 
signal.
TABLE 5.15.
Signal linearity, precision and sensitivity using the
standard AAS/ETA conditions
Solution. Sample jug Cr/L. Absorbance. RSD %. Value :
Jig Cr/L. (if recovery 75%). regressioi
0.6125 0.03 0.011 11 0.66
1 .25 0.05 0.015 8.9 1.19
2.5 0.10 0.024 3.8 2.50
5.0 0.21 0.041 2.8 4.99
10.0 0.42 0.076 2.7 10.01
20.0 0.83 0.144 1 .0 /
30.0 1 .25 0.210 0.86 /
n = 5.
Linear regression analysis using the least squares method 
produced (y = jug Cr/L and x = peak height in mm)
1. y = 0.1469x - 1.00 (r = 0.9999) using all the above values.
2. y = 0.1433x - 0.88 (r = 1.0000) using values up to and including
10,ug Cr/L ( 0.42 jug/L in a sample). This range is more relevant to
serum chromium determinations and was used for the regression line 
values in table 5.14 above. The standard error of the mean was 0.04 jug 
Cr/L, which is equivalent to 0.0013 jug/L in a sample giving 95% 
confidence limits of plus or minus 0.0026 pg Cr/L.
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5.6. CONCLUSIONS.
The electrothermal atomisation conditions developed are not 
entirely satisfactory. The precision of the alpha-2-globulin-bound Cr 
determinations is significantly worse for pool I and highly 
significantly worse for pool II compared with that of unprocessed 
chromium solutions of similar concentrations. The precision of the 
total protein-bound chromium determination is not significantly 
different from that of unprocessed material. The AAS/ETA relative 
response discussed in the last chapter was also found to be less 
satisfactory for the alpha-2-globulin-bound Cr series (82% compared 
with 99.5% for the total protein-bound Cr stream). The poor precision 
and response tend to confirm that the extra acidity of the 
alpha-2-globulin-bound Cr precipitates is reducing the efficiency of 
the wash procedure in removing the excess hfacac. However the 
advantages of a similar wash treatment for the standards and both 
sample streams are obvious. The three injections for each sample reduce 
the contribution to the overall precision by the AAS/ETA stage to a 
level sufficient to produce useful analytical data. However the value
of the determinations has certain limitations which will be discussed
in chapter VIII.
Traces of hfacac derivatives cause a reduction in both the size 
of and precision of the chromium signal. The addition of ammonium 
acetate minimizes the former but does not appear to help with the.
latter, and is only useful following a process which leaves only 
minimal traces of the fluorinated diketone. The disadvantages of adding 
ammonium acetate are the obligatory use of uncoated graphite tubes, and 
the restriction of the tube life to about 100 firings. The reduced tube 
life is not a major drawback in the light of the increasing memory 
effects reported earlier. The initial successful tests with ammonium 
acetate had been made with a pyrolytically coated tube but it was a 
much used one, and presumably much of its coating in the critical 
central zone had been lost.
The failure of coated tubes to cope with ammonium acetate
solutions may be due to the less penetrable surface compared with 
standard electrographite tubes. The failure of the injected material to 
penetrate the surface may lead to more extensive redistribution at the 
necessarily high temperature drying stage. However this does not appear 
to occur on observation with the naked eye using a mirror. The use of
pyrolytically coated tubes with ammonium acetate solution may be 
possible with a suitably programmed drying ramp.
In general pyrolytically coated graphite tubes were found to be 
superior in terms of sensitivity and memory effects, although 
of course, they were not suitable for the methods developed in this 
study. The only significant carryover demonstrated, was with uncoated 
tubes after 100 firings, rising to highly significant after 200 cycles. 
Uncoated tubes do however have some advantages. Sensitivity decreases 
with use for both types of tube but the fall is steeper for coated 
ones. The standard electrographite tubes show minimal and steady 
changes in sensitivity over their useful life.
Manning et al (14) reported that pyrolytically coated tubes 
showed higher sensitivity than ordinary tubes for chromium in 1976, and 
this has been confirmed by many workers. Veillon et al (1) reported 
that pyrolytically coated, tubes retained less chromium than uncoated 
ones. However, Slavin (15) criticised Veillons work on retained 
chromium. The temperature gradient along a furnace tube exceeds 1000° C 
and Slavin claimed that much of the radio chromium measured by Veillon 
had participated in the measurement and then condensed on the cooler 
edges of the tube. Veillon in a later publication (16) confirmed that 
the 51 Cr had been concentrated near the tube ends. The work by Veillon 
on the retention of chromium by graphite tubes had involved urine 
samples, which have a high chloride content, and the apparent lack of 
retained radio chromium in the central zone suggests that "analyte 
occlusion" is not a factor in halide interference. The evidence against 
"volatile chromium" has been .discussed earlier and the formation of a 
non-atomic chromium at the atomisation stage, in the presence of the 
halide, appears to be the most probable mechanism for interference by 
chloride and fluoride.
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CHAPTER VI.
THE DEVELOPMENT OF A METHOD FOR THE DETERMINATION 
OF CHROMIUM IN URINE.
The composition of urine is more variable than that of blood. 
The volume passed per 24 hours depends primarily on the amount of water 
consumed. The concentrations of analytes are for this reason only 
useful, in general, for detecting gross changes in an acute situation. 
The amount of analyte excreted per 24 hours is more meaningful, but is 
related to the size of the individual concerned. Creatinine excretions 
are related to the size of the subject, and reporting analytes in 
relation to a fixed mass of creatinine is probably the most 
satisfactory parameter for urines. The sample volume taken for analysis 
can in a similar way be related to the creatinine concentration of the 
specimen.
6.1. OPTIMISATION OF THE PRETREATMENT PROCESS.
The method developed for the determination of Cr in serum/plasma 
was adapted for urine. The concurrent protein precipitation and 
dehydration step used for serum was replaced by evaporation. An acidic 
solvent miscible with hfacac was necessary to dissolve the dried 
residue. Acetic acid proved to be satisfactory, and the addition of 
sulphuric acid, chosen because it is a strong acid free from water, 
improved the recovery. The method adopted, CDUI is listed in the 
experimental section at the end of the chapter (E601). Method CDUI was 
used throughout the development process except for the variations 
detailed in the particular experimental procedure. The recoveries were 
monitored using radioactive chromium added as the chloride, before the 
initial evaporation stage. The radioactive chromium measurements were 
carried out as outlined in chapter IV (E405).
6.1.1.Medium for the Conversion of Cr to the hfacac Complex.
The results of a number of experiments carried out to find the 
optimum medium for the conversion of the urinary Cr to the hfacac 
complex are summarised in table 6.1 below, together with details of the 
experimental variables.
TABLE 6.1.
Optimisation of the medium for formation of the Cr/hfacac complex.
Evap. temp. Volume. % sulphuric Volume Recovery
0 C. acetic acid ^ uL. acid v.v. hfacac. i. ii.
80 250 zero 250 60 61
80 500 zero 250 62 40
Ambient. 250 zero 250 54 54
80 250* zero 250 56 59
80 250 1 250 77 76
80 250 5 250 83 77
80 250 7.5 250 82 81
80 250 10 250 80 67
* 2 hrs. at 75° C between adding the acetic acid and the hfacac •
Duplicate aliquots of urine corresponding to 10.4 ^imol 
creatinine, and spiked with 51 Cr so that each sample contained 3 ng 
were used in all these investigations. The sample size was chosen to 
present a reasonable challenge (equivalent to about 1.5 mL of an 
average urine), so that in these preliminary experiments the analyte 
recoveries would respond to the conditions in a readily observable 
manner. The investigations indicated that neither low temperature 
drying, or pretreatment of the residue with hot acetic acid were 
beneficial. However the addition of 5 to 7.5 % v.v. sulphuric acid to
the acetic acid resulted in significant improvements.
6.1.2. Optimum Temperature.
An experiment was carried out to determine the optimum 
temperature for the conversion of the Cr to the hfacac complex. The 
results are listed in table 6.2 below.
TABLE 6.2.
Optimisation of temperature.
Temperature. 51 Cr recovery, %.
0 C. i. ii. Mean.
50 56 63 60
75 76 73 75
100 37 34 36
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The spiked urine pool used in 6.1.1. above was used, and the sample 
volumes used were again equivalent to 10.4 /imol creatinine. The acetic 
acid used contained 5% sulphuric acid v.v. and 250 ,uL of this and of 
hfacac, were added to the residue obtained after evaporation at 75° C. 
The optimum temperature appears to be 75° C.
6.1.3. Sample Volume.
The recoveries from sample volumes equivalent to 10.4 and 20.8 
jumol creatinine were compared using the conditions and urine pool 
described in section 6.1.2. above, but only at 75 0 C. The tests were 
carried out in duplicate and the results are listed in table 6.3. 
below.
TABLE 6.3.
Effect of sample size on recovery.
Sample volume 51 Cr recovery. 9-\ < •
= ,mnol creatinine. i. ii. Mean.
10.4 76 73 75
20.8 47 56 52
The recovery is clearly sensitive to the quantity of dried 
solids. The effect of increasing the volumes of acetic acid/sulphuric 
acid and hfacac to 500 i^L was investigated, using urine volumes 
equivalent to a range of creatinines from 12 to 72 ,umol. All the 
samples were spiked with 2.0 ng 51Cr. The results are summarised in 
table 6.4 below.
TABLE 6.4.
Effect of urine "concentration" on 51 Cr recoveries.
Urine. n=1. Sample creatinine, jamol. 51 Cr recovery, %.
1. 12.0 74
2. 15.6 75
3. 21.6 64
4. 27.6 64
5. 28.4 71
6. 72.4 54
The experiment was repeated on two urines, the volumes of 
the aliquots taken corresponding to about 20 ^ umol creatinine. The 51 Cr
spike was again 2.0 ng per sample. The results are listed in table 6.5 
below.
TABLE 6.5.
51 Cr recovery using standard sample volume.
51 „ .Cr recoveries, %.
Urine. n=2. Sample creatinine, jnmol. i. ii. Mean.
1 . 21 .8 76 73 75
2. 18.6 83 81 82
The conclusions from the above experiments were that the volume 
of urine taken for Cr determination should be : 20/x mL, where x = the 
creatinine concentration in mmol/L, and that 500 jiL of acetic acid 
(containing 7.5% v.v. sulphuric acid) and 500 ;uL of hfacac should be 
used for each sample. The above urine volume corresponds to about 3 mL 
of an average urine sample. The increase in acetic acid and hfacac to 
double that used for serum samples increases the blank value, but does 
not double it, and allows the urine sample size to be increased by a 
factor of two. The recoveries from urine samples must be similar to the 
standard recoveries for reliable calibrations to be made, as the 
fraction of the high blank which is susceptible to the recovery 
differences is very difficult to measure.
6.2. CHARACTERISTICS OF THE METHOD.
The characteristics of method CDUI are discussed below.
6.2.1. Recovery.
Table 6.6. below lists the recovery and distribution of 2.0 
ng 51Cr added to a sample of urine equivalent to 20 ^mol of 
creatinine.
The high value for the "lost" 51 Cr is difficult to explain, the 
values quoted for the residue and phosphate buffer wash solution are 
not strictly true, as the petroleum spirit extract must be removed from 
the Tuftainer before washing with buffer, to obtain these as separate 
values. However, even when the standard procedure was followed, and the 
residue and phosphate buffer wash 51 Cr are not separated, a similar 
high value was found for the lost 51 Cr. A possible explanation is that 
the 51Cr in the residue is difficult to measure with accuracy, because 
of the insoluble nature of the charred mass, and the low efficiency for 
51 Cr of the gamma counter used.
TABLE.6.6.
Recoveries and 51 Cr distribution.
n=4. Cr
Solution. Mean.
Phosphate buffer. 6.8
Water wash. <1
Petroleum spirit. <1
Ammonia,EDTA. 74.5
Residue. 8.4
Total. 89.7
51 Cr unaccounted for. 10.3
S.D. 
1 .7 
/
/
1 .9
2.5
/
/
(cf Standard mean 75%)
6.2.2. AAS/ETA Relative Response.
The relative signals given by Cr in the processed materials 
compared with unprocessed materials was measured as described in 
chapter IV, section 4.13.2. Incremental peak heights using spikes 
equivalent to 0.5 jig Cr/L were used on pools of processed materials. A 
summary of the relative responses are given in table 6.7 below.
TABLE 6.7.
Relative responses, processed and unprocessed materials. 
Material. Mean response %. R.S.D. n.
Unprocessed standard. 100 4.5 5
Processed standard. 93 4.9 5
Urine. 95 5.1 8
The relative responses of urines and processed standards were 
compared using Student's t test. The responses did not differ 
significantly.
6.2.3. Detection Limit.
The detection limit is governed in this method by the precision 
of the relatively high blank. A gross signal > blank + (4 X blank SD) 
can be detected with 95% confidence, providing that the Cr recoveries 
of tests and standards are not significantly different. Thus a sample 
Cr level equal to (4 X blank SD) in jug Cr/ 10 mmol creatinine equals 
the detection limit. Table 6.8 below lists the detection limits of the 
four best batches, together with a selection of the best detection
limits in the literature. The published values are in p.g Cr/L, however 
in our laboratory the mean adult creatinine is 13 mmol/L, and 24 hr. 
urine volumes are usually between 1 and 2 litres, therefore the figures 
are broadly comparable.
TABLE 6.8.
Blank values, and derived detection limits.
Jig Cr/ 10 mmol creatinine.
Batch. Blank. S.D. Detection
1 . n=4 0.11 0.017 0.07
2. n=4 0.11 0.012 0.05
3. n=4 0.13 0.012 0.05
4. n=3 0.07 0.010 0.04
Mean. 0.105 0.013 0.05
Reference. Detection limit jug Cr/L.
Veillion et al, (1). 0.03
Brodie et al, (2). 0.05
Halls et al, (3). 0.08
Kumpulainen et al, (4) • 0.05
Nomiyama et al, (5). 0.1
Vanderlinde et al, (6) • 0.055
The detection limit is broadly similar to the
published to date.
6.3. SUMMARY.
A pretreatment process has been developed that will extract and 
concentrate about 75% of the Cr in a urine sample corresponding to 20 
^umol of creatinine into 120,uL of solution. The final solution appears 
to be suitable for conventional AAS/ETA without background correction. 
However individual samples need to have a radioactive Cr spiked aliquot 
processed in parallel to monitor the recovery. The detection limit is 
about 0.05 jig Cr/ 10 mmol creatinine.
EXPERIMENTAL SECTION CHAPTER VI.
E601. Urine chromium determination, standard method CDUI.
METHOD.
The determinations were carried out in quadruplicate, and two of the 
four were spiked with radioactive chromium , as the chloride, at a 
concentration equivalent to 0.5 ,ug Cr/ 10 mmol creatinine.
1. y mis of urine were added to a Tuftainer, where y = 20/x, and x = 
the creatinine concentration of the urine in mmol/L.
2. The urine samples were evaporated to dryness in a desiccator 
containing an open vessel of sulphuric acid at 75 0 C.
3. The sealed Tuftainers were allowed to cool to ambient temperature.
4. 500 ph of acetic acid (purified by ion-exchange resin treatment) 
containing 7.5% v.v. Aristar sulphuric acid was added, and the 
Tuftainers contents were mixed on an orbital mixer for two hours, and 
then thoroughly vortexed. The orbital mixer "swirls" the solvent over 
the residue encouraging solution.
5. 500 ,ul of hfacac double distilled from petroleum spirit was added.
6. The Tuftainers were firmly capped and the contents vigorously mixed 
on a vortex mixer.
7. Standards.
Tuftainers were washed x 2 with 4 mL of propan-2-ol and x 2 with 
4 mL of purified acetic acid. 500 /XL of purified acetic acid containing 
7.5% v.v. sulphuric acid and chromium (as the nitrate) at x 8 the 
nominal value was then added to the Tuftainer, followed by 500 jiL of 
hfacac. The containers were then firmly capped and vigorously mixed on 
a vortex mixer.
The nominal values of the standards in jig Cr/ 10 mmol creatinine 
were:
i ) Zero.
ii) 0.25
iii) 0.5
iv) 1.0
The zero standard was set up in quadruplicate, the others in duplicate.
8. All further treatment refers to both tests and standards.
All Tuftainers were heated at 75 0 C in an oven (fan assisted ovens may 
give contamination problems) and the container caps were carefully 
checked for tightness after 15 minutes.
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9. The Tuftainers were cooled in a freezer at -20° C for 1 hour.
10. 8 ml of petroleum spirit were added to all Tuftainers.
11. Tuftainer were heated at 75 0 C for 4 hours. Then cooled to ambient 
temperature on a roller mixer.
12. 4 mL of 2.2M dipotassium hydrogen phosphate,0.01M EDTA was added to 
all Tuftainers.
13. Containers placed on a roller mixer for 1 hour.
14. Tuftainers centrifuged at 3000 rpm for 15 minutes and then the 
petroleum spirit extracts were removed and added to 13 mL screw cap 
polypropylene tubes containing 4 mL of pure water.
15. The petroleum spirit extracts were then washed for 1 hour with the 
water on a roller mixer.
16. The petroleum spirit was then removed and extracted with 500 jiL of 
4.25M ammonia, 0.005M EDTA in a similar polypropylene tube overnight on 
a roller mixer. The ammonia had been distilled under isothermal 
conditions and the EDTA was the di-ammonium salt.
17. The ammonia/EDTA solutions were removed and evaporated in 12 x 75 
mm polypropylene tubes in a desiccator over concentrated sulphuric acid 
at 75 0 C.
18. 120 ^ iL of 0.5M ammonia, 0.7M acetic acid was added to the residues. 
The tubes were capped and then vortexed at 80° C for 10 minutes.
19. The tubes were then centrifuged at 3000 rpm for 10 minutes to 
return any evaporated water which had condensed on the upper walls of 
the tubes to the base.
20. The chromium concentrations in the solutions were determined using 
atomic absorption spectrometry under the standard conditions described 
in chapter IV (E406).
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CHAPTER VII.
CONTAMINATION CONTROL.
Nieboer and Jusys (1) stated that interlaboratory comparisons 
and the use of standard reference materials clearly show contamination 
to be the limiting factor in trace and ultratrace analyses.
The difficulties encountered in this work were consistent with 
the above statement. The reduction and control of the relatively high 
and variable blank was a major problem, and one that was not entirely 
overcome.
7.1. ENVIRONMENT.
The steps taken to minimise contamination from the immediate 
environment in the present investigation are detailed below.
The time containers were open was reduced to the minimum, and 
all dispensing and transfer operations were carried out in a fume 
cupboard reserved for this purpose. The work was carried out on a 
frequently changed sheet of Benchkote, and the fume cupboard fan was 
switched on only when potentially harmful hfacac was being dispensed. 
The interior of the fume cupboard, which was constructed of uPVC was 
regularly washed down with 10% Decon. The enclosure had no stainless 
steel or chromium plated surfaces or fittings.
Evaporation stages, the only ones in which vessels were open 
for longer than a minute were carried out in small desiccators, with 
not more than four tubes or two tuftainers per desiccator. The 
evaporations were all carried out at 75 0 C in a hot air oven. The 
desiccators were sealed (PTFE taps) for procedures related to serum or 
urine chromium determinations, and contained an open vessel of 
concentrated sulphuric acid to remove ammonia / and or water 
vapour, so encouraging evaporation, and preventing drips from the inner 
surface of the lid.
Talc free latex gloves were put on, and rinsed on the exterior 
with pure water and dried with paper towels prior to all experimental 
procedures.
The data reported by Sansoni et al (2) on the composition of the 
dust in the unfiltered air from a laboratory atmosphere are reproduced 
in table 7.1 below.
TABLE 7.1.
Trace element levels in laboratory dust. 
Element. mg/kg dust. Element. mg/kg dust.
Al 3000 Mg 2390
As 55 Mn 116
Br 23 Na 2950
Ca 2690 Ni 70
Cd 3 P 1150
Cl 2 Pb 2150
Co 9 S 20000
Cr 39 Sb 15
Cu 213 Sn 10
F 1 Sr 14
Fe 3230 Ti 258
I 3 V 259
K 7920 Zn 1640
The data in the above table indicates that although chromium 
represented a trace element in laboratory dust, to increase the value 
of a typical reagent blank by 100% would have required less than 1 jig 
of dust.
7.2. CONTAINERS.
Cleaning should remove "less strongly bound" material from the 
container walls, but active adsorption sites should not be created. The 
contamination tests, and hence the cleaning methods used for particular 
pieces of equipment must be related to the uses to which they are to be 
put: clearly "less strongly bound" is a relative term.
Containers made from relatively hydrophobic materials used for 
aqueous solutions at ambient temperature were less critically tested 
than ones exposed to acidic organic solvents at elevated temperatures. 
Equipment and reagents were tested under the conditions of use 
whenever practicable.
Three cleaning protocols were compared on the polypropylene 
tubes. Two treatments involved a 24 hour soak at ambient temperature in 
either acetic acid plus 5% sulphuric acid or 10% nitric acid, followed 
by 10 rinses in pure water. The third set of tubes were merely rinsed
10 times in pure water. The tubes were tested in their respective roles
in method CDIII. all the tubes produced results equivalent to a
contribution of less than 0.005 jig Cr/L to a 4 ml sample, and this
included the reagent blank. However with both types of polypropylene
tubes random tests on unrinsed specimens showed some high chromium 
values and rinsing is clearly necessary.
7.2.1. Universal Containers.
These are 30 mL polystyrene containers with a screw cap, and
were used for sample collection, and storage of some aqueous reagents
at ambient temperatures or less. Universal containers were used new, 
untreated: there was no evidence of contamination from these bottles
under the conditions under which they were used.
7.2.2. 12 X 75 mm polypropylene tubes.
These tubes were used for the evaporation of the ammonia /EDTA 
back extraction solutions prior to AAS/ETA. The ten rinses in pure 
water was adopted as the standard treatment and the push-on 
polyethylene caps were similarly treated.
7.2.3. 13 mL screw cap polypropylene tubes.
The screw cap polypropylene tubes were used at the petroleum
spirit extract wash stage of the chromium determination procedure. New 
tubes from sealed packs were used after 10 rinses with pure water 
immediately before use, both tubes and tops were so treated.
The screw cap polypropylene tubes were also used for the storage 
of purified acetic acid and hfacac. The tubes used for reagent storage 
were soaked in 5% v.v. sulphuric acid in acetic acid for 48 hours, and 
then rinsed at least 15 times with pure water. The final rinse was with 
purified acetic acid for the storage of this reagent and with Aristar 
grade sulphuric acid for the distilled hfacac. The distilled hfacac was 
stored over Aristar grade sulphuric acid as detailed in the section on 
the treatment and storage of the diketone.
7.2.4. Tuftainers.
The reactions carried out in the tuftainers, particularly the 
conversion of chromium to the hfacac complex at 75 0 C make this the 
most critical container in terms of contamination. The investigation of 
various protocols for cleaning new tuftainers was investigated using 
method CDI. Reagent blanks were processed in the tuftainer and "cold" 
blanks in screw cap polypropylene tubes were used as reference reagent 
blanks to assess the relative contribution from the container.
The details of the cleaning protocols and results are summarised 
in table 7.2 below.
TABLE 7.2.
Comparison of various cleaning protocols for new Tuftainers.
Protocols.
1. All soaked in 10% decon for 24 hours at ambient temperature.
2. Rinsed in tap water.
3. 3/4 filled with
A. 10% nitric acid, ambient temperature.
B. tfacac, 125° C.
C. Acetylacetone 125 0 C.
D. 5% v.v. sulphuric acid inacetic acid, 125° C.
All tuftainers 24 hours upright, and then 24 hours inverted. 
After cooling
4. B and C rinsed 3 times with propan-2-ol.
5. All rinsed thoroughly with tap water then pure water.
6. Rinsed with propan-2-ol, then toluene.
Results.
Cr ;ug/L (equivalent values in a processed sample). 
Protocol. i. ii. iii. iv. Mean.
A. 1.2 3.4 2.3 lost. 2.3
B. All greater than 10 p.g/h.
C. 2.9 1.9 2.4 1.1 2.1
D. 0.05 0.07 0.06 0.06 0.06
Protocol D appeared to be very effective in cleaning new 
tuftainers. This treatment was on new Tuftainers before they were 
introduced to the stock in use. The procedure removed that Cr present 
in the new container which was available for contamination of the 
tests. The acetic acid/sulphuric acid solution is a good solvent for 
many Cr species, and the organic acid presumably makes better contact 
with, and penetrates, the surface micro-irregularities better, than an 
inorganic acid, or aqueous solution can.
Routine cleaning of Tuftainers.
The routine cleaning protocol listed in table 7.3 below was used 
to return the containers to the same condition after each batch of 
tests.
TABLE 7.3.
Protocol for the routine cleaning of Tuftainers.
Purpose. 
Removes organic 
material which 
chars if left. 
Removes any Cr 
from surface, 
particularly 
screw threads. 
Oxidises and 
dissolves any 
organic material 
left.
Removes traces 
of oxidant, wets 
container, and 
removes residual Cr.
Note. If the hot nitric acid stage is omitted a gradual build up of 
charred organic material takes place. The Tuftainers were examined when 
cool, after the nitric acid treatment, and containers showing a 
relatively deeper colour were subjected to repeated stage 3 treatments 
until no difference from the other Tuftainers could be seen.
7.2.5. Polypropylene bottles.
Polypropylene bottles of 250, 500 and 1000 mL capacity were used 
for reagent storage and for treating reagents with ion-exchange resins. 
The new bottles were soaked in 5% v.v. sulphuric acid in acetic acid 
(AR grades) for 24 hours, and then thoroughly rinsed in tap water 
followed by at least 15 rinses in pure water. The bottles were then 
rinsed in the fluids which they were to contain. Pre-rinses in 
propan-2-ol were used before introducing solvents not miscible with 
water.
7.2.6. Finnpipette tips.
Tips were stored in sealed plastic containers and carefully
Stage. Treatment.
1. 24 hr. soak at 75 0 C in 10% Decon solution, 
tops and bases in separate 2L flasks, then 
thorough rinse in tap water.
2. Immerse the tuftainers in 5% v.v. sulphuric 
acid in acetic acid at ambient temperature, 
then thorough rinse in a) tap water, and b) 
pure water. Remove from flasks.
3. 3/4 fill individual Tuftainers with conc. 
nitric acid (AR) and heat at 75 0 C in an 
upright position, 24 hrs., then invert and 
repeat heat treatment.Thoroughly rinse in 
pure water individually.
4. 3/4 fill with 10% v.v. hydrochloric acid 
(Aristar) in propan-2-ol (AR), and repeat 
heating, inversion cycle of stage 3.
removed wearing washed latex gloves. The tips were rinsed three times 
in the solution to be dispensed, except when dispensing serum, three 
rinses in pure water were then used.
7.2.7. Polythene transfer pipettes.
These were stored in sealed plastic containers and rinsed three 
times in the pure solvent corresponding to the major component of the 
solution to be transferred, inverting to rinse all the internal 
surface. A minimal immersion in the solution to be transferred was 
carefully made when aspirating.
7.3. REAGENTS.
Two techniques, distillation and treatment with ion-exchange 
resins were used for the purification of reagents. The purification 
processes used together with the initial and final chromium 
concentrations are summarised in table 7.4 below. The methods used for 
the determinations of the chromium concentrations are outlined in the 
experimental section at the end of the chapter.
TABLE 7.4.
Comparison of purification treatments and initial and final
Reagent.
1.Acetic acid. 
(Aristar).
2.Ammonia. 
(Aristar). 
Cr conc. in 
16M soln.
3.hfacac.
i ) BDH batch 
572021 OB.
chromium concentrations. 
Treatment. Cr jaq/L .
Untreated. 4.8
Distillation using magnetic stirrer 
and teflon condenser. 1.3
Double distillation. Mean. 0.2
Best. 0.05
Resin treatment.
i) 'Dowex' 50W-X8 0.14
ii) 'Amberlite' IR-120 1.9
Untreated. 1.14
Boiling water bath, teflon condenser. 0.14
Resin treatment, 'Amberlite' IRA 400. 0.64
Isothermal distillation. 0.15
Untreated. 9.7
Distillation at b.pt. in borosilicate. 
Distillation X 1. 2.6
Distillation X 2. 1.4
Distillation X 3. 1.1
TABLE 7.4. continued.
Reagent.
hfacac.
BDH. continued.
Treatment. Cr jig/L.
0.6
ii)Koch-Light. 
99560.
4. Hydrochloric acid. 
(Aristar.)
Cr conc. 
corrected to 
12M soln.
5. Petroleum spirit. 
120-160° C, b.pt. 
(AR).
6. Toluene.
(Aristar).
7. Propan-2-ol. 
(Aristar).
Distillation X 4.
Distillation at 56 ° C in
borosilicate glass. 0.4
Distillation from an equal volume of 
toluene, boiling water bath, teflon 
condenser. Distillation X 2. <0.02
Untreated. 0.32
Distilled from an equal volume of 
petroleum spirit, boiling water bath, 
teflon condenser. Distilled X 2. <0.02
Untreated. 1.8
Distillation, boiling water bath, 
teflon condenser. 0.2
Isothermal distillation. 0.3
Untreated. 0.007
Treated with 'Amberlite1 monobed 
ion-exchange resin MB-1. <0.002
Treated with 'Amberlite' monobed 
ion exchange resin MB-1. <0.002
Untreated. 0.03
Distilled in borosilicate glass. 0.09
Treated with 'Amberlite' monobed
ion-exchange resin MB-1. <0.002
7.3.1. Ion-exchange Resin Treatment.
A mixed bed ion-exchange resin can be expected to remove
chromium present as ionic species, either anionic or cationic. However
ion-exchange resins can be effective in both base and acid catalysed 
reactions. Experiments confirmed that a mixed bed resin can remove
chromium present as complexes which are susceptible to either acidic or
basic conditions, in both propan-2-ol and petroleum spirit. The resin 
treatments were carried by mixing solvent and resin in about 10:1 v.v. 
proportions on a roller mixer. Petroleum spirit was treated in a 
similar manner with sulphuric acid and aluminium oxide in two other
experiments. The purification of propan-2-ol and petroleum spirit was 
investigated using radioactive chromium labelled complexes with the 
ligands listed below. The procedures used in the preparation of the 
complexes are outlined in E704.
i) Benzoylacetone. (benzoylac).
ii) 4,4,4-trifiuoro-1-(2-thienyl)butane-1,3-dione. (thenoylac).
iii) 1.1.1,5,5,5-hexafluoropenta-2,4-dione...(hfacac).
The results of the treatment are given in table 7.5 below.
In conclusion, ion-exchange resin treatment is an attractive 
purification process as it can be readily carried out in the period 
preceding use, and contamination from the storage container should be 
minimal. Thorough washing with pure water appears to be necessary
before using the resins on reagents. A wash of at least 48 hours
duration, gently mixing the resin using 1:10 resin:water volumes is 
satisfactory. The wash presumably redistributes the chromium present in 
the resin skeleton onto the true ion exchange sites. Contamination of
the reagents by microparticulate material derived from the resin could 
be a problem but can be avoided in practice by decanting the "fines" at 
the water wash stage.
7.3.2. Distillation.
The ideal equipment for producing high quality reagents for 
trace metal determinations by distillation is the vitreous silica 
sub-boiling apparatus. This appliance uses quiescent evaporation of the 
liquid via infrared heating at the surface to prevent violent boiling. 
The efficiency of the process is due to the prevention of the formation 
of fine particles of spray, and to the high purity and inert character 
of the vitreous silica.
A simple piece of equipment with similar characteristics was 
therefore designed, this appliance is illustrated in figure 7.1 and 
described below.
A long necked 100 mL polypropylene flask was used as the boiler, 
and a glass beaker water bath on a magnetic stirrer hotplate was used 
to heat the boiler. The water level in the water bath was maintained 
above the level of fluid in the boiler, and stirred vigorously with a 
teflon coated spinbar. The high water level and vigorous stirring 
minimise spray formation, and the long necked flask is effective in 
reducing spray transfer to the distillate. Direct heating using a 
borosilicate flask with the teflon coated spinbar inside was used for
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TABLE 7.5.
A) Radioactive chromium content of the treated propan-2-ol.
% 51 Cr remaining.
24 hrs. 48 hrs. 60 hrs.
Chromium chloride. <0.1 <0.1 <0.1
benzoylac. 0.6 0.6 0.6
thenoylac. 0.3 <0.1 <0.1
hfacac. <0.1 <0.1 <0.1
B) Radioactive chromium content of the treated petroleum spirit.
i) 'Amberlyst' resin treatment.
% 51
24 hr.
benzoylac. 34 
thenoylac. 63 
hfacac. 89 
ii) 'Amberlite1 monobed resin
Cr remaining. 
48 hr. 
30 
60 
82
treatment.
Q. 51"D Cr remaining.
24 hr. 48 hr. 60 hr
benzoylac. 3.9 3.9 3.9
thenoylac. 0.01 <0.01 <0.01
hfacac. 0.07 0.02 0.02
iii)Sulphuric acid treatment.
9- 51*o Cr remaining.
24 hr. 48 hr.
benzoylac. 2.0 1 .4
thenoylac. 2.0 0.5
hfacac. 102 104
iv) Aluminium oxide treatment
% 51 Cr remaining.
24 hr. 48 hr.
benzoylac. 31 30
thenoylac. 56 57
hfacac. 3 <0.01
distillation above 100 p C. A.teflon tube connected between two teflon 
"tube to joint" connectors was used to to produce a chemically inert 
condensing surface. A wide bore PVC tube between two wash bottle heads
o
o
CO H
Eh
Ofal
MO
O
OO
EH£
gfaH
OiM
aoH
EH
ah;H
EHCO
Piwcoaw
o u
w
g
EH
ao2faw
EH
fafaD0Hfa
163.
*
which sealed round the teflon tube formed a water jacket.
Mitchell (3) reported sub-boiling distilled hydrochloric acid to 
have a chromium content of 0.3 ng/g. The simple equipment described 
above produced hydrochloric acid of 0.5, ng/g after one distillation.
The most successful method found for the purification of hfacac 
was distillation from an equal volume of petroleum spirit (120-160 0 C 
b.pt.) using the boiling water bath variation outlined above. A sample 
of hfacac containing 13.8 jig 51 Gr/L ,was treated and a distillate 
containing only 0.28% of the added 51Cr was produced.
The data on other materials produced using this equipment can be 
found in table 7.4.
7.3.3. Isothermal distillation.
Hildebrand et al (4) stated that from thermodymamic principles a 
purification process based on vapourisation and condensation of the 
vapour is more efficient the lower the temperature at which the process 
is conducted. Isothermal distillation can produce a high purity but 
medium strength product from volatile reagents, and this technique was 
used to purify both ammonia and hydrochloric acid.
The isothermal distillations were carried out using a large 
desiccator, and the data on the distillates can be found in table 7.4.
7.4. STORAGE OF PURIFIED REAGENTS.
Ammonia as a 5M solution, and hydrochloric acid as a 6M solution
were stored in 30 mL polystyrene containers at minus 20° C.
The acetic acid was stored in screw cap polypropylene tubes at 
minus 20° C and thawed out at ambient temperature immediately prior to 
use.
The hfacac was stored in similar polypropylene tubes in 10 mL
aliquots, with 1 mL of sulphuric acid (Aristar grade) in each tube. The
sulphuric acid reconverted any hydrated hfacac produced during 
distillation and tests indicated that sulphuric acid removed simple 
Cr(III) ions irreversibly from the diketone.
The storage at low temperature minimises extraction of chromium 
from the containers and the dissolving of any particulate matter 
present. A very small amount of petroleum spirit distills over with the 
hfacac in the distillation process and during the low temperature 
storage when miscibility is reduced some separates from the diketone 
and can be removed from the surface. All fluids were stored in an
upright position.
Propan-2-ol and petroleum spirit were resin treated over the 24 
hours prior to commencing a batch of tests. Centrifugation at 3000 rpm, 
for 30 minutes to minimise contamination by particulate matter was 
carried out, in the treatment bottles on the day of use.
The phosphate buffer used was made by dissolving 500g of 
dipotassium hydrogen orthophosphate (tri-hydrate) in pure water in the 
original container. EDTA as the diammonium salt (3.62g, Spectrosol 
grade) was added and the solution made up to 1 litre in a graduated 
polypropylene bottle.
7.5. SAMPLE COLLECTION.
The controversy about the effects of stainless steel needles on 
sample collection was mentioned in chapter III. Kumpulainen et al (5) 
and Versieck et al (6) both produced evidence that blood samples 
collected using stainless steel needles were contaminated with Cr from 
the needle. The results of the investigations by Kumpulainen and 
Versieck together with data from 8 samples taken for routine laboratory 
tests and subjected for total protein-bound Cr as a part of this work 
are summarized in table 7.6.
TABLE 7.6.
Effect of stainless steel needles on serum Cr levels.
Serum Cr jig/L.
Ref. Plastic catheter samples.
Individual samples tested.
(5). Mean 0.12 SD 0.05 n=6
CDIII. Mean 0.11 SD 0.04 n=43
(This work).
(6). Mean 0.16 SD 0.083 n=20
Range 0.038 to 0.352 
Note. The 4 successive 20 ml samples were 
collected using an irradiated needle on a 
plastic tube, simulating a venepuncture.
Steel needle samples. 
Pool from 20 samples. 
Mean 0.43
Sample. Cr.
1. 0.13
2. 0.07
3. 0.07
4. 0.16 
Mean 0.25
4
samples. 
Sample.
1.
2.
SD 0.05 
Sample. Cr.
5. 0.10
6. 0 . 10
7. 1.10
8 . 0.20
successive 20 mL
Cr. Sample. Cr. 
89.9 3. 10.4
12.7 4. 15.9
Versieck's "irradiated needle" may have undergone some 
structural changes during the exposure to the neutron flux, and the 
results reported on the samples taken in the simulated venepuncture 
experiment are therefore possibly invalid. Kumpulainen may have found 
only a few of the 20 samples were contaminated if the samples had been 
tested individually. Vanderlinde (8) reported a mean serum Cr level of
0.075 j^ig/L on samples taken using stainless steel needles. The 
conclusion is that although blood samples taken through stainless steel 
needles are not always contaminated with Cr the possibity of this 
occurring must be rigorously excluded.
7.5.1. Serum and Plasma.
Samples were taken during oral glucose tolerance tests. Blood 
was taken from an anterior cubital vein without stasis. A "Medicut" 
polyethylene intravenous cannula was used. The needle was removed after 
piercing the vein and a plastic tap was substituted for the syringe. 
The first 10 mL of blood flowing from the indwelling plastic cannula 
were discarded and 4 fasting samples of about 25 mL were collected into 
polystyrene universal containers, labelled 1 to 4, in order. A 5 mL 
sample was collected into a tube containing potassium fluoride/oxalate 
mixture for glucose determinations. The tap and cannula were flushed 
with "Hepsal" sterile heparinised saline (10 units heparin/mL) to 
prevent clotting after this and all other sampling sessions. On one 
occasion blood was collected into universal bottles containing 100 juL 
of heparin. The specimens were stored at 4 0 C and the plasma separated 
after centrifugation at 4 0 C. Total protein-bound Cr and 
alpha-2-globulin-bound Cr determinations were commenced within 2 hours 
of sample collection.
A solution containing 50 g glucose was given orally after the 
collection of the fasting samples, samples of blood were then taken 
every 30 minutes for three hours. The first 10 mL of blood were 
discarded and the next 5 mL taken into a fluoride/oxalate tube for 
glucose measurement. Two 25 mL samples were then collected for chromium 
and insulin determinations. The blood collected for chromium and 
insulin determinations was allowed to clot at 4 0 C, and the separated 
serum was stored at minus 20° C.
7.5.2. Urine.
Urine samples were collected from males only directly into 
universal containers, after discarding the first 20 mL. Samples of
urine were collected fasting and at 1,2 and 3 hours after imbibing the 
glucose solution. Samples of urine were also collected from a number of 
young males, before and after vigorous exercise. Males only were used 
for urine collection because of the contamination problem with female 
donors.
7.6. CONCLUSIONS.
The contamination control procedures outlined in this chapter 
were not entirely successful. This is indicated by comparison of the 
blank values recorded with those of other workers who reported similar 
serum chromium levels, see table 7.7 below. The control procedures were 
accepted however under the dual constraints of time and monetary 
resources.
The theoretical contribution to the blank was relatively easy to 
deduce for many reagents, and these values are listed below in table 
7.7 together with the blanks reported by some workers and
referred to above.
TABLE 7.7.
Contributions to a theoretical reagent blank.
Reagent. Cr p.g/l>. Contribution to blank, ,ug Cr/L.
Acetic acid. 0.2 0.01
Ammonia. 0.14 0.007
hfacac. 0.02 0.001
Theoretical blank. 0.02
Experimental blank.
All batch mean. 0.08
Lowest batch mean. 0.04
Blanks by other workers.
Veillon, et al,(7). 
Vanderlinde, et al,(8). 
Offenbacher, et al,(9). Serum.
0.02
0.03
0.02
Citrated plasma. 0.03 
Heparinised plasma. 0.05
The teflon condenser, magnetic stirrer distillation appliance 
was very successful for purifying acetic acid, ammonia, hfacac and 
hydrochloric acid.
The contribution to a serum sample processed by the 
alpha-2-globulin-bound chromium procedure by hydrochloric acid was 
computed to be <0.002 jig Cr/L, as an experiment indicated that less 
than 10% of the chromium present in this reagent was present in the 
precipitated protein, and some of this probably represents exchanged 
rather than additive chromium.
The contributions by propan-2-ol and petroleum spirit are more 
difficult to deduce as no detectable chromium was found in the purified 
reagents. However the mean serum total protein-bound chromium was found 
to be 0.10 ;ug/L compared with a mean alpha-2-globulin-bound chromium 
of 0.07 i^g/L. Therefore, as less than 10% of the chromium in the 
acidified propan-2-ol used for the latter fraction is precipitated, the 
propan-2-ol probably makes a very modest contribution. The treatment 
with ion-exchange resin was convenient and appeared to be effective for 
reducing the chromium concentrations in the propan-2-ol and petroleum 
spirit, both of which are used in relatively large volumes. The mixed 
bed resin Amberlite MB1 was demonstrated to remove chromium present as 
the simple solvated Cr(III) ion, and to break down complexes 
susceptible to either base catalysed or acid catalysed degradation.
In summary, the experimental blank values recorded are not 
entirely satisfactory relative to the very low values found for serum 
chromium levels in normal subjects. However the purification methods 
used did reduce reagent chromium levels to ultra low levels. The 
cleaning procedure adopted for the containers identified as the major 
chromium contamination source was effective in significantly reducing 
the chromium elution. A sampling procedure was used for blood 
collection which avoided the obvious potential contamination from 
stainless steel needles.
EXPERIMENTAL SECTION CHAPTER VII.
E701. AAS/ETA conditions.
The standard conditions listed in chapter IV (E406) were used.
Uncoated profile graphite tubes were used at all times.
E702. Radioactive chromium determinations.
All measurements of radioactive chromium were carried out as
described in chapter IV (E405).
E703. Methods used in reagent chromium determinations.
1. Acetic acid.
i) 500 pL of acetic acid was evaporated in 12 X 75 mm polypropylene 
tubes at 100B C in a desiccator with the tap open.
ii) Residue dissolved in 100 pL of 0.1M acetic acid, 0.0125M EDTA at 
80° C in a vortex heater.
iii) Chromium concentration measured using AAS/ETA.
2. Ammonia.
i) 25 jiL of 0.05M EDTA was added to 500 pL of ammonia in a 12 X 75 mm 
polypropylene tube prior to evaporation at 100° C in a desiccator 
containing an open vessel of sulphuric acid.
ii) Residue dissolved in 100 pL of 0.1M acetic acid at 800 C in a 
vortex heater.
iii) Chromium concentration measured using AAS/ETA.
3. Hydrochloric acid.
i) 500 juL of hydrochloric acid was evaporated at 800 C in 12 X 75 mm 
polypropylene tubes in a desiccator containing an open vessel of 
sulphuric acid.
ii) Residue dissolved in 100 pL of 0.1M acetic acid, 0.0125M EDTA at 
803 C for 10 minutes on a vortex heater.
iii) Chromium concentration measured using AAS/ETA.
4. Propan-2-ol.
i) 10 mL of propan-2-ol plus 100 pL of 0.025M EDTA were evaporated in 
Tuftainers standing in the updraught zone against the rear wall of 
a fume cupboard, at ambient temperature overnight.
ii) Residue dissolved in 100 u^L of 0.1M acetic acid at 8 0 0 C for 30 
minutes on a vortex heater.
iii) Chromium concentrations measured using AAS/ETA.
5. Petroleum spirit.
i) 10 mL of petroleum spirit plus 50 i^L of acetic acid were
evaporated in Tuftainers standing in the updraught zone against
the rear wall of a fume cupboard, at ambient temperature
overnight.
A blank of 50 pL of acetic acid was also evaporated.
ii) Residue dissolved in 100 pL of 0.1M acetic acid, 0.0125M EDTA at 
800 C for 30 minutes on a vortex heater.
iii) Chromium concentration measured using AAS/ETA.
6. Toluene.
The chromium determinations on toluene were carried out in an 
identical manner to the determinations on petroleum spirit above.
7. hfacac.
Treated as "blank" in standard method CDIII, but no heating at 75 
o C. Blank similar but without hfacac.
E704. Preparation of complexes.
The complexes listed below were used for petroleum spirit and 
propan-2-ol purification investigations.
i) Benzoylacetone. (benzoylac).
ii) 4,4,4-trifluoro-1-(2-thienyl)butane-1,3-dione. (thenoylac).
iii) 1.1.1,5,5,5-hexafluoropenta-2,4-dione. (hfacac).
Method.
0.1g of benzoylac and thenoylac were each dissolved in 1000 /lL 
of acetone. Acetic acid (10 jiL) and 25 ;iL of radioactive chromium as 
the chloride (6.9 mg Cr/L) were added to the two solutions above and to 
1000 pL of hfacac. The solutions were then incubated at 5 0 0 C for three 
hours. Aliquots (20 mL) of both propan-2-ol and petroleum spirit were 
then individually spiked with 50 j^iL of the three radioactive chromium 
solutions. Aliquots of the two solvents were also directly spiked with 
an equivalent amount of radioactive chromium as the chloride.
The solutions were thoroughly mixed on a roller mixer for 30 
minutes. The solutions were then centrifuged at 3000 rpm for 10 minutes 
and 500 ;uL aliquots removed for use as reference solutions. The 
radioactive chromium concentrations in the reference solutions are 
listed below in table 7.8. Chromium chloride is clearly virtually 
completely insoluble in petroleum spirit, and 51 Cr concentrations in 
this solvent can therefore be taken as the true concentrations of the
particular chromium complexes in the solvents. The excess Cr in 
propan-2-ol being present as chromium chloride.
TABLE 7.8.
Radioactive chromium in reference solutions.
51 Cr ^ g/L. 
Petroleum spirit.
Chromium chloride. <0.001 
benzoylac 0.100
thenoylac 0.219
hfacac 0.046
Propan-2-ol.
Total 51 Cr. 51 Cr as complex
0.345 /
0.223 0.100
0.387 0.219
0.057 0.046
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CHAPTER VIII.
CHROMIUM LEVELS IN SERUM AND URINE.
The serum chromium levels found using method CDIII, and the 
urinary chromium excretion as determined using method CDUI, are 
discussed, and compared with other values reported in the literature, 
in this chapter.
8.1. SERUM CHROMIUM.
The total protein-bound chromium was found to represent at least 
95% of the serum chromium (Chapter IV, section 4.2.), in agreement with 
Lim et al (1). The values found for this parameter should therefore be 
similar to the total serum chromium levels reported by other workers.
The serum chromium concentrations reported over the last decade 
(table 3.1, Chapter III) appear to fall into three main groups, as 
summarised in table 8.1 below. The members of each group tend to 
support their own results by citing the other members in the group.
The mean levels reported by the group I members form the 
"tightest" grouping, the overall mean is 0.125 and the relative 
standard deviation is a modest 23%. A similar tight group including 7 
reported mean values cannot be assembled at any other part of the serum 
chromium "spectrum". The samples analysed by 5 of the members of group 
I were, as reported and discussed in Chapter III, section 3.1.1.1. and 
Chapter VII, section, 7.5., taken with stringent precautions against 
sample contamination. Members of group I have attributed the higher 
values reported by other workers to contamination from stainless steel 
needles. The most popular argument put forward by workers reporting 
higher values, is that a volatile chromium fraction present in 
biological fluids has been wholly, or partly lost, by those reporting 
lower values. The volatile chromium controversy has been discussed in 
chapter III, section 3.4.1., and there appears to be good evidence that 
the volatile biological chromium fraction is mythical, and that workers 
reporting low values have taken adequate precautions against losses by 
volatilisation.
The mean value for total protein-bound chromium using method 
CDIII for 43 samples taken with stringent precautions against sample
contamination from 11 subjects was 0.11 jig/L, with a standard deviation 
of 0.04 ^ig/L. This value clearly supports group I, and if included 
gives a group mean of 0.123 jxg Cr/L, with a relative standard deviation 
of 22%.
TABLE 8.1.
Serum chromium levels over the last decade.
Reference. Mean Cr, jig/L. Year.
Group I (group mean 0.125, RSD 23%, n=7).
Versieck et al,(2). 0.16 1979-
Kayne et al,(3). 0.14 197£.
Vanderlinde et al,(4). 0.075 1979.
Kumpulainen et al,(5). 0.12 1983.
Anderson et al,(6). 0.12 1984.
Veillon et al,(7). 0.11 1984.
Offenbacher et al,(8). 0.15 (plasma 0.27) 1986.
This study (CDIII). 0.11
Group II (group mean 1.14, RSD 54%, n==7).
Liu et al,(9). 1 .7 1978.
Kasperek et al,(10). 0.45 1979.
Seeling et al,(11). 0.70 (plasma 1 .25) 1979.
Thompson,(12). 2.0 1980.
Abraham et al,(13). 1 .6 1981 .
Liu et al,(14). 1.0 1982.
Morris et al,(15). 0.56 1985.
Group III (group mean 6.8, RSD 27%, n=4).
Newman et al,(16). 6.0 1978.
Salvadeo et al,(17). 8.2 1979.
Gedik et al,(18). 4.6 1980.
Simonoff et al,(19). 8.5 1984.
RSD = relative standard deviation.
The relatively low values found for serum chromium using method 
CDIII are clearly not false due to the loss of a volatile Cr fraction 
derived from the biological sample. The specimens are never heated 
above 75 0 C, and are in sealed containers at all temperatures above 
ambient. The loss of Cr as the volatile hfacac complex is very unlikely 
as shown in Chapter IV, section 4.6.1. (<1% lost in 48 hrs. at ambient
temps, open vessel), and is of equal opportunity for both tests and 
standards. The compositions of processed standards and samples are 
almost identical, and reasonable proof has been given that the AAS/ETA 
measurements are valid (chapter V).
An equally confident case cannot be made for the validity of the 
radioactive Cr spike as a meaningful guide to recovery of the native 
Cr, even after equilibration. The experiments reported in chapter IV, 
section 4.2. clearly indicate that the added 51 Cr exchanged with the 
native element. The recovery tests carried out in this study are 
suspect if lower levels than the ones found are postulated, as the 
percentage of the added 51 Cr present as native molecular species of 
which Cr is a normal component (excluding transferrin) would then be 
very low, reducing their contribution to the recovery. The reverse is 
true if the supposition is that the values found using method CDIII are 
falsely low, and under these circumstances the recovery tests appear to 
be more reliable, The recovery of haemoglobin-derived iron reported in 
chapter IV, section 4.12.1. gives some support to the validity of the 
pretreatment used. The administration of radioactive Cr to a human 
subject, the only completely satisfactory route to recovery 
confirmation, was considered to be unjustified on ethical grounds.
The pretreatment used in method CDIII has virtually nothing in 
common with the pretreatments used in any of the methods cited in group 
I, which include: 2 using dry ash, 2 wet oxidative digestion, 1 partial 
digestion with bacterial protease, 1 direct injection, and 1 (6) with
no . information. The agreement shown by 8 methods with such diverse 
methodology tends to support the overall mean of 0.123 }ig Cr/L, as the 
best guide to the true value.
8.1.1. Analytical Characteristics.
The major analytical characteristics of 7 of the 8 methods cited 
in group I, table 8.1, are summarised in table 8.2 below, in comparison 
with method CDIII.
A comparison of the precisions of the 7 methods is difficult to 
make, as this parameter has been determined on specimens with 
inappropriately high Cr concentrations in many reports. The level of 
19.51 )ig Cr/g quoted in reference (2) is probably a mi;S print, but 
19.91 ng/g would be an unsuitable concentration. The high value of 13% 
for a specimen with a mean level of 0.06 ,ug Cr/L for method CDIII must 
be considered in this light. The high blank value of 0.08 jig Cr/L is
TABLE 8.2.
Analytical characteristics of serum Cr methods.
Sample Pretreatment Detection Precision.
Reference. ;uL. and measurement. Blank, limit. Mean. SD. RSD.
(2). 1000 Dry ash, NAA. 0.0478 19.51(a) 1.39 7.1
(0.0262-0.0704) n=6.
(3). 500 Digestion, nitric acid, / / / /
peroxide. AAS/ETA.BC.WI.
(4). 500 Digestion, nitric acid, / / / /
peroxide. AAS/ETA.BC.WI.
(5). 100 Direct injection, 0.05 0.43(b) 0.048 11.1
AAS/ETA.BC.WI. Std.Add. n=4
(7). 1000-2000 Dry ash. 0.02 0.03 0.27(b) 0.050 18.5
AAS/ETA.BC.WI. n=26
0.27(c) 0.020 7.4
n=8
(8). 500 Partial digestion, 0.02 0.03 0.29(b) 0.030 10.3
bacterial protease, n=12
AAS/ETA.BC.Zeeman. Std.Add. 0.50(c) 0.014 2.8
Auto-sampler. 0.10(c) 0.006 6.3
CDIII. 4000 Solvent extraction as 0.08 0.03 0.13(d) 0.009 7.0
hfacac complex. AAS/ETA. n=6
Note:
0.06(c) 0.008 13.0
"Mean" in above table refers to the sample used for precision 
tests, not to reference range mean.
BC= background correction, WI= tungsten iodide.
Std.Add.calibration by standard additions.
Cr concentrations are in ;ug/L, except for (a) where ;ig/g are 
quoted!
SD = standard deviation in the same units as relevant mean.
RSD = relative standard deviation %.
(b) between batch precision. (c) within batch precision.
(d) between batch precision, but on mean of quadruplicate tests.
the principal disadvantage with method CDIII, and is clearly 
significantly inferior to the value of 0.02 reported by both (7) and
(8). The method of Offenbacher et al (8) appears to be very impressive, 
with a conveniently small sample requirement, simple pretreatment, and 
very good precision with a low blank value. However a high quality AAS 
instrument is required with high sensitivity, as the sample was diluted 
1 in 2, and the background correction system used reduces sensitivity, 
as reported in chapter III, section 3.3.1.1.1. The auto-sampler used 
may have made significant contributions to the precision. Background 
correction is required and the expensive Zeeman system may be 
obligatory,
8.2. ALPHA-2-GLOBULIN-BOUND SERUM CHROMIUM.
The alpha-2-globulin-bound serum chromium cannot be compared 
with others in the literature, as no other worker has attempted to 
fractionate serum chromium. The hypothesis was that
alpha-2-globulin-bound Cr would show a greater relative response than 
total serum Cr to a glucose challenge. This paramater was considered to 
be less prone to modest contamination at the sampling stage, as added 
Cr(III) is initially bound predominantly by the beta-globulin 
transferrin, and to a lesser extent by albumin.
The mean alpha-2-globulin-bound serum Cr was 0.07 ;ug/L, compared 
with 0.10 ^ig/L for the total protein-bound Cr on the same samples (36 
specimens from 4 subjects). The determination is less prone to recovery 
problems than the total protein-bound Cr stream. The within batch 
precision on a pool of routine laboratory specimens produced a relative 
standard deviation of 1.6%, with a mean value of 0.92 p.g Cr/L 
(standard deviation 0.015 p.g Cr/L), demonstrating that the method would 
be excellent, if the analyte levels were ten times higher.
8.3. URINARY CHROMIUM.
The urinary Cr levels reported over the past decade can be 
divided into three groups in a similar manner to the serum Cr values, 
and are listed in table 8.3 below. All the methods listed use AAS/ETA.
The three methods in group I are all direct injection techniques 
with tungsten iodide background correction, and standard additions 
calibration. Veillon et al (20) and Anderson et al (21) probably used 
identical techniques, both reported that their urine method had been 
verified by stable isotope gas chromatography/mass spectrometry, and 
also by a method using the wavelength modulated echelle monochromator 
AAS developed by Harnley et al (30). However, Guthrie et al (22) in
group II used the wavelength modulated echelle monochromator AAS 
system and reported a level of 0.5 jug Cr/L, also confirmed by stable 
isotope dilution gas chromatography/mass spectrometry. Veillon et al
(20) argued that as Cr absorption had been proven to be between 0.5 and
1.0% by radiotracer experiments, and as diets in the U.S.A. supplied 
only about 100 jig Cr/day, excretions must be less than 1 j^ig/day. Egila 
et al (31) using tube wall, platform and probe atomisations with 
Zeeman correction reported good agreement by all three techniques with 
the method of Halls et al (28) in group III. However the samples used 
were all from subjects on Cr supplementation and were reported to be in 
the range 1.6 to 7.4 ,ug Cr/L.
TABLE.8.3.
Urine chromium levels reported over the last decade.
Reference. Mean Cr, j^ig/L. Year.
Group I (group mean 0.13, RSD 15%, n=3).
Veillon et al,(20). 0.15(i) 1981.
Kumpulainen et al,(5). 0.13 1983.
Anderson, et al,(21). 0.11(i) 1983.
Group II (group mean 0.44, RSD 19%, n=5).
Guthrie et al,(22). 0.50(i) 1978.
Vanderlinde et al,(4). 0.40 1979.
Nomiyama et al,(23). 0.48 1980.
Brodie et al,(24). 0.50 1984.
Morris et al,(25). 0.31 1985.
This study (CDUI). 0.33
Group III (group mean 0.85, RSD 25%, n=5).
Kayne et al,(3). 1.10 1978.
Routh et al,(26). 0.79 1980.
Ping et al,(27). 0.72 (20 to 35 yrs.). 1982.
0.39 (47 to 69 yrs.).
Halls et al,(28). 0.80 1983.
Mianzhi et al,(29). 1.00 1983.
(i) reported to be confirmed by stable isotope dilution,
gas chromatography/mass spectrometry.
The mean urinary Cr obtained using method CDUI was 0.57 )ig
Cr/day (SD 0.3) based on a creatinine excretion of 13 mmol/day, and 
this gives a mean Cr concentration of 0.33 pg/L if a mean daily urinary 
excretion of 1.75 litres is assumed. The value is in agreement with 
group II in table 8.3, but is not compatible with group I.
8.3.1. Analytical Characteristics.
The major analytical characteristics of some of the methods in 
table 8.3 above are listed in table 8.4 below. The methods selected 
were those from the first two groups which provided suitable 
information in the report. ,Method CDUI is included for comparative 
purposes.
TABLE 8.4.
Analytical characteristics of urinary Cr methods.
Reference. Methodology.
(20)
(5).
(23)
(24)
(28),
CDUI 
Note:
limit.
0.03Direct injection.
BC.WI. Std.Add.
Direct injection.
BC.WI. Std Add.
Direct injection. 0.10
No BC.
Direct injection. 0.05
BC.D2. Auto-sampler Std.Add.
Direct injection dil 1/2. 0.08
BC.D2.
Solvent Ext., hfacac complex. 0.05
Precision 
Mean SD.
0.14(a) 0.012
n=40
0.13(a) 0.011
n=10
RSD.
8.6%
8.7%
0.5 0.05 10 '
0.58 0.104 18%
0.79 0.103 13%
0.43(b) 0.056 13%
"Mean" (jig Cr/L) in above table refers to the sample used for 
precision tests, not to reference range mean.
SD = standard deviation in ;ig Cr/L.
BC= background correction, WI= tungsten iodide, D2= deuterium.
(a) between batch precision.
(b) between batch precision but on mean of duplicate tests.
The conclusion from table 8.4 is that direct injection 
techniques are suitable for urinary Cr determinations, particularly if 
tungsten iodide background correction is available. The atomisation, 
and particularly the ashing temperatures must be very carefully
controlled to obtain useful results. The ability of Nomiyama et al (23) 
to obtain apparently satisfactory results without background correction 
using a direct injection of undiluted urine, is in contradiction to the 
findings of other workers in this field.
8.4. SERUM CHROMIUM RESPONSE TO A GLUCOSE CHALLENGE.
A number of workers have investigated the serum/plasma Cr 
profile through a glucose tolerance test, but the reported results have 
been contradictory.
8.4.1. CDIII Cr Levels in Response to a Glucose Challenge.
In the present study oral glucose tolerance tests were carried 
out on 4 normal subjects, and samples were collected for serum Cr, 
serum insulin and plasma glucose as detailed in chapter VII.
The overall mean serum Cr results for the glucose tolerance test 
samples are given in table 8.5 below.
TABLE 8.5.
Serum chromium levels during an oral glucose tolerance test.
Total protein-bound Cr, Alpha-2-globulin-bound Cr.
Sample. Mean. SD. Mean SD.
Fasting. 0.11 0.02 0.06 0.02
30 min. 0.12 0.02 0.05 0.005
60 min. 0.12 0.02 0.07 0.01
90 min. 0.12 0.04 0.07 0.03
120 min. 0.09 0.03 0.05 0.01
150 min. / / 0.08 0.03
180 min. 0.12 0.02 0.07 0.02
n=3 n=4, fasting to
n=3, 120 to 180 !
The specimens taken during the oral glucose tolerance tests 
were also subjected to glucose determinations, and insulin 
determinations were carried out on two series of samples. The methods 
used for the glucose and insulin determinations are given in appendix 
B. The data from the individual glucose tolerance tests are listed in 
table 8.6 below.
TABLE 8.6.
Chromium, glucose and insulin levels on normal subjects
during an oral glucose tolerance test.
Total Cr. GTF Cr. Glucose. Insulin.
Sample. JJ.g/L. ;ig/L. mmol/L. mU/L.
Subject A, female, 18 yrs.
Fasting. 0.11 0.07 4.4 <10
30 min. 0.12 0.06 10.1 51
60 min. 0.14 0.06 11.2 47
90 min. 0.14 0.04 8.6 30
120 min. 0.12 0.04 4.5 <10
150 min. / 0.05 3.5 <10
180 min. 0.14 0.05 4.0 <10
Subject B, male, 19 yrs.
Fasting. 0.13 0.07 4.5 <10
30 min. 0.10 0.05 8.1 34
60 min. 0.12 0.08 7.7 34
90 min. 0.08 0.09 6.5 51
120 min. 0.06 0.06 5.1 21
150 min. 0.12 0.10 4.2 12
180 min. 0.10 0.07 4.0 10
Subject C, male, 53 yrs.
Fasting. 0.10 0.07 5.3
30 min. 0.14 0.05 7.5
60 min. 0.10 0.19 3.8
90 min. 0.15 0.10 4.5
120 min. 0.09 0.06 4.4
150 min. / 0.08 4.1
180 min. 0.11 0.08 3.6
Subject D, female, 46 yrs.
Fasting. 0.04 4.8
30 min. 0.05 5.3
60 min. 0.08 4.5
90 min. 0.05 6.8
Note:
Total Cr = total protein-bound Cr., GTF Cr = alpha-2-globulin-•bound Cr
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The oral glucose tolerance test was repeated on subject C, but 
11 sequential fasting samples were taken, and 4 specimens 60 minutes 
after the glucose ingestion. The large number of fasting samples were 
taken to confirm that the fasting values recorded were not falsely 
elevated, through a failure to wash out traces of Cr from the 
initial venepuncture. The total protein-bound Cr and 
alpha-2-globulin-bound Cr levels were determined, in duplicate on the 
specimens. The results are summarised in table 8.7 below.
TABLE 8.7.
Fasting and 60 minute post glucose serum Cr values.
i) Sequential fasting samples, total protein-bound Cr.
Sample No. Cr jug/L (Mean of duplicate determinations).
1 . 0 . 10
2. 0.08
3. /
4. 0.14
5. 0.08
6 . 0 .12
7. 0.07
8. 2.95 rejected.
9. 0.10
10. 0.09
11. 0.07
ii) Mean values, total protein-bound Cr and alpha-2-globulin-bound Cr.
Cr jng/L.
Total protein-bound Cr. Alpha-2-globulin-bound Cr. 
Sample. Mean. SD. n. Mean. SD. n.
Fasting. 0.094 0.024 9 0.051 0.008 6
60 minute. 0.090 0.051 6 0.056 0.016 6
Student's t tests confirmed that there were no significant
differences between the fasting and 60 minute post glucose samples, for 
either of the two serum chromium parameters in the table above.
8.4.2. Fall in Plasma Chromium.
Davidson et al (32), reported that an intravenous glucose load
produced a rapid fall in plasma Cr. An oral glucose challenge was found
to produce a less well marked decline. The reported results are
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characteristic of group III (high) methodology (table 8.1) and are 
summarised in table 8.8 below.
TABLE 8.8.
Plasma Cr response to a glucose load, Davidson et al (32).
Plasma Cr jig/L. Plasma Cr jig/L
Sample. Mean. SD. Sample. Mean. SD.
Fasting. 4.7 0.15 40 min. 3.12 0.21
10 min. 3.89 0.29 50 min. 3.24 0.23
20 min. 3.48 0.17 60 min. 3.16 0.19
30 min. 3.31 0.19
The means are from 10 normal subjects . SD= standard deviation.
8.4.3. Rise in Serum Cr.
Gedik et al (18), reported significant increases in serum Cr for 
normal subjects, and for those with adult, or juvenile onset diabetes 
mellitus. Chromium levels before and during the oral glucose tolerance 
tests were found to be not significantly different in the three groups. 
The results are summarised in table 8.9 below, and again the results 
are "high" (group III of table 8.1).
TABLE 8.9.
Serum Cr responses to a glucose load, Gedik et al (18).
Serum Cr jig/L.
Sample. Normal (n=10). Adult onset; DM (n=9). Juvenile (:
Mean. SD. Mean. SD. Mean. SD.
Fasting. 4.6 0.6 4.7 0.9 4.4 0.9
30 min. 7.0 0.7 7.6 0.9 5.8 0.8
60 min. 6.4 0.7 7.2 0.6 6.5 0.9
90 min. 6.0 0.5 5.9 0.7 6.5 0.9
120 min. 5.5 0.7 3.7 0.5 5.3 0.8
SD= standard deviation.
The reference range was reported to be 4.4 to 6.1 jag Cr/L. The 
method used was that of Pekarek et al (33). However Pekarek reported 
the mean normal serum Cr to be 1.62 jig/L.
8.4.4. Rise in normal status, fall in deficient subjects.
Liu et al (9) investigated the "relative Cr response" (RCR) as
an indicator of Cr status. The RCR was defined as :
100 x (1 hr. serum Cr)/(fasting serum Cr).
The 27 subjects tested were re-examined after receiving 5 g of 
brewer's yeast daily for 3 months. The results are summarised in table
8.10 below. The Cr concentrations are characteristic of group II 
methodology (table 8.1).
TABLE 8.10.
Relative Cr response, Liu et al (35).
Serum Cr ^ ug/L.
Fasting. 60 min. RCR %.
A. Normal. (n=15).
Baseline. 1.67 1.43 107
Post yeast. 1.46 1.86 140
B. Hyperglycaemic. (n=12).
Baseline. 1.89 1.03 81
Post yeast. 0.94 1.03 149
Note. The RCRs reported do not appear to refer to the mean Cr levels 
of the groups, but to the 73% of normals and the 75% of hyperglycaemics 
who showed an improved response.
8.4.5. Response to Glucose Challenge, Conclusions.
The serum Cr responses reported by other workers and referred to 
above are all based on serum Cr levels which appear to be at least ten 
times higher than the values indicated by method CDIII, and they do not 
agree on Cr levels, or on the direction of the response. A method with 
a low recovery could give a reproducible profile, a technique producing 
grossly elevated values would not be expected to do so. The higher 
levels, if due to contamination, or measuring signals from, or unduly 
influenced by, matrix components independent of chromium, should be 
random in distribution. The ability of a method to demonstrate a 
reproducible, characteristic pattern of serum Cr levels, in response to 
a glucose challenge, must be taken as evidence that the values found 
are not falsely elevated. This argument would be reinforced if 
different, characteristic reproducible patterns were given by classes 
of subjects with abnormalities of carbohydrate metabolism.
A glucose tolerance profile using one of the group I serum Cr 
techniques (table 8.1) has not been reported. Method CDIII failed to
demonstrate a significant change in either total protein-bound serum 
Cr, or alpha-2-globulin-bound Cr. However a simpler technique with 
superior precision such as the one developed by Offenbacher et al (8) 
would be more sensitive in this respect. The insulin level in human 
serum is about 0.15 nmol/L, assuming that the total Cr concentration is 
about 0.12 >ug/L ( 2 nmol/L), then as little as 10% of the total serum 
Cr could be true GTF Cr, if it is assumed that the concentrations 
of insulin and GTF in moles per litre are similar. The changes in total 
serum Cr would then be a relatively modest 50%, even if the GTF levels 
changed in parallel to the insulin levels.
In summary, the developed method for measuring total 
protein-bound Cr, and alpha-2-globulin-bound Cr has failed to 
demonstrate a response of either of these parameters to a glucose 
challenge in normal subjects. Saner (34) stated in 1981 that there was 
general agreement that an increase in plasma Cr levels occured after 
glucose administration, but this still awaits indisputable proof, as 
evidence based on acceptable Cr levels has yet to be produced.
8.5. DIAGNOSTIC VALUE OF URINE CHROMIUM DETERMINATIONS.
The diagnostic value of urinary Cr determinations is a matter of
some controversy, and this is to be expected in the light of the 
uncertainty about the validity of the analytical methods used.
The urinary Cr should reflect the level of non-protein-bound Cr,
and therefore, possibly "free GTF" levels. The concept that the
alpha-2-globulin-bound Cr represents a reserve of GTF, in equilibrium 
with a low level of the free factor , is a reasonable one by analogy 
with the thyroid hormones. The free GTF and its degradation products 
would be excreted in the urine. Anderson et al investigated the
effects of Cr supplementation and a glucose load on urinary excretion
(21). The baseline Cr levels in these investigations were in group I of
table 8.3, and well below the 1 jug Cr/day maximum, derived from
radiotracer absorption studies and dietary considerations, discussed 
earlier (section 8.3).
8.5.1. Urinary Chromium Response to a Glucose Challenge.
Anderson et al (21) investigated the urinary Cr response 
following a glucose load on a large number of subjects, both before and 
after Cr supplementation. The mean daily Cr excretion increased from
0.22 ;ug/day to 0.99 ^ig/day on a schedule of 200 ,ug Cr, as the chloride,
per day. The urinary Cr concentration was found to correlate 
significantly with the creatinine concentration for urine samples taken 
after a morning void, and 90 minutes after glucose ingestion, both 
before and during Cr supplementation. However there was no correlation 
between Cr concentration and 90 minute glucose levels, or fasting or 90 
minute insulin levels.
8.5.1.1. Urinary chromium response to a glucose challenge, using 
method CDU1.
In the present study two subjects were investigated and the 
results are summarised in table 8.11 below. Duplicate tests plus 
duplicate recovery spikes were set up for each sample.
TABLE 8.11.
Urinary Cr before and after a glucose load.
,ug Cr/10 mmol creatinine. 
Subject B. Subject C.
n=1 . Mean. SD. Mean. SD.
Fasting. 0.58 0.26 0.16 0.04
60 min. post 0.94 0.14 0.22 0.06
glucose.
SD= standard deviation.
There is insufficient data for reliable statistical analysis in 
the above table. The method for urine was developed very late in the 
project and there was insufficient time to carry out further 
investigations. A low priority had been allocated to this field, as 
Anderson et al had found no significant response. The results justify 
the analysis of more samples from a larger number of subjects.
8.5.2. Effects of Exercise on Urinary Chromium Excretion.
Vigorous exercise induces increases in glucose utilization and 
consequent changes in urinary Cr excretion could occur.
8.5.2.1. Effect of exercise on urinary Cr, investigation using 
method CDU1.
Urine specimens were collected immediately prior to, and 
immediately after runs of 5 to 10 miles duration. Two male subjects B 
and D, aged 19 and 24 years respectively, provided a total of 16 pairs 
of pre, and post run urines. The results are summarised in 8.12 below. 
The urine determinations were carried out in duplicate, plus two spiked
aliquots to monitor the recovery. 
TABLE 8.12.
Urinary Cr, before and after vigorous exercise.
;ug Cr/10 mmol creatinine.
Pre exercise. Post exercise.
Mean. SD. Mean. SD.
Subject B. (n=6) 
Subject D. (n=10) 0.49
0.59 0.15
0 .12
0.60
0.42
0.32
0.25
SD= standard deviation.
Student's t test confirmed that there was no significant 
difference between the pre and post exercise urine Cr levels.
8.5.2.2. Effects of Exercise on Urinary Chromium Excretion,
Anderson et al.
Anderson et al (35) investigated the effects of vigorous 
exercise on urinary Cr excretion. Nine male runners were asked to run a 
6 mile course at or near their maximal capacity, and urine samples were 
collected immediately prior to, immediately following and 2 hours after 
running. The mean urinary Cr/creatinine ratio was significantly 
increased in the 2 hour post exercise urine, relative to the pre-run 
sample. The mean factor was 4.7, with a range of 1.5 to 8.6.
8.5.2.3. Effect of exercise in urinary Cr, conclusions.
In the light of the report by Anderson et al the tests should be 
repeated on specimens collected 2 hours after the termination of the 
vigorous exercise.
8.5.3. Value of Urinary Chromium Determinations Discussed.
The value of urinary Cr determinations appears to be limited to 
toxicological studies, and confirmation of compliance in Cr 
supplementation studies.
The determinations on specimens collected before and after a 
glucose load should be repeated in the light of the results recorded in 
table 8.11., and if a significant change is demonstrated for normal 
subjects, then this test may possibly be of value.
8.6. CONCLUSIONS.
The value of this study is clearly very limited. The method 
developed for the determination of serum Cr has the disadvantages of a
large sample requirement and modest throughput. Contamination is 
difficult to control and about 1 in 12 determinations must be rejected 
because of obvious failure in this field. The total protein-bound Cr 
and urine Cr determinations are prone to recovery problems, and this 
parameter must be strictly monitored, and results on samples with 
recoveries below the minus 2 standard deviation limit rejected. However 
the radioactive spike provides a recovery check independent of the 
AAS/ETA values, and hence four independent results are available if 
tests and spikes are set up in duplicate.
The alpha-2-globulin-bound Cr procedure is more robust, but 
failed to demonstrate a response to a glucose challenge. The high 
blanks, and consequent high detection limits of the developed methods 
have prevented a confident definition of the lower limits of the normal 
range for the measured parameters. However all other methods developed 
to date appear to have similar failings.
The data from this work has made very modest contributions to 
the highly controversial serum and urinary Cr fields. The data from 
serum Cr determinations have given added weight to the argument that 
the mean serum Cr level in normal humans is about 0.12 jig/L. A second 
contribution is that about one third of the Cr in human serum is 
normally bound to transferrin, the other two thirds being mainly 
bound by proteins of the alpha-2-globulin fraction.
The data from this project indicates that neither serum total 
protein-bound Cr or alpha-2-globulin-bound Cr levels, show changes of 
similar proportions to those demonstrated for either insulin or glucose 
values, in response to a glucose load. However, more modest responses 
of these parameters may occur.
The value of the urinary Cr data is limited to supporting the 
urinary excretion level at less than 1 jig Cr/day in normal subjects.
Contributions to analytical chemistry outside the field 
discussed above are necessarily very small. The simple cheap 
distillation equipment described in chapter VII, section 7.3.2., can 
produce distillates of extremely high purity. The analytical methods 
developed can possibly be adapted for other trace metals in 
serum/plasma and urine, as beta-diketones form complexes with the 
majority of trace metals which are of interest to the clinical chemist. 
The metal beta-diketonates are generally suitable for solvent 
extraction and some may be produced under similar conditions, a certain
amount of multi-element analysis may thus be possible. The following 
trace metals which are of current interest in clinical chemistry, as 
reported in chapter I, table 1.3, are reported by Moshier et al (36) 
to form complexes with hfacac: aluminium, nickel(II) and manganese(II). 
The concentration of aluminium in serum is probably higher than that of 
chromium by a factor of at least one hundred, and the factor for the 
other two metals is possibly about five (see chapter I, table 1.1). The 
methods may be more satisfactory for analytes present at higher levels, 
as the precision recorded on a pool with elevated Cr values was good, 
as described in section 8.2. The simplified back extraction described 
in chapter IV, section 4.12.1. is suitable for metals which form labile 
complexes with hfacac.
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APPENDIX A.
EQUIPMENT AND REAGENTS USED.
Milli-RQ Water Purifier.
Quality 1 megohm-cm resistivity.
Supplied by :
Millipore UK Ltd.,
Millipore House,
Abbey Road,
London NW10 7SP.
NE 1600 Gamma Counter.
Used in the 57 Co mode.
Supplied by :
Nuclear Enterprises Ltd.,
Sighthill,
Edinburgh EH11 4EY.
MX10 10 Roller Mixer.
Supplied by :
Coulter Electronics Ltd.,
Coldharbour Lane,
Harpenden,
Hertfordshire.
Beckman TJ-6R Refrigerated Centrifuge.
RCF 1500 g at 3000 rpm.
Supplied by :
Beckman - RIIC Ltd.,
Progress Road,
Sands Industrial Estate,
High Wycombe,
Buckinghamshire HP12 4JL.
SP 2900 Atomic Absorption Spetrometer.
Equiped with SP9-01 Digital Flameless Atomiser.
DP 101 Computing Integrator.
Supplied by :
Pye Unicam Ltd.,
York Street,
Cambridge CB1 2PX.
6.a) Finnpipettes.
Continously adjustable micropipettes.
Code. Range jiL. Set volume. Mean. n=10 RSD%
H40/25 5 to 50 25 24.9 1 .94
50 49.8 1 .64
H40/26 50 to 250 125 121 0.32
250 246 0.26
H40/27 200 to 1000 250 252 0.25
500 502 0.32
1000 1006 0.16
H40/29 1000 to 5000 4000 3960 0.73
Used with polypropylene tips.
Desiccators.
Jencons Dry - Seal Desiccators.
4" and 12".
PTFE tubing.
Cat. No . H66/7 normal wall.
0.25" id, 0.025" wall, 
d) PVC high pressure terylene reinforced hose. 
Cat. No. TR 24.
0.75" id, 1.125" od.
Supplied by :
Jencons Scientific Ltd.,
Mark Road,
Hemel Hempstead,
Hertfordshire.
7. Teflon connector.
Tube to joint connector 1206.
Supplied by :
Chemplast Inc.,
150 Dey Road,
Wayne,
New Jersey 07470,
U.S.A.
ii.
8. Quickfit Wash Bottle Head,
Dreschsel/ADJ.
Code MF 27/3/13 
Supplied by:
J.Bibby Science Products Ltd.,
Stone,
Staffordshire ST15 OSA.
9. Tuftainers.
Teflon PFA vials.
15 mL capacity, Cat. No. 14045.
Manufacturers state:
Teflon -PFA-main chain carbon fluorine backbone contains 
perfluoroalkoxy (PFA) side chains connected through flexible 
oxygen links. Stable -196 0 C to 260° C.
All Tuftainer products are moulded from Teflon-PFA, no 
plasticisers or other organics are added , making Tuftainers the 
product of choice for handling severe corrosive liquids, and for 
trace metal analysis. Knurled closure, 4 ribbed areas on body. 
Inner secondary seal. Seamless. Radiused inner corners.
Marking area in centre of cap.
Supplied by :
Pierce and Warriner (UK) ltd.,
44 Upper Northgate Street,
Chester,
Cheshire CH1 4EF.
10.a) Universal Containers.
30 mL polystyrene:' screw cap bottle.
Code 33621. 
b) Polythene Transfer Pipettes.
Code 28928.
Supplied by :
L.I.P. (Equipment and Services) Ltd.,
111, Dockfield Road,
Shipley,
West Yorkshire BD17 7AS.
iii.
.a) 12 X 75 mm polypropylene tube.
Code 55/526.
Cap (skirted).
Code 65/719.
b) 13 mL polypropylene screw cap tube plus cap.
Code 60/541.
Supplied by :
Sarstedt Ltd.,
68 Boston Road,
Beaumont Leys,
Leicester LE4 1AW.
Chemicals.
Supplied by :
A. BDH Chemicals Ltd.,
Broom Road,
Parkstone,
Poole BH12 4NN.
Ammonia Aristar. Product 45200.
Acetic acid Aristar. Product 45001.
Acetic acid AR. Product 10001.
Benzoyl acetone. Product 27347.
Chromium III nitrate, standard solution, "Spectrosol" for
atomic spectroscopy. 1 mL = 1 mg Cr. Product 14137.
Decon 90. General purpose surfactant, especially suitable for
biological and radioactive work. Product 56022.
EDTA (diammonium salt). "Spectrosol" grade. Product 14111.
1,1,1,5,5,5-Hexafluoropenta-2,4-dione. Product 28623.
Hydrochloric acid Aristar. Product 45002.
Nitric acid AR. Product 10168.
Perchloric acid Aristar (70%). Product 45008.
Petroleum spirit AR (120 to 160 0 C b.pt.). Product 10182.
di-Potasium hydrogen orthophosphate AR. Product 10349.
Propan-2-ol Aristar. Product 45103.
Propan-2-ol AR. Product 10224.
Sulphuric acid Aristar. Product 45006.
2-Thenoyltrifluoroacetone. Product 13128.
Toluene Aristar. Product 45109.
Ion-exchange resins.
Amberlite IRA 400 AR grade.
Amberlite IR 120 (H) AR grade.
Amberlite monobed MB1 AR grade.
Amberlyst 15 macroreticular strong acid.
Amberlyst 27 macroreticular strong base.
Dowex 50WX8 (H) standard grade.
B. Koch-Light Ltd.,
37 Hollands Road,
Haverhill,
Suffolk,
CB9 8PU.
1,1,1,5,5,5-Hexafluoropenta-2,4-dione.
C. Amersham International PLC.,
Amersham,
Buckinghamshire.
51 Cr. Chromic/" Chloride in 0.1M hydrochloric acid.
Code CJS 2.
Materials used in blood collection.
1. Medicut cannula, size 1.7 mm.
Supplied by :
Sherwood Medical Industries Ltd.,
London Road,
County Oak,
Crawley,
West Sussex RH10 2TL.
2. Hepsal sterile heparinised saline, 10 units heparin per mL. 
Supplied by :
Weddel Pharmaceuticals Ltd.,
Wrexham,
CLWYD LL13 9PX.
3. 3-way Stopcock, VYGON VG1.
Supplied by :
Vygon UK Ltd.,
Bridge Road,
Cirencester,
Gloucestershire C17 1PT.
Product 55005. 
Product 55001. 
Product 55007. 
Product 55137. 
Product 55137. 
Product 55162.
Product 3055-55.
APPENDIX B.
ANALYTICAL rO ZLVticTDS,
Creatinine Determination in Urine.
Technicon AA1 system, no dialysis, using the reaction between
creatinine and 3,5-dinitrobenzoic acid.
Adapted from the method of Parekh,A.C., and Sims,C.,
Clin. Chem., 23 (1977) p.2066.
Technicon AA1 system supplied by :
Technicon Instruments Co. Ltd.,
Hamilton Close,
Basingstoke,
Hampshire RG21 2YE.
Glucose Determinations in Blood.
Beckman Glucose Analyser II.
Glucose oxidase method, partial pressure of oxygen measured.
Supplied by :
Beckman-RIIC Ltd.,
Progress Road,
Sands Industrial Estate,
High Wycombe,
Buckinghamshire HP12 4JL.
Insulin Determinations in Serum.
Insulin RIA kit, code 1M78.
Supplied by :
Amersham International PLC.,
Amersham,
Buckinghamshire.
Serum Iron Determinations.
CFA 2000 Rotochem Centrifugal Analyser.
Ferrozine reagent.
Supplied by :
Travenol Laboratories Inc.,
9299 Washington Boulevard,
Savage,
Maryland 20863.
U.S.A.
APPENDIX C.
STATISTICAL METHODS.
Student's t test was used to compare the means of two series of 
results as a test for significant difference. The formulae used were 
taken from :
Statistics for Analytical Chemistry. (1984) p.54-55. 
by J.C.Miller and J.N.Miller.
Published by John Wiley and Sons, New York.
1. Applied when the standard deviations of the two series were not 
significantly different.
The "pooled" estimate of standard deviation was calculated from the 
individual standard deviations si and s^by using the equation:
2.s = {nt- 1>s* + (n^ _- 1)sw/(n( + .nt- 2)
Then t is given by:
t = (x,- xt)/sJ(1/n,+ 1/n^)
where t has (n + n -2) degrees of freedom.
2. Applied when the standard deviations of the two series were 
significantly different.
t = (Xj- "x^)/y (s^/Uj + s^/n^)
and the number of degrees of freedom was calculated from:r
degrees of freedom = <
(s?/n i + SfVnt,)
(sf/n! ) + (s*/n».) \ - 2
n,+ 1 n^+ 1V,n'
the result being rounded to the nearest whole number.
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